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Cancer is an umbrella term that encompasses a collection of related diseases.
In all types of cancer, as cells become unregulated, they begin to divide un-
controllably and spread into surrounding tissues. From early to late stages of
disease progression, there are many alterations that occur and many criteria that
must be met for cancer to proliferate uncontrollable, resist cell death, avoid the
immune system, and metastasize. Targeted therapy have been developed for
a wide range of dysregulated cancer pathways using different modalities and
mechanism of actions. However, due to the diversity of cancer, the same treat-
ment that may be effective for one type of cancer may not be responsive on
another. Furthermore, patients may carry resistance forms of the disease. To
alleviate this, new strategies have been developed to target specific mutations
of known dysregulated proteins and to use combination therapies that target
multiple pathways. However, both methods require vast amount of knowl-
edge on the biological interactions and mechanism of actions that takes place
within the cell. To address this knowledge gap, we believe that the metabolism
can be used as a tool to better understand the dysregulations of signaling and
gene expression. There is a great opportunity to study the system as a whole
to gain key insights for combination therapies that target different regulatory
pathways, such as the metabolism and signaling. In this work, we leveraged
our current understanding of signaling transduction, transcription factor, and
metabolic networks to develop an integrated systems biology approach to quan-
titatively unravel the mechanisms that regulate cancer. Ultimately, we were able
to establish a computational model that incorporated mechanistic understand-
ing of multiple layers of cellular decision making. We believe this work will be
useful in the development and evaluation of new combination therapy across
all form of cancers.
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1.1 Schematic of how a system of ordinary differential equations
(ODEs) are implemented to represent a network of biological in-
teractions. The rate of change with respect to time of each in-
dividual species is represented by a mass balances. The rate of
accumulation or depletion of the species are determined by the
rate of reactions. The diagram shows an example of a substrate
(S) being converted to product (P) at the rate of v1, while the
presence of drug (D) inhibits the reaction. . . . . . . . . . . . . . . 3
1.2 Simplified schematic of the human complement system. The
complement cascade is activated through three pathways: the
classical, the lectin, and the alternative pathways. Complement
initiation results in the formation of classical or alternative C3
convertases, which amplify the initial complement response and
signal to the adaptive immune system by cleaving C3 into C3a
and C3b. C3 convertases further react to form C5 convertases
which catalyze the cleavage of the C5 complement protein to C5a
and C5b. C5b is critical to the formation of the membrane attack
complex (MAC), while C5a recruits an adaptive immune response. 4
1.3 Flux balance analysis is formulated as a linear programming
problem with an objective function to be maximized or mini-
mized subjected to a set of constraints on the fluxes and the rate
of accumulation of depletion. . . . . . . . . . . . . . . . . . . . . . 8
1.4 (Caption next page.) . . . . . . . . . . . . . . . . . . . . . . . . . . 9
x
1.4 (Previous page.) Multi-scale modeling of cancer metabolism
[204]. (A) Flux Balance Analysis (FBA). The arrows repre-
sent fluxes of species within a reduced representation of cell
metabolism and cell growth. Key steps associated with three
hypotheses are labeled: (1) Warburg effect, (2) Reverse War-
burg and (3) Glutamine addiction. The uptake and production
rates are qi/n [g/g-DW-hr] for the ith metabolite and the nth
metabolic phenotype. We impose the maximum growth rate, ,n
[hr-1], for a given metabolic phenotype of each cell type as an
objective function within the FBA. (B) Cell: Biomass (Xm [g])
growth of each cell type is modeled as a Monod-like process pa-
rameterized by the same maximum growth rates used in FBA
that are modulated by functions of metabolite concentrations,
fn(Cj)Monod. The change in Volume of the cell (Vm [L]) is cal-
culated from biomass growth by applying a constant density of
the cell ([g-DW/L]). Yield coefficients (Yi/n [g-DW/g]) for each
metabolite (i) and corresponding metabolic phenotype (n) are
defined in terms of the uptake and production rates (qi/n) ob-
tained from FBA. Extracellular space: Species balances for each
explicit metabolite follow reaction-diffusion kinetics and govern
the concentration profiles of metabolite at the multicellular scale.
These equations (Eqs 1-4 in text) are integrated into and solved
within an agent-based model (ABM; iDynoMiCS). (C) ABM sim-
ulations: i) Radial, two dimensional growth: Tumor cells grow
radially out from an initial cluster of cells with metabolites sup-
plied at the edge of the cell mass such that radial gradients of
concentration emerge (color map;red is high and blue is low con-
centration). Two phenotypes are displayed (red: tumor cells
and blue: stromal cells). As the tumor grows, concentration
gradients of metabolites become significant, making the tumor
growth a diffusion-limited process that can result in different
growth dynamics as well as distinct spatial distribution of cell
subpopulations. ii) Axial, one dimensional growth: Layers of tu-
mor cells (red) and stromal cells (blue) are initiated near a blood
vessel that supplies metabolites (from the top), such as glucose
and oxygen in the blood stream. Growth pushes cells deeper
into the tissue, away from the vessel, such that strong gradients
of metabolite can again occur. iii) Krogh length calculation: To
evaluate the impact of diffusion limitations in a simple model,
we treat cells as continuum with uniform, zeroth order kinetics
of metabolite consumption to calculate the distance over which
the concentration of limiting metabolites falls to zero within the
tumor mass; we refer to this distance as the Krogh length of a
given metabolite. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
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2.1 Schematic of the effective ATRA differentiation circuit. Above a
critical threshold, ATRA activates an upstream Trigger, which
induces signalsome complex formation. Signalsome activates
the mitogen-activated protein kinase (MAPK) cascade which in
turn drives the differentiation program and signalsome forma-
tion. Both Trigger and activated cRaf-pS621 drive a phenotype
gene expression program responsible for differentiation. Trigger
activates the expression of a series of transcription factors which
in combination with cRaf-pS621 result in phenotypic change. . . 51
2.2 Model analysis for ATRA-induced HL-60 differentiation. A:
BLR1 mRNA versus time following exposure to 1µM ATRA at
t = 0 hr. B: cRaf-pS621 versus time following exposure to 1µM
ATRA at t = 0 hr. Points denote experimental measurements,
solid lines denote the mean model performance. Shaded regions
denote the 99% confidence interval calculated over the parame-
ter ensemble. C: Signalsome and cRaf-pS621 nullclines for ATRA
below the critical threshold. The model had two stable steady
states and a single unstable state in this regime. D: Signalsome
and cRaf-pS621 nullclines for ATRA above the critical threshold.
In this regime, the model had only a single stable steady state.
E: Morphology of HL-60 as a function of ATRA concentration (t
= 72 hr). Experimental data in panels A and B were reproduced
from Wang and Yen [242], data in panel E is reported in this study. 52
2.3 Model simulation following exposure to 1µM ATRA. A: BLR1
mRNA versus time with and without MAPK inhibitor. B: cRaf-
pS621 versus time following pulsed exposure to 1µM ATRA with
and without BLR1. Solid lines denote the mean model perfor-
mance, while shaded regions denote the 99% confidence inter-
val calculated over the parameter ensemble. C: Western blot
analysis of phosphorylated ERK1/2 in ATRA washout experi-
ments. Experimental data in panels A and B were reproduced
from Wang and Yen [242], data in panel C is reported in this
study. The images of the raw gel for panel C is given in the Sup-
plemental Materials. . . . . . . . . . . . . . . . . . . . . . . . . . . 53
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2.4 Model simulation of the HL-60 gene expression program follow-
ing exposure to 1µM ATRA at t = 0 hr. A: Scaled CD38 and
CD11b expression versus time following ATRA exposure at time
t = 0 hr. B: Scaled Gene expression at t = 48 hr following ATRA
exposure. Gene expression was normalized to expression in the
absence of ATRA. The gene expression is quantified by the pro-
tein fold change of quantified Western blot data (from at least
three biological repeat nuclear lysates) using ImageJ. Experimen-
tal data in panels A and B were reproduced from Jensen et al.
[119]. Model simulations were conducted using the ten best pa-
rameter sets collected during model identification. Solid lines
(or bars) denote the mean model performance, while the shaded
region (or error bars) denote the 95% confidence interval calcu-
lated over the parameter ensemble. . . . . . . . . . . . . . . . . . 54
2.5 Model simulation of HL-60 cell-cycle arrest following exposure
to 1µM ATRA at t = 0 hr. A: Predicted p21 and E2F expression
levels for the best parameter set following ATRA exposure at
time t = 0 hr. B: Estimated fraction of HL-60 cells in G0 arrest
following ATRA exposure at time t = 0 hr. Solid lines (or bars)
denote the mean model performance, while the shaded region
(or error bars) denotes the 95% confidence estimate of the poly-
nomial model. Experimental data in panel B was reproduced
from Jensen et al. [119]. . . . . . . . . . . . . . . . . . . . . . . . . 55
2.6 Robustness of the HL-60 differentiation program following ex-
posure to 1µM ATRA at t = 0 hr. A: Singular value decom-
position of the average system response (l2-norm between the
perturbed and nominal state) following pairwise gene knockout
simulations using the top ten best fit parameter sets. The rows
denote the deleted genes, while columns denote the response
mode. B: Singular value decomposition of the average system
response (l2-norm between the perturbed and nominal state) fol-
lowing the pairwise removal of protein-DNA connections for the
top ten best fit parameter sets. The rows denote protein-DNA
interactions at the labeled promoter, while the columns denote
the top ranked response modes (combinations of deletions). The
percentage at the top of each column describes the fraction of the
variance in the system state captured by the node combinations
in the rows. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
2.7 Robustness of the HL-60 differentiation program following ex-
posure to 1µM ATRA at t = 0 hr. Protein fold change at t = 48 hr
(rows) in single and double knock-out mutants (columns) rela-
tive to wild-type HL-60 cells. The responses were grouped into
>2,4 and 8 fold changes. The best fit parameter set was used to
calculate the protein fold change. . . . . . . . . . . . . . . . . . . . 57
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2.8 Investigation of a panel of possible Raf interaction partners in
the presence and absence of ATRA. A: Species identified to pre-
cipitate out with Raf: first column shows Western blot analysis
on total Raf immunoprecipitation with and without 24 hr ATRA
treatment and the second on total lysate. B: The expression of
species considered that did not precipitate out with Raf at lev-
els detectable by Western blot analysis on total lysate. C: Ef-
fect of the Raf inhibitor GW5074 on Raf interactions as deter-
mined by Western blot analysis of total Raf immunoprecipita-
tion. The Authors note the the signal associated with Src was
weak. D: Cell Cycle distribution as determined by flow cytom-
etry indicated arrest induced by ATRA, which was increased by
the addition of GW5074. E: Expression of the cell surface marker
CD11b as determined by flow cytometry indicated increased ex-
pression induced by ATRA, which was enhanced by the addi-
tion of GW5074. F: Inducible reactive oxygen species (ROS) as
determined by DCF flow cytometry. The functional differentia-
tion response of ATRA treated cells was mitigated by GW5074.
GAPDH was used as a loading control. The black lines frame
groupings from independent gels and each image is typical of
three repeats. Images of the raw gels for panels A, B C and F are
given in the Supplemental Materials. . . . . . . . . . . . . . . . . 58
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2.9 This schematic diagram shows the hypothetical principal path-
ways in the ATRA–induced signaling that results in cell differ-
entiation in the HL-60 myeloid leukemia model [238, 34, 35, 208,
21, 207]. It is based on modules and feedback loops. There
are three main arms (shown top to bottom): 1. Direct ATRA
targeting of RAREs in genes such as CD38 or BLR1; 2. For-
mation of a signalsome that has a regulatory module that in-
cludes Vav (a guanine nucleotide exchange factor), CBL and
SLP-76 (adaptors), and Lyn (a Src family kinase) that regulates a
Raf/Mek/Erk axis that incorporates Erk to Raf feedback, where
the regulators are modulated by AhR and CD38 receptors; and
3. Direct ATRA targeted up regulation of CDKI to control RB
hypophosphorylation. The Raf/Mek/Erk axis is embedded in
the signalsome and subject to modulation by the regulators.
The output of the signalsome is discharge of the Raf from the
cytosol to the nucleus where it binds (hyper)phospho-RB and
other targets, including NFATc3, which enables activation of the
ATRA bound RAR/RXR poised on the BLR1 promoter, and also
GSK3, phosphorylation of which relieves its inhibitory effect on
RARα. CDKI directed hypophosphorylation of RB releases Raf
sequestered by RB to go to NFATc3, GSK3, and other targets.
A significant consequence of the nuclear RAF is ergo ultimately
to enable or hyperactivate transcriptional activation by RARα to
drive differentiation. It might be noted that this proposed gen-
eral model provides a mechanistic rationalization for why cell
cycle arrest is historically oft times perceived as a precondition
for phenotypic maturation. . . . . . . . . . . . . . . . . . . . . . . 59
3.1 HL60 transcription factor network structure from literature
sources. Figure shows interactions between protein nodes with
black arrows indicating transcriptional activation and red lines
indicating transcriptional repression. Phenotypic markers are
shown on the right, with black indicating activation and red re-
pression. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
3.2 ATRA, D3, and combination induced expression of key proteins
in the gene regulatory network at 48 hours after induction. The
error bars represent standard errors, 491 samples for simulated
data, and 3 samples for experimental measured data. The dotted
horizontal line indicated the baseline level of protein at time 0hr. 86
xv
3.3 Dynamic phenotypic markers of ATRA, D3, and combination in-
duced differentiation of HL60. The simulation captured time-
course experimental measurements of CD38 (blue), CD11b (red),
and CD14 (purple). The points are experimental measurements
with error bars representing standard error. The black lines are
the simulated average of the 491 parameter set ensemble, with
the darker colored band representing 99 % standard error of the
simulated mean, and the lighter colored bands meaning 99 %
confidence interval. . . . . . . . . . . . . . . . . . . . . . . . . . . 87
3.4 Sensitivity analysis comparing ATRA and D3 induced HL60 dif-
ferentiation. The parameters are ranked ordered from low to
high sensitivity with the parameters that are more sensitive for
ATRA and D3 treatment fall on the right and left side of the 45
degree line respectively. The diamonds represent the weight pa-
rameters (W), the squares are saturation constants (Ks), and the
circles are cooperativity coefficients (n). . . . . . . . . . . . . . . . 88
3.5 Sensitivity analysis comparing ATRA and D3 induced HL60 dif-
ferentiation. The parameters are ranked ordered from low to
high sensitivity with the parameters that are more sensitive for
ATRA and D3 treatment fall on the right and left side of the 45
degree line respectively. The diamonds represent the weight pa-
rameters (W), the squares are saturation constants (Ks), and the
circles are cooperativity coefficients (n). . . . . . . . . . . . . . . . 89
3.6 Sensitivity analysis comparing D3 and combination induced
HL60 differentiation. The parameters are ranked ordered from
low to high sensitivity with the parameters that are more sensi-
tive for D3 and combination treatment fall on the right and left
side of the 45 degree line respectively. The diamonds represent
the weight parameters (W), the squares are saturation constants
(Ks), and the circles are cooperativity coefficients (n). . . . . . . . 90
3.7 The frequency of off-axis appearance of ranked-order sensitivity
comparison between different treatments. The grey circle indi-
cate ATRA vs D3 comparison, with ATRA sensitive parameters
in the positive region and D3 sensitive parameters in the neg-
ative. The blue data is the ATRA vs combination comparison,
while the red is the D3 vs combination comparison. . . . . . . . 91
3.8 Log of the 36 cost functions associated all three treatment plot-
ted for three different 495-parameter-set-ensemble. Blue is the
ensemble generated using parameter estimation, red and purple
are ensembles generated randomly and using Sobol sequences
respectively. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
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4.1 Phenotypic analysis of HL-60 cells treated with RA/bosutinib.
(A) HL-60 cells were cultured in the presence of 1RA or 1RA
and 0.25bosutinib as indicated. CD38 expression was assessed
by flow cytometry following 24, 48, and 72h treatment periods.
Gating to discriminate positive cells was set to exclude 95% of
untreated controls (n=3). Error bars indicate SEM. (B) Normal-
ized means of CD38 expression per cell at 24, 48, or 72h (n=3). (C)
CD11b expression was assessed by flow cytometry at 48 and 72h
(n=3). *p¡.05 comparing RA-treated samples to RA/bosutinib-
treated samples. Two-tailed paired-sample t-tests were used to
determine significance. (D) Normalized means of CD11b expres-
sion per cell at 48and 72h (n=3). *p¡.05 comparing RA-treated
samples to RA/bosutinib-treated samples. (E) Cell cycle dis-
tribution showing the percentage of cells in G1/G0 was ana-
lyzed using flow cytometry with propidium iodide staining at
24, 48, and 72h (n=4). *p¡.05 comparing RA-treated samples to
RA/bosutinib-treated samples. (F) Cell counts were taken at 24,
48, and 72h using a hemocytometer and 0.2% Trypan Blue exclu-
sion staining (n=3). . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
4.2 HL-60 cells treated with RA/bosutinib displayed enhanced res-
piratory burst and p47phox expression. (A) HL-60 cells were
cultured in the presence of 1RA or 1RA and 0.25bosutinib as in-
dicated. Respiratory burst was analyzed by measuring inducible
reactive oxygen species (ROS) production by flow cytometry us-
ing the 2,7-dichlorofluorescein (DCF) assay. Gates to determine
percent increase of expression with treatment were set to exclude
95% of the DMSO-treated control population for each culture
condition; TPA-treated samples show induced ROS (n=3). Er-
ror bars indicate SEM. *p¡.05 comparing RA-treated samples to
RA/bosutinib-treated samples. Two-tailed paired-sample t-tests
were used to determine significance. (B) HL-60 cells were cul-
tured for 48h in the presence of 1RA or 1RA and 0.25B as in-
dicated and whole cell lysate was collected. Twenty five micro-
gram of lysate per lane was run. Western blots of PAGE-resolved
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CHAPTER 1
INTRODUCTION
1.1 Mathematical Modeling of Biological Networks
The use of computational tools and mathematical modeling has long con-
tributed to our understanding of biochemical networks, in particular, there is a
long history of quantitative mechanistic modeling [6]. Currently, there are many
existing mathematical approaches to characterize biochemical networks such as
cellular metabolism and its regulation [26, 71, 51, 8, 152, 180, 138, 186, 36, 247].
The two modeling approaches that will be discussed in this work are the kinetic
modeling and constraint-based modeling approaches.
1.1.1 Kinetic Modeling
Kinetic models are constructed by creating a mathematical representation of bi-
ological interactions of a network. This approach is one of the most common
modeling approaches for signaling transaction networks using mass action ki-
netics. ODE kinetic models often require extensive prior knowledge of network
structure, rate constants and initial conditions [131]. An example of how ODE
models can be implemented is shown in Fig 1.1. Using this methodology, Lauf-
fenburger and coworkers developed early biophysical and kinetic models of
epidermal growth factor receptor (EGFR) signaling in fibroblastic cells and in-
terleukin 2 receptor signaling in T-cells [78, 214]. Additional ODE models were
developed focusing on downstream signaling due to the presence of growth
factors and its effect on cell fate decisions [200, 132]. ODE models have also
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been used in the studies of enzyme facilitated reaction networks. For instance,
the human complement system is a complex system where proteases cleave in-
active substrate into active product (Fig.1.2). Interestingly, these active prod-
ucts can combine to produce new proteases that facilitate downstream reactions
therefore acting as a species and an enzyme.
Complement is an important pathway in innate immunity. The complement
cascade involves many soluble and cell surface proteins, receptors and regu-
lators [239, 240]. Traditionally, complement models have been formulated as
systems of linear or non-linear ordinary differential equations (ODEs). For ex-
ample, Hirayama et al., modeled the classical complement pathway as a system
of linear ODEs [95], while Korotaevskiy and co-workers modeled the classical,
lectin and alternative pathways as a system of non-linear ODEs [139]. More
recently, large mechanistic models of sections of complement have also been
proposed. For example, Liu et al., analyzed the formation of the classical and
lectin C3 convertases, and the regulatory role of C4BP using a system of 45 non-
linear ODEs with 85 parameters [154]. Zewde and co-workers constructed a
detailed mechanistic model of the alternative pathway which consisted of 107
ODEs and 74 kinetic parameters and delineated between the fluid, host and
pathogen surfaces [259]. Recently, we estimated an ensemble of experimentally
validated reduced order complement models using multiobjective optimization
[197]. The modeling approach combined ordinary differential equations with
logical rules to produce a complement model with a limited number of equa-
tions and parameters. Although we will not discuss the model in detail for this
thesis, this earlier work of reduced-ordered modeling in combination with log-
ical rules was the foundation of much of the work presented in this thesis.
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Figure 1.1: Schematic of how a system of ordinary differential equations
(ODEs) are implemented to represent a network of biological
interactions. The rate of change with respect to time of each in-
dividual species is represented by a mass balances. The rate of
accumulation or depletion of the species are determined by the
rate of reactions. The diagram shows an example of a substrate
(S) being converted to product (P) at the rate of v1, while the
presence of drug (D) inhibits the reaction.
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Figure 1.2: Simplified schematic of the human complement system. The
complement cascade is activated through three pathways: the
classical, the lectin, and the alternative pathways. Comple-
ment initiation results in the formation of classical or alterna-
tive C3 convertases, which amplify the initial complement re-
sponse and signal to the adaptive immune system by cleaving
C3 into C3a and C3b. C3 convertases further react to form C5
convertases which catalyze the cleavage of the C5 complement
protein to C5a and C5b. C5b is critical to the formation of the
membrane attack complex (MAC), while C5a recruits an adap-
tive immune response.
4
1.1.2 Constraint-based Modeling
As discussed above, there are many existing mathematical approaches to char-
acterize biochemical networks such as cellular metabolism and its regulation
[26, 71, 51, 8, 152, 180, 138, 186, 36, 247]. However, many of these methods re-
quire detailed kinetic and concentration information that are difficult or even
impossible to obtain. Even with the growing data bases for cellular components
and development of new reduced order modeling approaches [198], the appli-
cations of many mechanistic modeling methods are limited by the lack of kinetic
and concentration information.
To overcome the lack of kinetic information, alternative course-grained mod-
eling approaches have been used to study flux distributions of metabolic net-
works. In the post-genomics era, large-scale stoichiometric reconstructions of
microbial metabolism popularized by static, constraint-based modeling tech-
niques such as flux balance analysis (FBA) have become standard tools [146].
Since the first genome-scale reconstruction of Escherichia coli MG1655 by Ed-
wards and Palsson [62], the reconstruction of over 100 organisms has followed
[69]. These organisms included prokaryotes such as E. coli [68] or B. subtilis [182]
were highly sought after in bioprocessing to maximize yields of desired prod-
ucts. More recently, network reconstructions have been completed on humans
as well [55, 226]. FBA is a course-grained modeling approach that relies on a
pseudo-steady-state assumption to reduce unidentifiable kinetic models into an
underdetermined linear algebraic system that can be solved efficiently even for
large systems. Traditionally, FBA models lack descriptions of metabolic regula-
tion and control mechanisms that cells need for adapting to different chemical
and environmental stimulus. FBA models instead chooses pathways in the net-
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work by prescribing an objective function on metabolism. The use of an objec-
tive function is crucial for FBA models since predictions are highly dependent
on the objective function used for the analysis. Common objective functions
include maximizing growth [146, 161, 24, 61, 230], ATP production [191], and
the production of desired products [233]. The utilization of objective function
in FBA models is a huge advantage over mechanistic models because with little
to no kinetic parameters, the maximization of biomass production allows for a
wide range of predictions that are consistent with experimental observations for
microbial systems [146, 161, 199, 59, 108, 41, 60, 24].
In the last decade, FBA has increased in accuracy and utility by incorpo-
rating additional biological knowledge from regulatory constraints, thermody-
namics, and alternative classes of objective functions [130]. Second generation
FBA models initially approached regulatory constraints as Boolean logic op-
erators [41] that arise based on environmental cues. Palsson and coworkers
took a bioinformatics approach and incorporated transcription and translation
through the use of the E-Matrix to regulate the metabolism [225]. Meanwhile
other second generation FBA models focused on incorporating constraints at a
physiological level through the use of crowding constraints, enzyme solubility,
or membrane economics that constrain the upper limit on the sum of certain or
all the flux vectors [10, 210, 262]. The accuracy of the prediction from constraint-
based models such as FBA is based heavily on the constraints implemented to
reduced the solution space. Second generation FBA models introduce addi-
tional constraints that reshape and reduce the solution space to redirect the flux
distribution guided by the objective function in a way that more accurately de-
scribe biological behaviors.
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Recently, constraint-based modeling like flux balance analysis has been im-
plemented to optimize the production of small molecules or biologics. Genome-
scale reconstructions for human has been achieved by Palsson and coworkers
[56] and adopted in studies of cancer metabolism [210, 263, 204]. In one of our
previous work, Multi-scale computational study of the Warburg effect, reverse
Warburg effect and glutamine addiction in solid tumors, we took a multi-scale
modeling approach to describe the intracellular, cellular,and multicellular be-
haviors of cells within a tumor (Fig. 1.4). With this framework, we investi-
gated the following hypotheses: Warburg Effect/Aerobic glycolysis, Reverse
Warburg, and Glutamine Addiction. We begin by translating hypotheses from
experimental studies into constraints and objectives within the FBA (Fig.1.4 A).
We used FBA to obtain the yield coefficients (Y = maximum growth rate/flux of
metabolite) for use in Monod-like kinetics of cellular growth at the individual
cell level (Fig.1.4B). Finally, we simulated the growth dynamics of these cells at
the multicellular scale to elucidate the implications of these metabolic scenar-
ios (Fig.1.4BC). We addressed the impact of the metabolic phenotypes implied
by current hypotheses on the growth dynamics of tumor cells in the resource-
limited microenvironments that emerge after tumor initiation. This modeling
framework opened a new avenue to explore the impact of different metabolic
profiles at a tissue-scale.
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Figure 1.4: (Caption next page.)
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Figure 1.4: (Previous page.) Multi-scale modeling of cancer metabolism
[204]. (A) Flux Balance Analysis (FBA). The arrows repre-
sent fluxes of species within a reduced representation of cell
metabolism and cell growth. Key steps associated with three
hypotheses are labeled: (1) Warburg effect, (2) Reverse War-
burg and (3) Glutamine addiction. The uptake and production
rates are qi/n [g/g-DW-hr] for the ith metabolite and the nth
metabolic phenotype. We impose the maximum growth rate, ,n
[hr-1], for a given metabolic phenotype of each cell type as an
objective function within the FBA. (B) Cell: Biomass (Xm [g])
growth of each cell type is modeled as a Monod-like process
parameterized by the same maximum growth rates used in
FBA that are modulated by functions of metabolite concentra-
tions, fn(Cj)Monod. The change in Volume of the cell (Vm [L])
is calculated from biomass growth by applying a constant den-
sity of the cell ([g-DW/L]). Yield coefficients (Yi/n [g-DW/g])
for each metabolite (i) and corresponding metabolic pheno-
type (n) are defined in terms of the uptake and production
rates (qi/n) obtained from FBA. Extracellular space: Species
balances for each explicit metabolite follow reaction-diffusion
kinetics and govern the concentration profiles of metabolite at
the multicellular scale. These equations (Eqs 1-4 in text) are in-
tegrated into and solved within an agent-based model (ABM;
iDynoMiCS). (C) ABM simulations: i) Radial, two dimensional
growth: Tumor cells grow radially out from an initial cluster of
cells with metabolites supplied at the edge of the cell mass such
that radial gradients of concentration emerge (color map;red is
high and blue is low concentration). Two phenotypes are dis-
played (red: tumor cells and blue: stromal cells). As the tumor
grows, concentration gradients of metabolites become signifi-
cant, making the tumor growth a diffusion-limited process that
can result in different growth dynamics as well as distinct spa-
tial distribution of cell subpopulations. ii) Axial, one dimen-
sional growth: Layers of tumor cells (red) and stromal cells
(blue) are initiated near a blood vessel that supplies metabolites
(from the top), such as glucose and oxygen in the blood stream.
Growth pushes cells deeper into the tissue, away from the ves-
sel, such that strong gradients of metabolite can again occur.
iii) Krogh length calculation: To evaluate the impact of diffu-
sion limitations in a simple model, we treat cells as continuum
with uniform, zeroth order kinetics of metabolite consumption
to calculate the distance over which the concentration of limit-
ing metabolites falls to zero within the tumor mass; we refer to
this distance as the Krogh length of a given metabolite.
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1.2 Current Approach in Cancer Therapy
Cancer is an umbrella term that encompasses a collection of related diseases.
Douglas Hanahan and Robert Weinburg characterized that the hallmarks of
cancer comprise six biological capabilities acquired during the multistep devel-
opment of human tumors [87].They include sustaining proliferative signaling,
evading growth suppressors, resisting cell death, enabling replicative immor-
tality, inducing angiogenesis, and activating invasion and metastasis.
The National Cancer Institute divides cancer into solid and liquid cancers.
At the tissue level, solid cancers can aggregate and form solid tumours, which
can be benign and malignant. Benign tumors can grow large, however they can
be surgically removed and will not return, whereas malignant tumors some-
times do. As opposed to benign tumors, malignant tumors grow they can
metastasize by breaking off and traveling to distant sites in the body through
the blood or the lymph system and form new tumors far from the original tu-
mor. At the tissue level, therapeutic interventions are aimed to prevent tumors
from metastasizing with anti-angiogentic compounds that targets Vascular en-
dothelial growth factor and Vascular endothelial growth factor receptors.
At the intracellular level, there are a multitude of combinations of genetic
mutation that can contribute to the hallmarks of cancer. For instance tumor
cells alter their metabolism to maintain unregulated cellular proliferation and
survival, but this transformation leaves them reliant on constant supply of nu-
trients and energy [231]. In addition to dysregulated glucose metabolism for
growth, accumulating evidences suggest that utilization of amino acids and
lipids contributes significantly to cancer cell metabolism [231].
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There currently exist a wide range of clinical interventions that targets can-
cers in different stages with different modalities. The most common treatments
involve chemotherapy. Most of the chemotherapeutic agents available for can-
cer treatment function by interfering with cell division or DNA synthesis. Based
on their mechanism of action (MOA), chemotherapeutic agents can be catego-
rized as alkylating agents, antimetabolites, anthracyclines, topoisomerase in-
hibitors and plant alkaloids. Due to the detrimental side effects and subtypes of
cancer that are not effect by tradition chemotherapies, there have been a great
amount of effort devoted into developing targeted therapies.
Targeted therapies can modulate a variety of biological functions. Hormone
therapies attempt to inhibit the growth of hormone-sensitive tumors such as
prostate cancer [1]. Hormone therapies can work by inhibiting the native pro-
duction of the hormone or interfering with the action of the hormone post pro-
duction. However, cancers that are initially sensitive to hormone therapy can
develop resistance and become unresponsive. For instance, Rogers and cowork-
ers leveraged computational modeling to study castrate resistance prostate can-
cer [129]. Other modalities of therapy are required when hormone therapy is not
responsive or not applicable to the tumor type. Cells uses signal transduction
networks to relay information sensed from their surrounding, whether chemical
or physical. However in cancer, often times the receptors that sense chemical or
physical cues, or associated signaling molecules, become mutated and deregu-
lated leading to a constant activation. Signal transduction inhibitors attenuates
signaling molecules from activating downstream pathways that regulate the ex-
pression of oncogenes or tumor suppressors. Gene expression modulators mod-
ify the function of proteins that play a role in controlling gene expression. There
are many other therapies that targets different aspects of disease progression
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such as: angiogeneis inhibitors, immunotherapies, antibodies, apoptosis induc-
ers, and cancer vaccines. Recently, there has been a growth in the development
of targeted therapies aimed at the metabolism.
1.3 Cancer Metabolism
Cancer cells are known to rewire their metabolism to promote growth, sur-
vival, and long-term maintenance. Although cancer is a genetically diverse
disease, the common feature of this altered metabolism is increased glucose
uptake, and fermentation of glucose to lactate in the presence of oxygen per-
sists. This phenomenon was first observed by Otto Warburg in the 1920s, who
later proposed that dysfunctional mitochondria is the root of aerobic glycolysis
[243] and further hypothesized that this event is the primary cause of cancer.
This phenomenon, later known as the Warburg Effect, is thought to be required
for tumor growth [65, 209]. Until recently, the majority of studies of cancer
metabolism focused on glucose metabolism, specifically the increased conver-
sion of glucose to lactate. In addition to glycolysis, this observation showed that
mammalian cells rely on both glucose and glutamine, and some cancer cells also
exhibited addiction to glutamine despite the fact that it is a nonessential amino
acid that can be synthesized from glucose. The high rate of glutamine uptake
exhibited by glutamine-dependent cells does not appear to result solely from its
role as a nitrogen donor in nucleotide and amino acid biosynthesis. In addition
to its role in replenishing carbon in the TCA cycle, glutamine also contributed
to a wide range of pathways in cells, producing amino acids, nucleotides and
fatty acids, as well as playing an important role in reactive oxygen species (ROS)
homeostasis, mTOR activation, and the hexosamine biosynthesis pathway [216].
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Metabolism is regulated by signaling events upstream that informs cel-
lular decision making. For example, phosphoinositide 3-kinase (PI3K) sig-
naling is linked to both growth control and glucose metabolism. The
PI3K/AKT/mTOR pathway is an intracellular signal transduction pathway
that promotes metabolism, proliferation, cell survival, growth and angiogen-
esis in response to extracellular signals. This is mediated through serine and/or
threonine phosphorylation of a range of downstream substrates. Key proteins
involved are phosphatidylinositol 3-kinase (PI3K) and AKT (Protein Kinase B).
The PI3K/AKT/mTOR pathway has many downstream effects and is care-
fully regulated. One important regulatory point of the PI3K-AKT pathway is
the PI3K phosphorylation of phosphatidylinositol (4,5)-bisphosphate (PIP2) to
phosphatidylinositol (3,4,5)-trisphosphate (PIP3) which in turn activates AKT.
Phosphatase and tensin homolog (PTEN) is a mainregulator which converts
PIP3 into PIP2. Simiarily, protein phosphatase 2A (PP2A), which dephospho-
rylates AKT at Thr308, and phosphatase PHLPP, which dephosphorylates Akt
at Ser473, are also two negative regulation proteins. Upon activation (phospho-
rylated at Thr308 and Ser473), AKT can be translocated from the plasma mem-
brane to activate its downstream targets such as mTOR that can effect cell cycle
progression, proliferation, apoptosis, and glucose metabolism. Recent studies
have shown other interactions between signaling and metabolism go beyond
the traditional understanding (ie. signaling induces gene expression that alters
the metabolism). For instance, AKT has recently been shown to directly activate
hexokinase II by phosphorylation at Thr473, leading to increased mitochondria
bound hexokinase II. Interestingly, AKT also interacts with phosphofructose ki-
nase 1 platelet isoform by phosphorylating PFKP at Ser386. This phosphory-
lation inhibits the binding of TRIM21 E3 ligase to PFKP and the subsequent
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ubiquitylation and degradation of PFKP [194, 17].
1.4 HL60 differentiation
Differentiation induction chemotherapy (DIC), using agents such as the vita-
min A derivative all-trans retinoic acid (ATRA), is a promising approach for the
treatment of many cancers [25, 222, 30, 229, 148]. For example, ATRA treatment
induces remission in 80–90% of promyelocytic leukemia (APL) PML-RARα-
positive patients [178], thereby transforming a fatal diagnosis into a manageable
disease [37]. However, remission is sometimes not durable and relapsed cases
exhibit emergent ATRA resistance [244, 73]. To understand the basis of this re-
sistance, we must first understand the ATRA-induced differentiation program.
Toward this challenge, lessons learned in model systems, such as the lineage-
uncommitted human myeloblastic cell line HL-60 reported to closely resemble
patient derived cells [90], could inform our analysis of the differentiation pro-
grams occurring in patients. Patient derived HL-60 leukemia cells have been a
durable experimental model since the 1970’s to study differentiation [18]. HL-
60 undergoes cell cycle arrest and either myeloid or monocytic differentiation
following stimulation; ATRA induces G1/G0-arrest and myeloid differentia-
tion in HL-60 cells, while 1,25-dihydroxy vitamin D3 (D3) induces arrest and
monocytic differentiation. Commitment to cell cycle arrest and differentiation
requires approximately 48 hr of treatment, during which HL-60 cells undergo
two division cycles.
Sustained mitogen-activated protein kinase (MAPK) pathway activation is
a defining feature of ATRA-induced HL-60 differentiation. ATRA drives sus-
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tained activation of the Raf/MEK/ERK pathway, leading to arrest and differ-
entiation [254]. Betraying a feedback loop, MEK inhibition results in the loss
of ERK as well as Raf phosphorylation and the failure to arrest and differenti-
ate in response to ATRA [101]. Retinoic acid (and its metabolites) are ligands
for the hormone activated nuclear transcription factors retinoic acid receptor
(RAR) and retinoid X receptor (RXR) [164]. RAR/RXR activation is necessary for
ATRA-induced Raf phosphorylation [101] in concert with the formation of an
ATRA-induced signalsome complex at the membrane, which drives MAPK ac-
tivation. While the makeup of the signalsome complex is not yet known, we do
know that it is composed of Src family kinases Fgr and Lyn, PI3K, c-Cbl, Slp76,
and KSR, plus transcription factors AhR and IRF1 [33, 205, 208, 255, 165]. Sig-
nalsome activity is driven by ATRA-induced expression of CD38 and putatively
the heterotrimeric Gq protein-coupled receptor BLR1 [32, 241]. Members of the
BLR1 transcriptional activator complex, e.g. NFATc3 and CREB, are phosphory-
lated by ERK, JNK or p38 MAPK family members suggesting positive feedback
between the signalsome and MAPK activation [251, 150]. BLR1 overexpression
enhanced Raf phosphorylation and accelerated terminal differentiation, while
Raf inhibition reduced BLR1 expression and ATRA-induced terminal differen-
tiation [242]. The expression of signalsome components, e.g. BLR1, was Raf
dependent, while Raf activation depended upon the signalsome. A previous
computational study of ATRA-induced differentiation of HL-60 cells suggested
that the BLR1-MAPK positive feedback circuit was sufficient to explain ATRA-
induced sustained MAPK activation, and the expression of a limited number
of functional differentiation markers [223]. Model analysis also suggested that
Raf was the most distinct of the MAPK proteins. However, this previous study
developed and analyzed a complex model, thus leaving open the critical ques-
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tion of what is the minimal positive feedback circuit required to drive ATRA-
induced differentiation. The activation of ATRA bound RARα/RXR regulates
the expression of the transcription factors CCATT/enhancer binding protein α
(C/EBPα), PU.1, and Egr-1. The transcription factors PU.1 and C/EBPα are
master regulators and have positive effects on both granuolytic (ATRA) and
monocytic (vitamin D3) maturation, however their ratio determines granulo-
cytic versus monocyctic lineage selection. Similarly, two antagonistic repres-
sors, Gfi-1 and EGR-1 lie directly downstream of PU.1 and C/EBPα. Gfi-1
represses monocytic differentiation and promotes granulocytic different ion,
while EGR-1 acts conversely. In turn, these transcription factors, in combination
with cRaf-pS621, regulates the expression of downstream phenotypic markers
such as CD38, CD11b or p47Phox.
1.5 Outlook
Although cancer is a genetically diverse disease, a common feature between
the different type of cancers is altered metabolism. Cancer cells rewire their
metabolism to uptake more glucose to produce lactate as an inefficient way of
energy production. We believe that metabolism can be used to better under-
stand the deregulation of signaling and gene expression. There is a great oppor-
tunity to utilize a systems approach to evaluate combination therapy targeting
consisting of different modalities and modes of action. In this work, we lever-
aged our current understanding of signaling transduction, and metabolic net-
works to develop a systems approach to quantitatively unravel the mechanisms
that regulate the hallmarks of cancer. More specifically, we combined a top-
down approach starting from the signaling, and a bottom-up approach from
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the metabolism to better understand how the cells respond to environmental
cues.
In Chapter 2, we utilized our understanding of ATRA-induced differentia-
tion programming in HL-60 cells to develop computational tools that can in-
tegrate signal transduction networks with transcription factor networks. In
Chapter 3, we expanded on this work and explored combination treatment of
ATRA and D3 to further investigate the transcription factor network and treat-
ment specific pathway sensitivity. In Chapter 4, we describe the experimental
exploration of the combination therapies using the SRC family kinase, Bosu-
tinib and ATRA in HL-60 cells. In Chapter 5, we transitioned our focus to-
wards metabolism. We developed a novel constraint-based model that elimi-
nated the pseudo-steady state assumption and captured metabolite dynamics.
In addition, we used this modeling framework to determine the metabolite mea-
surements that contributed to the best model performance. In Chapter 6, we
leveraged our understanding of metabolite selection from our previous studies
and developed analytical techniques to quantify metabolite abundance. Finally,
chapter 7 concludes with future work.
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CHAPTER 2
AN EFFECTIVE MODEL OF THE RETINOIC ACID INDUCED HL-60
DIFFERENTIATION PROGRAM
2.1 Abstract
1 In this study, we present an effective model All-Trans Retinoic Acid (ATRA)-
induced differentiation of HL-60 cells. The model describes reinforcing feed-
back between an ATRA-inducible signalsome complex involving many proteins
including Vav1, a guanine nucleotide exchange factor, and the activation of the
mitogen activated protein kinase (MAPK) cascade. We decomposed the effec-
tive model into three modules; a signal initiation module that sensed and trans-
formed an ATRA signal into program activation signals; a signal integration
module that controlled the expression of upstream transcription factors; and a
phenotype module which encoded the expression of functional differentiation
markers from the ATRA-inducible transcription factors. We identified an en-
semble of effective model parameters using measurements taken from ATRA-
induced HL-60 cells. Using these parameters, model analysis predicted that
MAPK activation was bistable as a function of ATRA exposure. Conformational
experiments supported ATRA-induced bistability. Additionally, the model cap-
tured intermediate and phenotypic gene expression data. Knockout analysis
suggested Gfi-1 and PPARγ were critical to the ATRA-induced differentiation
program. These findings, combined with other literature evidence, suggested
that reinforcing feedback is central to hyperactive signaling in a diversity of cell
fate programs.
1This work is published and adopted from Scientific Reports
https://doi.org/10.1038/s41598-017-14523-5
2.2 Introduction
Differentiation induction chemotherapy (DIC), using agents such as the vita-
min A derivative all-trans retinoic acid (ATRA), is a promising approach for the
treatment of many cancers [25, 222, 30, 229, 148]. For example, ATRA treatment
induces remission in 80–90% of promyelocytic leukemia (APL) PML-RARα-
positive patients [178], thereby transforming a fatal diagnosis into a manageable
disease [37]. However, remission is sometimes not durable and relapsed cases
exhibit emergent ATRA resistance [244, 73]. To understand the basis of this re-
sistance, we must first understand the ATRA-induced differentiation program.
Toward this challenge, lessons learned in model systems, such as the lineage-
uncommitted human myeloblastic cell line HL-60 reported to closely resemble
patient derived cells [90], could inform our analysis of the differentiation pro-
grams occurring in patients. Patient derived HL-60 leukemia cells have been a
durable experimental model since the 1970’s to study differentiation [18]. HL-
60 undergoes cell cycle arrest and either myeloid or monocytic differentiation
following stimulation; ATRA induces G1/G0-arrest and myeloid differentia-
tion in HL-60 cells, while 1,25-dihydroxy vitamin D3 (D3) induces arrest and
monocytic differentiation. Commitment to cell cycle arrest and differentiation
requires approximately 48 hr of treatment, during which HL-60 cells undergo
two division cycles.
Sustained mitogen-activated protein kinase (MAPK) pathway activation is
a defining feature of ATRA-induced HL-60 differentiation. ATRA drives sus-
tained activation of the Raf/MEK/ERK pathway, leading to arrest and differ-
entiation [254]. Betraying a feedback loop, MEK inhibition results in the loss
of ERK as well as Raf phosphorylation and the failure to arrest and differenti-
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ate in response to ATRA [101]. Retinoic acid (and its metabolites) are ligands
for the hormone activated nuclear transcription factors retinoic acid receptor
(RAR) and retinoid X receptor (RXR) [164]. RAR/RXR activation is necessary for
ATRA-induced Raf phosphorylation [101] in concert with the formation of an
ATRA-induced signalsome complex at the membrane, which drives MAPK ac-
tivation. While the makeup of the signalsome complex is not yet known, we do
know that it is composed of Src family kinases Fgr and Lyn, PI3K, c-Cbl, Slp76,
and KSR, plus transcription factors AhR and IRF1 [33, 205, 208, 255, 165]. Signal-
some activity is driven by ATRA-induced expression of CD38 and putatively the
heterotrimeric Gq protein-coupled receptor BLR1 [32, 241]. BLR1 (also known
as CXCR5), identified as an early ATRA (or D3)-inducible gene using differen-
tial display [252], is necessary for MAPK activation and differentiation [241],
and drives signalsome activity. Studies of the BLR1 promoter identified a non-
canonical RARE site consisting of a 17 bp GT box approximately 1 kb upstream
of the transcriptional start that conferred ATRA responsiveness [241]. Mem-
bers of the BLR1 transcriptional activator complex, e.g. NFATc3 and CREB, are
phosphorylated by ERK, JNK or p38 MAPK family members suggesting posi-
tive feedback between the signalsome and MAPK activation [251, 150]. BLR1
overexpression enhanced Raf phosphorylation and accelerated terminal differ-
entiation, while Raf inhibition reduced BLR1 expression and ATRA-induced ter-
minal differentiation [242]. In particular, Raf phosphorylation of the NFATc3
transcription factors at the BLR1 promoter enables transcriptional activation at
the RARE by ATRA bound to RAR/RXR [80]. BLR1 knock-out cells failed to ac-
tivate Raf or differentiate in the presence of ATRA [242]. Interestingly, both the
knockdown or inhibition of Raf, also reduced BLR1 expression and functional
differentiation [242]. Thus, the expression of signalsome components e.g., BLR1
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was Raf dependent, while Raf activation depended upon the signalsome. A
previous computational study of ATRA-induced differentiation of HL-60 cells
suggested that the BLR1-MAPK positive feedback circuit was sufficient to ex-
plain ATRA-induced sustained MAPK activation, and the expression of a lim-
ited number of functional differentiation markers [223]. Model analysis also
suggested that Raf was the most distinct of the MAPK proteins. However, this
previous study developed and analyzed a complex model, thus leaving open
the critical question of what is the minimal positive feedback circuit required to
drive ATRA-induced differentiation.
In this study, we explored this question using a minimal mathematical model
of the key architectural feature of ATRA induced differentiation of HL-60 cells,
namely positive feedback between an ATRA-inducible signalsome complex and
MAPK activation. The ATRA responsive signalsome-MAPK circuit was then
used to drive a downstream gene expression program which encoded for the
expression of intermediate and functional differentiation markers. The effective
model used a novel framework which integrated logical rules with kinetic mod-
eling to describe gene expression and protein regulation, while largely relying
upon biophysical parameters from the literature. This formulation significantly
reduced the size and complexity of the model compared to the previous study
of Tasseff et al., while increasing the breadth of the biology described [223].
The effective model, despite its simplicity, captured key features of ATRA in-
duced differentiation of HL-60 cells. Model analysis predicted the bistability of
MAPK activation as a function of ATRA exposure; conformational experiments
supported ATRA-induced bistability. Model simulations were also consistent
with measurements of the influence of MAPK inhibitors, and the failure of BLR1
knockout cells to differentiate when exposed to ATRA. In addition, the expres-
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sion of intermediate and phenotypic differentiation markers as also captured
following ATRA exposure. Lastly, we showed through immunoprecipitation
and inhibitor studies, that the guanine nucleotide exchange factor Vav1 is poten-
tially a new ATRA-inducible member of the signalsome complex functioning as
a regulator that contributes to signal amplification in the signalsome. Taken to-
gether, these findings when combined with other literature evidence, suggested
that reinforcing feedback was central to differentiation programs generally, and
necessary for ATRA-induced differentiation. The model answers a biologically
important question that is not easily experimentally attacked, namely given the
complexity of the signaling machine and the pathways it embodies, is there a
critical small suite of molecules that are the action elements seminal to eliciting
ATRA-induced cell differentiation and G0 arrest.
2.3 Results
We constructed an effective model of ATRA-induced HL-60 differentiation
which described signaling and gene expression events following the addition
of ATRA (Fig. 5.1). HL-60 is a NCI-60 cell model that is widely used model
for studying the mechanism of action of ATRA. There is an immense body of
literature on HL-60, therefore it was chosen for modeling. For molecules where
there was not explicit HL-60 literature, then literature for well-known interac-
tions from other experimental systems was curated to fill lacuna for the model-
ing. The model connectivity was developed from literature and the studies pre-
sented here (Table 3.1). We decomposed the ATRA program into three modules;
a signal initiation module that sensed and transformed the ATRA signal into
activated cRaf-pS621 and the ATRA-RAR/RXR (Trigger) signals (Fig. 5.1A); a
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signal integration module that controlled the expression of upstream transcrip-
tion factors given cRaf-pS621 and activated Trigger signals (Fig. 5.1B); and a
phenotype module which encoded the expression of functional differentiation
markers from the ATRA-inducible transcription factors (Fig. 5.1C). In particu-
lar, Trigger (a surrogate for the RARα/RXR transcriptional complex) regulated
the expression of the transcription factors CCATT/enhancer binding protein α
(C/EBPα), PU.1, and Egr-1. In turn, these transcription factors, in combination
with cRaf-pS621, regulated the expression of downstream phenotypic markers
such as CD38, CD11b or p47Phox. Each component of these modules was de-
scribed by a mRNA and protein balance equation. Additionally, the signal initi-
ation module also described the abundance of activated species e.g., Trigger and
cRaf-pS621 whose values were derived from unactivated Trigger and cRaf pro-
tein levels. Lastly, because the population of HL-60 cells was dividing, we also
considered a dilution term in all balance equations. The signal initiation mod-
ule contained nine differential equations, while the signal integration and phe-
notype modules were collectively encoded by 54 differential equations. Model
parameters were taken from literature (Table 2.2), or estimated from experimen-
tal data using heuristic optimization (see materials and methods).
The signal initiation module recapitulated sustained signalsome and MAPK
activation following exposure to 1µM ATRA (Fig. 2.2A-B). An ensemble of ef-
fective model parameters was estimated by minimizing the difference between
simulations and time-series measurements of BLR1 mRNA and cRaf-pS621 fol-
lowing the addition of 1µM ATRA. We focused on the S621 phosphorylation site
of cRaf since enhanced phosphorylation at this site is a defining characteristic of
sustained MAPK signaling activation in HL-60. The effective model captured
both ATRA-induced BLR1 expression (Fig. 2.2A) and sustained phosphoryla-
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tion of cRaf-pS621 (Fig. 2.2B) in a growing population of HL-60 cells. Together,
the reinforcing feedback within the signalsome and its embedded MAPK signal-
ing axis led to sustained activation over multiple cellular generations. However,
the effective model failed to capture the decline of BLR1 message after 48 hr of
ATRA exposure. This suggested that we captured the logic leading to the onset
of differentiation, but failed to describe program shutdown. Much of the focus
in the literature has been on understanding the initiation of differentiation, with
little attention paid to understanding how a program is terminated. This is a
potential new direction that could be explored. Next, we tested the response of
the signal initiation module to different ATRA dosages.
The signal initiation model was bistable with respect to ATRA induction
(Fig. 2.2C-D). Phaseplane analysis predicted two stable steady-states when
ATRA was present below a critical threshold (Fig. 2.2C), and only a single
steady-state above the threshold (Fig. 2.2D). In the lower stable state, neither
the signalsome nor cRaf-pS621 were present (thus, the differentiation program
was inactive). However, at the higher stable state, both the signalsome and
cRaf-pS621 were present, allowing for sustained activation and differentiation.
Interestingly, when ATRA was above a critical threshold, only the activated state
was accessible (Fig. 2.2D). To test these findings, we first identified the ATRA
threshold. We exposed HL-60 cells to different ATRA concentrations for 72 hr
(Fig. 2.2E). Morphological changes associated with differentiation were visible
for ATRA ≥ 0.25 µM, suggesting the critical ATRA threshold was near this con-
centration. Next, we conducted ATRA washout experiments to determine if ac-
tivated cells remained activated in the absence of ATRA. HL-60 cells locked into
an activated state remained activated following ATRA withdraw (Fig. 2.3C).
This sustained activation resulted from reinforcing feedback between the sig-
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nalsome and the MAPK pathway. Thus, following activation, if we inhibited
or removed elements from the signal initiation module we expected the signal-
some and MAPK signals to decay. We simulated ATRA induced activation in
the presence of kinase inhibitors, and without key circuit elements. Consistent
with experimental results using multiple MAPK inhibitors, ATRA activation in
the presence of MAPK inhibitors lowered the steady-state value of signalsome
(Fig. 2.3A). In the presence of BLR1, the signalsome and cRaf-pS621 signals were
maintained following ATRA withdraw (Fig. 2.3B, gray). On the other hand,
BLR1 deletion removed the ability of the circuit to maintain a sustained MAPK
response following the withdraw of ATRA (Fig. 2.3B, blue). Lastly, washout
experiments in which cells were exposed to 1µM ATRA for 24 hr, and then
transferred to fresh media without ATRA, confirmed the persistence of the self
sustaining activated state for up to 144 hr (Fig. 2.3C). Thus, these experiments
confirmed that reinforcing positive feedback likely drives the ATRA-induced
differentiation program. Next, we analyzed the ATRA-induced downstream
gene expression program following signalsome and cRaf activation.
The signal integration and phenotype modules described ATRA-induced
gene expression in wild-type HL-60 cells (Fig. 2.4). The signal initiation module
produced two outputs, activated Trigger and cRaf-pS621 which drove the ex-
pression of ATRA-induced transcription factors, which then in turn activated
the phenotypic program. We assembled the connectivity of the signal inte-
gration and phenotypic programs driven by Trigger and cRaf-pS621 from lit-
erature (Table 3.1). We estimated the parameters for the signal initiation, and
phenotype modules from steady-state and dynamic measurements of transcrip-
tion factor and phenotypic marker expression following the addition of ATRA
[117, 114, 116, 119]. However, the bulk of the model parameters were taken from
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literature [172] and were not estimated in this study (see materials and meth-
ods). The model simulations captured the time dependent expression of CD38
and CD11b following the addition ATRA (Fig. 2.4A), and the steady-state for
signal integration and phenotypic markers (Fig. 2.4B). Lastly, we used the pre-
dicted values of the p21 and E2F protein abundance to estimate a blackbox model
of ATRA-induced G0 arrest (Fig. 2.5). The phenotype module predicted p21 ex-
pression significantly increased and E2F expression decreased, in response to
ATRA exposure (Fig. 2.5A). We then used the ratio of these values in a poly-
nomial model to calculate the fraction of HL-60 cells in G0 arrest following the
addition of ATRA (Fig. 2.5B). The third-order polynomial model captured the
trend in measured G0-arrest values as a function of time, and was robust to un-
certainty in the measured data (Fig. 2.5B, gray). Taken together, the output of
the signal integration and phenotypic modules was consistent with time-series
and steady-state measurements, thereby validating the assumed molecular con-
nectivity. Moreover, outputs from the phenotype module described the trend in
ATRA-induced G0 cell cycle arrest. Next, we explored which proteins and pro-
tein interactions in the signal integration module most influenced the system
response.
The Gfi-1 and PPARγ proteins were important regulators of ATRA-induced
signal integration and phenotypic change (Fig. 2.6). We conducted pairwise
gene knockout simulations in the signal integration and phenotype modules to
estimate which proteins controlled the processing of the Trigger and cRaf-S621
signals. The difference between the system state with and without the gene
knockouts (encoded as a normalized state displacement matrix) was decom-
posed using Singular Value Decomposition (SVD). A panel of ten parameter
sets was sampled, and the average normalized displacement matrix was de-
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composed. The first six modes (approximately 36% of the total) described >95%
of the gene knockout variance, with the most important components of these
modes being the Gfi-1 and PPARγ proteins, and to a lesser extent PU.1, C/EBPα
and and AP1 (Fig. 2.6A). To better understand which protein-DNA connections
were important, we simulated the pairwise deletion of interactions between
these proteins and their respective regulatory targets. Singular value decompo-
sition of the normalized state displacement matrix assembled from the pairwise
connection deletions, suggested the first six modes (approximately 26% of the
total) accounted for >90% of the variance. Globally, the most sensitive interac-
tions controlled p47Phox and p21 expression, markers for cell-cycle arrest and
reactive oxygen formation phenotypic axes activated following ATRA addition
(Fig. 2.6B). While the p21 spot appeared small, it was the second highest ranked
response behind p47Phox, in the largest response mode. The interactions as-
sociated with these shifts likely involved important components; the deleted
interactions involved the action of PU.1, C/EBPα and cRaf at both the p47Phox
and p21 promoters, as well as PPARγ action for p21. Taken together, the gene
and interaction knockout studies showed that the action of PPARγ, Gfi-1 and
C/EBPα was consistently important over multiple target genes. The connection
knockout analysis also revealed robustness within the network. For example,
no pair of deletions qualitatively changed the expression of regulators such as
PU.1, Oct1, Oct4 or PPARγ. Thus, the expression of these species was robust to
disturbance in the connectivity. To better understand the combined influence
of the PPARγ and Gfi-1 deletions, we computed the fold change in the protein
levels in the single (Gfi-1−/− or PPARγ−/−) and double (Gfi-1−/− and PPARγ−/−)
mutants for the best fit parameter set (Fig. 2.7). Deletion of Gfi-1 led to a 2-4
fold increase in EGR-1, CD11b and C/EBPα expression, and a >8 fold increase
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in PU.1 abundance (Fig. 2.7,blue). On the other hand, deletion of PPARγ led
to >8 fold downregulation of CD38, p21, IRF1 and Oct1 (Fig. 2.7,red). Both
knockouts slightly increased E2F expression, but neither influenced the expres-
sion of p47Phox. The double mutant was qualitatively similar to the combined
behavior of the two single mutant cases. Taken together, Gfi-1 and PPARγ con-
trolled the cell-cycle arrest and receptor signaling axes, with PPARγ regulating
CD38, IRF1 and p21 expression while Gfi-1 controlled CD11b expression. These
simulations suggested deletion of PPARγ and Gfi-1 would not interfere with
reactive oxygen formation, but would limit the ability of HL-60 cells to arrest.
However, this analysis did not give insight into which components upstream of
the signal initiation module were important. Toward this question, we explored
the composition and regulation of the signalsome complex by experimentally
interrogating a panel of possible Raf interaction partners.
The full composition of the signalsome, and the kinase therein ultimately re-
sponsible for mediating ATRA-induced Raf activation is still not known. To ex-
plore this question, we conducted immunoprecipitation and subsequent West-
ern blotting to identify interactions between Raf and 19 putative interaction
partners. A panel of 19 possible Raf interaction partners (kinases, GTPases,
scaffolding proteins etc) was constructed based upon known signaling path-
ways. We did not consider the most likely binding partner, the small GTPase
RAS, as previous studies have ruled it out in MAPK activation in HL-60 cells
[242, 126]. Total Raf was used as a bait protein for the immunoprecipitation
studies. Interrogation of the Raf interactome thus suggested Vav1 was involved
with ATRA-induced initiation of MAPK activity (Fig. 2.8). Western blot anal-
ysis using total Raf and Raf-pS621 specific antibodies confirmed the presence
of the bait protein, total and phosphorylated forms, in the immunoprecipitate
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(Fig. 2.8A). Of the 19 proteins sampled, Vav1, Src, CK2, Akt, and 14-3-3 co-
precipitated with Raf, suggesting their co-existence in a complex was possible.
However, only the associations between Raf and Vav1, and Raf and Src were
ATRA-inducible (Fig. 2.8). The interaction between Vav1 and Raf was one of
the most prominent interactions in the panel, and it was crippled by inhibiting
Raf. Furthermore, the Vav1 and Src associations were correlated with Raf-pS621
abundance in the precipitate. Other proteins e.g., CK2, Akt and 14-3-3, gener-
ally bound Raf regardless of phosphorylation status or ATRA treatment. The
remaining proteins sampled were expressed in whole cell lysate (Fig. 2.8B), but
were not detectable in the immuno-precipitate with Raf IP; consistent with the
potential importance of the Raf-Vav interaction for signaling, it paralleled Raf
phosphorylation at S621, a putative telltale of the activated kinase. Further-
more, treatment with the Raf kinase inhibitor GW5074 following ATRA expo-
sure reduced the association of both Vav1 with Raf and Src with Raf (Fig. 2.8C),
although the signal intensity for Src was notably weak. However, GW5074 did
not influence the association of CK2 or 14-3-3 with Raf, further demonstrating
their independence from Raf phosphorylation. Interestingly, the Raf-Akt inter-
action qualitatively increased following treatment with GW5074; however, it
remained unaffected by treatment with ATRA. Src family kinases are known
to be important in myeloid differentiation [173] and their role in HL-60 differ-
entiation has been investigated elsewhere [33]. Given the existing work and
variable reproducibility in the context of the Raf immunoprecipitate, we did not
investigate the role of Src further in this study. Taken together, the immunopre-
cipitation and GW5074 results implicated Vav1 association to be correlated with
Raf activation following ATRA-treatment. Further, while we observed possible
immunoprecipitation of Src with Raf, the western blot results showed inconsis-
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tent results and significant non-specific binding; therefore we could not rule in
or out a Src/Raf interaction. Previous studies demonstrated that a Vav1-Slp76-
Cbl-CD38 complex plays an important role in ATRA-induced MAPK activation
and differentiation of HL-60 cells [208]. Here we did not observe direct interac-
tion of Raf with Cbl or Slp76; however, this interaction could could be involved
upstream. Next, we considered the effect of the Raf kinase inhibitor GW5074 on
functional markers of ATRA-induced growth arrest and differentiation.
Inhibition of Raf kinase activity modulated MAPK activation and differen-
tiation markers following ATRA exposure (Fig. 2.8D-F). ATRA treatment alone
statistically significantly increased the G1/G0 percentage over the untreated
control, while GW5074 alone had a negligible effect on the cell cycle distribution
(Fig. 2.8D). Surprisingly, the combination of GW5074 and ATRA statistically
significantly increased the G1/G0 population (82 ± 1%) compared with ATRA
alone (61 ± 0.5%). Increased G1/G0 arrest following the combined treatment
with GW5074 and ATRA was unexpected, as the combination of ATRA and
the MEK inhibitor (PD98059) has been shown previously to decrease ATRA-
induced growth arrest [254]. However, growth arrest is not the sole indication
of functional differentiation. Expression of the cell surface marker CD11b has
also been shown to coincide with HL-60 cells myeloid differentiation [94]. We
measured CD11b expression, for the various treatment groups, using immuno-
fluorescence flow cytometry 48 hr post-treatment. As with G1/G0 arrest, ATRA
alone increased CD11b expression over the untreated control, while GW5074
further enhanced ATRA-induced CD11b expression (Fig. 2.8E). GW5074 alone
had no statistically significant effect on CD11b expression, compared with the
untreated control. Lastly, the inducible reactive oxygen species (ROS) response
was used as a functional marker of differentiated neutrophils [32]. We measured
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the ROS response induced by the phorbol ester 12-O-tetradecanoylphorbol-13-
acetate (TPA) using flow cytometry. Untreated cells showed no discernible TPA
response, with only 7.0 ± 3.0% ROS induction (Fig. 2.8F). Cells treated with
ATRA had a significantly increased TPA response, 53 ± 7% ROS induction 48
hr post-treatment. Treatment with both ATRA and GW5074 statistically signif-
icantly reduced ROS induction (22 ± 0.6%) compared to ATRA alone. Interest-
ingly, Western blot analysis did not detect a GW5074 effect on ATRA-induced
expression of p47Phox, a required upstream component of the ROS response
(Fig. 2.8F, bottom). Thus, the inhibitory effect of GW5074 on inducible ROS
might occur downstream of p47Phox expression. However, the ROS producing
complex is MAPK dependent, therefore it is also possible that GW5074 inhib-
ited ROS production by interfering with MAPK activation (in which case the
p47Phox marker might not accurately reflect phenotypic conversion and differ-
entiation).
2.4 Discussion
In this study, we presented an effective model of ATRA-inducible differentiation
of HL-60 cells. The model consisted of three modules: a signal initiation module
that sensed and transformed the ATRA signal into activated cRaf-pS621 and the
ATRA-RAR/RXR (Trigger) signals; a signal integration module that controlled
the expression of upstream transcription factors given cRaf-pS621 and activated
Trigger signals; and a phenotype module which encoded the expression of func-
tional differentiation markers from the ATRA-inducible transcription factors.
The model described the transcription and translation of genes in each mod-
ule, and signaling events in each module in a growing population of HL-60
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cells. Model parameters were taken from literature, however, unknown coef-
ficients that appear in the promoter logic models were estimated from protein
measurements in HL-60 cells following ATRA exposure. Despite its simplicity,
the effective model captured key features of the ATRA induced differentiation
such as sustained MAPK activation, and bistability with respect to ATRA expo-
sure. The model also described the expression of upstream transcription factors
which regulated the expression of differentiation markers. Lastly, analysis of
the response of the model to perturbations identified Gfi-1 and PPARγ as mas-
ter regulators of ATRA-induced differentiation. We also found evidence of a
prominent regulatory role for a signaling molecule ATRA-inducible component
of the signalsome, Vav1. Vav1 is a guanine nucleotide exchange factor for Rho
family GTPases that activate pathways leading to actin cytoskeletal rearrange-
ments and transcriptional alterations [102]. The Vav1/Raf association correlated
with Raf activity, was ATRA-inducible and decreased after treatment with the
Raf inhibitor GW5074.
Naturally occurring cell fate decisions often incorporate reinforcing feed-
back and bistability [72, 142]. One of the most well studied cell fate circuits
is the Mos mitogen-activated protein kinase cascade in Xenopus oocytes. This
cascade is activated when oocytes are induced by the steroid hormone proges-
terone [249]. The MEK-dependent activation of p42 MAPK stimulates the ac-
cumulation of the Mos oncoprotein, which in turn activates MEK, thereby clos-
ing the feedback loop. This is similar to the signal initiation module presented
here; ATRA drives signalsome formation, which activates MAPK, which in turn
leads to more signalsome activation. Thus, while HL-60 andXenopus oocytes are
vastly different biological models, their cell fate programs share a similar archi-
tectural feature. Reinforcing feedback and bistability has also been implicated
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in hematopoietic cell fate determination. Laslo et al showed in nonmalignant
myelomonocytic cells that the counter antagonistic repressors, Gfi-1 and Egr-
1/2 (whose expression is tuned by PU.1 and C/EBPα), encode a bistable switch
that results in a macrophage, neutrophil or a mixed lineage population depend-
ing upon PU.1 and C/EBPα expression [142]. The current model contained the
Gfi-1 and Egr-1/2 agonistic switch; however, its significance was unclear for
HL-60 cells. The expression of Gfi-1, Egr-1/2, C/EBPα and PU.1 was not con-
sistent with the canonical lineage pattern expected from literature. For example,
Egr-1/2 expression (associated with a macrophage lineage) increased, while Gfi-
1 expression (associated with a neutrophil lineage) was unchanged following
ATRA exposure. Thus, HL-60 cells, which are a less mature cancer cell line, ex-
hibited a non-canonical expression pattern. Other unrelated cell fate decisions
such as programmed cell death have also been suggested to be bistable [5]. Still
more biochemical networks important to human health, for example the human
coagulation or complement cascades, also feature strong positive feedback ele-
ments [158]. Thus, while reinforcing feedback is often undesirable in human
engineered systems, it is at the core of a diverse variety of cell fate programs
and other networks important to human health.
Analysis of the signal integration and phenotype modules suggested Gfi-1
and PPARγ proteins were important regulators of ATRA-induced signal inte-
gration and phenotypic change. Model analysis showed that PU.1, Egr-1 and
C/EBPα expression increased in Gfi-1−/− mutants, where PU.1 expression was
upregulated by greater than 8-fold. Simulations suggested that combined Gfi-
1 + PPARg deletion crippled the ability of HL-60 cells to undergo neutrophilic
differentiation and function following ATRA exposure. This confirms previ-
ous literature showing that Gfi-1 KO mice lack normal neutrophils [98]. PU.1,
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a member of the ets transcription factor family, is a well known regulator of
granulocyte and monocyte development [76]. The relative level of PU.1 and
C/EBPα is thought to control macrophage versus neutrophil cell fate decisions
in granulocytic macrophage progenitor cells [43]. Simulations suggested that
combined Gfi-1 + PPARγ deletion crippled the ability of HL-60 cells to un-
dergo neutrophilic differentiation following ATRA exposure. p21 expression
decreased significantly, suggesting Gfi-1−/− + PPARγ−/− mutants were less likely
to G0-arrest following ATRA exposure. The expression of other neutrophilic
markers, such as CD38, also decreased in Gfi-1−/− + PPARγ−/− cells. On the other
hand, the expression of reactive oxygen metabolic markers, or other important
transcription factors such as Oct4 did not change. For example, model anal-
ysis suggested that the C/EBPα dependent interaction of PU.1 with the NCF1
gene, which encodes the p47Phox protein, was the most sensitive PU.1 connec-
tion; deletion of this connection removed the ability of the system to express
p47Phox. p47Phox, also known as neutrophil cytosol factor 1, is one of four
cytosolic subunits of the multi-protein NADPH oxidase complex found in neu-
trophils [63]. This enzyme is responsible for reactive oxygen species (ROS) pro-
duction, a key component of the anti-microbial function of neutrophils. While
p47Phox expression required C/EBPα and PU.1, neither Gfi-1 nor PPARγ dele-
tion increased expression. This suggested that p47Phox expression was satu-
rated with respect to C/EBPα and PU.1, and simultaneously not sensitive to
PPARγ abundance. Taken together, Gfi-1−/− + PPARγ−/− cells were predicted to
exhibit some aspects of the ATRA response, but not other critical features such
as cell cycle arrest. Hock et al showed that Gfi-1−/− mice lacked normal neu-
trophils, and were highly sensitive to bacterial infection [98]. Thus, the model
analysis was consistent with this study. However, other predictions concerning
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the behavior of the Gfi-1−/− + PPARγ−/− mutants remain to be tested.
Immunoprecipitation studies identified a limited number of ATRA-
dependent and -independent Raf interaction partners. We established potential
interactions between Raf and key partners such as Vav1, Src, Akt, CK2 and 14-
3-3. However, we were unable to detect the association of Raf with common
kinases and GTPases such as PKC, PKA, p38, Rac and Rho as observed in lit-
erature [137, 57]. To investigate the association of c-Raf and PKA or PKC, we
assessed both the expression levels and the associations of those important sig-
naling molecules. Surprisingly, the expression levels of PKA, PKCα and PKCγ
were not ATRA regulated, nor did we detect an association with Raf. We believe
that our current perception of the signaling pathway driving differentiation in
this model is novel. It also diverges from the classical perception in that its acti-
vation is not Ras driven. This has been reported by Katagiri et al that Ras is not
a driver in RA-induced differentiation in HL-60 [127]. Finally, we note that the
classical paradigms were typically derived in NIH3T3 cells where signal dura-
tion is rapid transient. By contrast in HL-60 it is a prolonged MAPK signaling
that drives RA-induced granulocytic differentiation.
All of these partners are known to be associated with Raf activation or func-
tion. Src is known to bind Raf through an SH2 domain, and this association has
been shown to be dependent of the serine phosphorylation of Raf [31]. Thus,
an ATRA inducible Src/Raf association may be a result of ATRA-induced Raf
phosphorylation at S259 or S621. We also identified an interaction between Raf
and the Ser/Thr kinases Akt and CK2. Akt can phosphorylate Raf at S259, as
demonstrated by studies in a human breast cancer line [264]. CK2 can also phos-
phorylate Raf, although the literature has traditionally focused on S338 and not
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S621 or S259[193]. However, neither of these kinase interactions were ATRA-
inducible, suggesting their association with Raf alone was not associated with
ATRA-induced Raf phosphorylation. The adapter protein 14-3-3 was also con-
stitutively associated with Raf. The interaction between Raf and 14-3-3 has been
associated with both S621 and S259 phosphorylation and activity [91]. Addi-
tionally, the association of Raf with 14-3-3 not only stabilized S621 phosphory-
lation, but also reversed the S621 phosphorylation from inhibitory to activating
[48]. Finally, we found that Vav1/Raf association correlated with Raf activity,
was ATRA-inducible and decreased after treatment with GW5074. The presence
of Vav1 in Raf/Grb2 complexes has been shown to correlate with increased Raf
activity in mast cells [212]. Furthermore, studies on Vav1 knockout mice demon-
strated that the loss of Vav1 resulted in deficiencies of ERK signaling for both
T-cells as well as neutrophils [40, 84]. Interestingly, while an integrin ligand-
induced ROS response was blocked in Vav1 knockout neutrophils, TPA was
able to bypass the Vav1 requirement and stimulate both ERK phosphorylation
and ROS induction [84]. It is possible that Vav1 is downstream of various inte-
grin receptors but upstream of Raf in terms of inducible ROS responses. Vav1
has also been shown to associate with a Cbl-Slp76-CD38 complex in an ATRA-
dependent manner; furthermore, transfection of HL-60 cells with Cbl mutants
that fail to bind CD38, yet still bind Slp76 and Vav1, prevents ATRA-induced
MAPK activation [208]. The literature suggest a variety of possible receptor-
signaling pathways, which involve Vav1, for MAPK activation; moreover, given
the ATRA-inducible association Vav1 may play a direct role in Raf activation.
We hypothesized that Vav1 is a member of an ATRA-inducible signalsome
complex which propels sustained MAPK activation, arrest and differentiation
(shown schematically in Fig. 2.9). Initially, ATRA-induced Vav1 expression
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drives increased association between Vav1 and Raf. This increased interaction
facilitates phosphorylation and activation of Raf by pre-bound Akt and/or CK2
at S621 or perhaps S259. Constitutively bound 14-3-3 may also stabilize the S621
phosphorylation, modulate the activity and/or up-regulate autophosphoryla-
tion. Activated Raf can then drive ERK activation, which in turn closes the posi-
tive feedback loop by activating Raf transcription factors e.g., Sp1 and/or STAT1
[135, 171, 260, 151]. We tested this working hypothesis using mathematical
modeling. The model recapitulated both ATRA time-course data as well as the
GW5074 inhibitor effects. This suggested the proposed Raf-Vav1 architecture
was at least consistent with the experimental studies. Further, analysis of the
Raf-Vav1 model identified bistability in phosphorylated ERK levels. Thus, two
possible MAPK activation branches were possible for experimentally testable
ATRA values. The analysis also suggested the ATRA-induced Raf-Vav1 archi-
tecture could be locked into a sustained signaling mode (high phosphorylated
ERK) even in the absence of a ATRA signal. This locked-in property could give
rise to an ATRA-induction memory. We validated the treatment memory prop-
erty predicted by the Raf-Vav1 circuit experimentally using ATRA-washout ex-
periments. ERK phosphorylation levels remained high for more then 96 hr after
ATRA was removed. Previous studies demonstrated that HL-60 cells possessed
an inheritable memory of ATRA stimulus [253]. Although the active state was
self-sustaining, the inactive state demonstrated considerable robustness to per-
turbation. For example, we found that 50x overexpression of Raf was required
to reliably lock MAPK into the activated state, while small perturbations had
almost no effect on phosphorylated ERK levels over the entire ensemble. CD38
expression correlated with the phosphorylated ERK, suggesting its involvement
in the signaling complex. Our computational and experimental results showed
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that positive feedback, through ERK-dependent Raf expression, could sustain
MAPK signaling through many division cycles. Such molecular mechanisms
could underly aspects of cellular memory associated to consecutive ATRA treat-
ments.
2.5 Methods
Effective gene expression model equations.
The ATRA differentiation model was encoded as a system of differential alge-
braic equations (DAEs) which described both signaling and gene expression
processes. We modeled transcription and translation as Ordinary Differential
Equations (ODEs), while signaling processes were assumed to quickly equili-
brate and were treated as a pseudo steady state system of algebraic equations.
The model formulation follows from a previous study of the Epithelial Messec-
nchymal Transition (EMT) [83]; in the current study additional attention was
paid to the formulation of the transcription and translation rates, and an up-
dated approach was taken to model the regulation of gene expression.
We decomposed the ATRA-induced differentiation program into three mod-
ules; a signal initiation module that sensed and transformed the ATRA signal
into activated cRaf-pS621 and the ATRA-RAR/RXR (activated Trigger) signals;
a signal integration module that controlled the expression of upstream tran-
scription factors given cRaf-pS621 and activated Trigger signals; and a pheno-
type module which encoded the expression of functional differentiation mark-
ers from the ATRA-inducible transcription factors. The output of the signal
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initiation module was the input to the gene expression model. For each gene
j = 1, 2, . . . ,G, we modeled both the mRNA (m j), protein (p j) and signaling
species abundance:
dm j
dt
= rT, j −
(
µ + θm, j
)
m j + λ j (2.1)
dp j
dt
= rX, j −
(
µ + θp, j
)
p j (2.2)
g
(
p1, . . . , pG, κ
)
= 0 (2.3)
where signaling species abundance was governed by the non-linear algebraic
equations g
(
p1, . . . , pG, κ
)
= 0. The model parameter vector is denoted by κ.
The terms rT, j and rX, j denote the specific rates of transcription, and translation
while the terms θm, j and θp, j denote first-order degradation constants for mRNA
and protein, respectively. The specific transcription rate rT, j was modeled as
the product of a kinetic term r¯T, j and a control term u j which described how the
abundance of transcription factors, or other regulators influenced the expression
of gene j.
The gene expression control term 0 ≤ u j ≤ 1 depended upon the combi-
nation of factors which influenced the expression of gene j. If the expression
of gene j was influenced by 1, . . . ,m factors, we modeled this relationship as
u j = I j
(
f1 j (·) , . . . , fmj (·)
)
where 0 ≤ fi j (·) ≤ 1 denotes a regulatory transfer func-
tion quantifying the influence of factor i on the expression of gene j, and I j (·)
denotes an integration rule which combines the individual regulatory inputs
for gene j into a single control term. In this study, the integration rule govern-
ing gene expression was the weighted fraction of promoter configurations that
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resulted in gene expression [174]:
u j =
WR1, j +
∑
n
Wn j fn j
1 + WR1, j +
∑
d
Wd j fd j
(2.4)
The numerator, the weighted sum (with weights Wn j) of promoter configura-
tions leading to gene expression, was normalized by all possible promoter con-
figurations (denominator). The likelihood of each configuration was quantified
by the transfer function fn j (which we modeled using Hill functions), while the
lead term in the numerator WR1, j denotes the weight of constitutive expression
for gene j. Given the formulation of the control law, the λ j term (which denotes
the constitutive rate of expression of gene j) was given by:
λ j = r¯T, j
(
WR1, j
1 + WR1, j
)
(2.5)
The kinetic transcription term r¯T, j was modeled as:
r¯T, j = VmaxT
(
LT,o
LT, j
) (
G j
KT +G j
)
(2.6)
where the maximum gene expression rate VmaxT was defined as the product of a
characteristic transcription rate constant (kT ) and the abundance of RNA poly-
merase (R1), VmaxT = kT (R1). The
(
LT,o/LT, j
)
term denotes the ratio of transcription
read lengths; LT,o represents a characteristic gene length, while LT, j denotes the
length of gene j. Thus, the ratio
(
LT,o/LT, j
)
is a gene specific correction to the
characteristic transcription rate VmaxT . If a gene expression process had no modi-
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fying factors, u j = 1. Lastly, the specific translation rate was modeled as:
rX, j = VmaxX
(
LX,o
LX, j
) (
m j
KX + m j
)
(2.7)
where VmaxX denotes a characteristic maximum translation rate estimated from
literature, and KX denotes a translation saturation constant. The characteristic
maximum translation rate was defined as the product of a characteristic trans-
lation rate constant (kX) and the Ribosome abundance (R2), VmaxX = kX (R2). As
was the case for transcription, we corrected the characteristic translation rate
by the ratio of the length of a characteristic transcript normalized by the length
of transcript j. The sequence lengths used in this study are given in Table 2.3;
the characteristic gene and mRNA lengths were given by the average lengths
computed from the values in Table 2.3.
Signaling model equations.
The signal initiation and integration modules required the abundance of cRaf-
pS621 and ATRA-RAR/RXR (activated Trigger) as inputs. However, the base
model described only the abundance of inactive proteins e.g., cRaf or RAR/RXR
but not the activated forms. To address this issue, we estimated pseudo
steady state approximations for the abundance of cRaf-pS621 and activated
Trigger. The abundance of activated trigger (xa,1) was estimated directly from
the RAR/RXR abundance (xu,1):
xa,1 ∼ xu,1
(
α · ATRA
1 + α · ATRA
)
(2.8)
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where α denotes a gain parameter; α = 0.0 if ATRA is less than a threshold, and
α = 0.1 if ATRA is greater than the differentiation threshold. The abundance
of cRaf-pS621 was estimated by making the pseudo steady state approximation
on the cRaf-pS621 balance. In general, the abundance of an activated signaling
species i was governed by:
dxi
dt
= r+,i (x,k) − (µ + kd,i) xi i = 1, . . . ,M (2.9)
The quantity xi denotes concentration of signaling species i, while R and M
denote the number of signaling reactions and signaling species in the model, re-
spectively. The term r+,i (x,k) denotes the rate of generation of activated species
i, while µ denotes the specific growth rate, and kd,i denotes the rate constant con-
trolling the non-specific degradation of xi. We neglected deactivation reactions
e.g., phosphatase activities. We assumed that signaling processes were fast com-
pared to gene expression; this allowed us to approximate the signaling balance
as:
x∗i '
r+,i (x,k)(
µ + kd,i
) i = 1, . . . ,M (2.10)
The generation rate was written as the product of a kinetic term (r¯+,i) and a
control term (vi). The control terms 0 ≤ v j ≤ 1 depended upon the combination
of factors which influenced rate process j. If rate j was influenced by 1, . . . ,m
factors, we modeled this relationship as v j = I j
(
f1 j (·) , . . . , fmj (·)
)
where 0 ≤
fi j (·) ≤ 1 denotes a regulatory transfer function quantifying the influence of
factor i on rate j. The function I j (·) is an integration rule which maps the output
of regulatory transfer functions into a control variable. In this study, we used
I j ∈ {min,max} and hill transfer functions [248]. If a process had no modifying
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factors, v j = 1. The kinetic rate of cRaf-pS621 generation r¯+,cRa f was modeled as:
r¯+,cRa f = k+,cRa f xs
(
xcRa f
K+,cRa f + xcRa f
)
(2.11)
where xs denotes the signalsome abundance, k+,cRa f denotes a characteristic ac-
tivation rate constant, and K+,cRa f denotes a saturation constant governing cRaf-
pS621 formation. In thus study, signalsome abundance was approximated by
the abundance of the BLR1 protein; BLR1 expression is directly related to Raf
nuclear translocation which in turn is related to activated signalsome. Thus,
BLR1 is an indirect measure of the signalsome. The formation of cRaf-pS621
was regulated by only a single factor, the abundance of MAPK inhibitor, thus
v+,cRa f took the form:
v+,cRa f =
(
1 − I
KD + I
)
(2.12)
where I denotes the abundance of the MAPK inhibitor, and KD denotes the in-
hibitor affinity.
Estimation of gene expression model parameters
Parameters appearing in the mRNA and protein balances, e.g., maximum tran-
scription and translation rates, the half-life of a typical mRNA and proteins (as-
sumed to be same for all transcripts/proteins), and typical values for the copies
per cell of RNA polymerase and ribosomes were estimated from literature (Ta-
ble 2.2). The saturation constants KX and KT appearing in the transcription and
translation rate equations were adjusted so that gene expression and translation
resulted in gene products on a biologically realistic concentration scale. Lastly,
we calculated the concentration for gene G j by assuming, on average, that a cell
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had two copies of each gene at any given time. Thus, the bulk of our model pa-
rameters were taken from literature, and were not adjusted during model identi-
fication. However, the remaining parameters, e.g., the Wi j values or parameters
appearing in the transfer functions fd j which appeared in the gene expression
control laws, were estimated from the experimental data discussed here. We
assumed promoter configuration weights were bounded between Wi j ∈ [0, 100];
all cooperativity coefficients ηi j appearing in the binding transfer functions fd j
were bounded between ηi j ∈ [0, 4]; and all disassociation constants Ki j appear-
ing in the binding transfer functions fd j were bounded between Ki j ∈ [0, 1000]
(nM).
Signaling and gene expression model parameters were estimated by mini-
mizing the squared difference between simulations and experimental protein
data set j. We measured the squared difference in the scale, fold change and
shape for protein j:
E j(k) =
(
M j (t−) − yˆ j (t−,k)
)2
+
T j∑
i=1
(
Mˆi j − yˆi j(k)
)2
+
T j∑
i=1
(
M′i j − y′i j(k)
)2
(2.13)
The first term in Eq. (3.10) quantified the initial scale error, directly before the ad-
dition of ATRA. In this case, M j (t−) (the approximate concentration of protein
j before the addition of ATRA) was estimated from literature. This term was
required because the protein measurements were reported as the fold-change;
thus, the data was normalized by a control value measured before the addi-
tion of ATRA. However, the model operated on a physical scale. The first term
allowed the model to capture physically realistic changes following ATRA ad-
dition. The second term quantified the difference in the fold-change of protein j
as a function of time. The terms Mˆi j and yˆi j denote the scaled experimental ob-
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servations and simulation outputs (fold-change; protein normalized by control
value directly before ATRA addition) at time i from protein j, where T j denoted
the number of time points for data set j. Lastly, the third term of the objective
function measured the difference in the shape of the measured and simulated
protein levels. The scaled value 0 ≤ M′i j ≤ 1 was given by:
Mˆi j =
(
Mi j −min
i
Mi j
)
/
(
max
i
Mi j −min
i
Mi j
)
(2.14)
whereM′i j = 0 andM′i j = 1 describe the lowest (highest) intensity bands. A sim-
ilar scaling was used for the simulation output. We minimized the total model
residual
∑
j E j using a heuristic direct-search optimization procedure, subject to
box constraints on the parameter values, starting from a random initial parame-
ter guess. Each downhill step was archived and used for ensemble calculations.
The optimization procedure (a covariance matrix adaptation evolution strategy)
has been reported previously [110].
Estimation of an effective cell cycle arrest model.
We formulated an effective N-order polynomial model of the fraction of cells
undergoing ATRA-induced cell cycle arrest at time t, Aˆ(t), as:
Aˆ (t) ' a0 +
N−1∑
i=1
aiφi (p(t), t) (2.15)
where ai were unknown parameters, and φi (p(t), t) denotes a basis function. The
basis functions were dependent upon the system state; in this study, we used N
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= 4 and basis functions of the form:
φi (p(t), t) =
(
t
T
+
p21
E2F
∣∣∣∣
t
)(i−1)
(2.16)
The parameters a0, . . . , a3 were estimated directly from cell-cycle measurements
(biological replicates) using least-squares. The form of the basis function as-
sumed p21 was directly proportional, and E2F inversely proportional, to G0-
arrest. However, this was one of many possible forms for the basis functions.
Cell culture and treatment
Human myeloblastic leukemia cells (HL-60 cells) were grown in a humidified
atmosphere of 5% CO2 at 37oC and maintained in RPMI 1640 from Gibco (Carls-
bad, CA) supplemented with 5% heat inactivated fetal bovine serum from Hy-
clone (Logan, UT) and 1× antibiotic/antimicotic (Gibco, Carlsbad, CA). Cells
were cultured in constant exponential growth [19]. Experimental cultures were
initiated at 0.1 × 106 cells/mL 24 hr prior to ATRA treatment; if indicated, cells
were also treated with GW5074 (2µM) 18 hr before ATRA treatment. For the cell
culture washout experiments, cells were treated with ATRA for 24 hr, washed
3x with prewarmed serum supplemented culture medium to remove ATRA,
and reseeded in ATRA-free media as described. Western blot analysis was per-
formed at incremental time points after removal of ATRA.
47
Chemicals
All-Trans Retinoic Acid (ATRA) from Sigma-Aldrich (St. Louis, MO) was dis-
solved in 100% ethanol with a stock concentration of 5mM, and used at a fi-
nal concentration of 1µM (unless otherwise noted). The cRaf inhibitor GW5074
from Sigma-Aldrich (St. Louis, MO) was dissolved in DMSO with a stock con-
centration of 10mM, and used at a final concentration of 2µM. HL-60 cells were
treated with 2µM GW5074 with or without ATRA (1µM) at 0 hr. This GW5074
dosage had a negligible effect on the cell cycle distribution, compared to ATRA
treatment alone.
Immunoprecipitation and western blotting
For immunoprecipitation experiments, cells were lysed as previously described.
300µg protein (in 300 µL total volume) per sample was pre-cleared with Protein
A/G beads. The beads were pelleted and supernatant was incubated with Raf
antibody (3µL/sample) and beads overnight. All incubations included protease
and phosphatase inhibitors in M-PER used for lysis with constant rotation at
4oC. Bead/antibody/protein slurries were then washed and subjected to stan-
dard SDS-PAGE analysis as previously described [208]. All antibodies were
purchased from Cell Signaling (Boston, MA) with the exception of α-p621 Raf
which was purchased from Biosource/Invitrogen (Carlsbad, CA), and α-CK2
from BD Biosciences (San Jose, CA).
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Morphology assessment
Untreated and ATRA-treated HL-60 cells were collected after 72 hr and cyto-
centrifuged for 3 min at 700 rpm onto glass slides. Slides were air-dried and
stained with Wright’s stain. Slide images were captured at 40X (Leica DM LB
100T microscope, Leica Microsystems).
Cell cycle quantification
1 x 106 cells were collected by centrifugation at 700 rpm and resuspended in
200 µl of cold propidium iodide (PI) hypotonic staining solution containing 50
µg/ml propidium iodine, 1 µl/ml Triton X-100, and 1 mg/ml sodium citrate (all
Sigma, St. Louis, MO). Cells were incubated at room temperature for 1 h and
analyzed by flow cytometry with a BD LSRII flow cytometer (BD Biosciences,
San Jose, CA) using 488-nm excitation and emission collected through 550 long-
pass dichroic and a 575/26 band-pass filters. Doublets were identified by a PI
signal width versus area plot and excluded from the analysis.
CD11b quantification
Expression of cell surface differentiation markers was quantified by flow cy-
tometry. 1 x 106 cells were collected from cultures and centrifuged at 700 rpm
for 5 min. Cell pellets were resuspended in 200 µl 37◦C PBS containing 2.5 µl
of phycoerythrin (PE)-conjugated CD11b (both from BD Biosciences, San Jose,
CA). Following 1 h incubation at 37◦C cell surface expression levels were ana-
lyzed by flow cytometry. PE was excited at 488 nm and emission was collected
through 505 long-pass dichroic and 530/30 band-pass filters.
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Respiratory burst quantification (ROS)
1 x 106 cells were collected and centrifuged at 700 rpm for 5 min. Pel-
lets were suspended in 500µl of PBS containing 5-(and-6)-chloromethyl-2’,7’-
dichlorodihydro-fluorescein diacetate acetyl ester (DCF, Molecular Probes, Eu-
gene, OR) with either DMSO carrier blank solution or 12-0-tetradecanoyl-
phorbol-13-acetate (TPA, Sigma, St. Louis, MO) suspended in DMSO. Cells
were incubated for 25min at 37◦C and then analyzed by flow cytometry as pre-
viously described. Oxidized DCF was excited by a 488nm laser and emission
was collected through a 505 long pass dichroic mirror and a 530/30nm band
pass filter. The shift in fluorescence intensity in response to TPA was used to
determine the percent cells with the capability to generate inducible oxidative
metabolites. Gates to determine percent positive cells were set to exclude 95%
of control cells not stimulated with TPA.
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Figure 2.1: Schematic of the effective ATRA differentiation circuit. Above
a critical threshold, ATRA activates an upstream Trigger, which
induces signalsome complex formation. Signalsome activates
the mitogen-activated protein kinase (MAPK) cascade which
in turn drives the differentiation program and signalsome for-
mation. Both Trigger and activated cRaf-pS621 drive a pheno-
type gene expression program responsible for differentiation.
Trigger activates the expression of a series of transcription fac-
tors which in combination with cRaf-pS621 result in pheno-
typic change.
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Figure 2.2: Model analysis for ATRA-induced HL-60 differentiation. A:
BLR1 mRNA versus time following exposure to 1µM ATRA at
t = 0 hr. B: cRaf-pS621 versus time following exposure to 1µM
ATRA at t = 0 hr. Points denote experimental measurements,
solid lines denote the mean model performance. Shaded re-
gions denote the 99% confidence interval calculated over the
parameter ensemble. C: Signalsome and cRaf-pS621 nullclines
for ATRA below the critical threshold. The model had two sta-
ble steady states and a single unstable state in this regime. D:
Signalsome and cRaf-pS621 nullclines for ATRA above the crit-
ical threshold. In this regime, the model had only a single sta-
ble steady state. E: Morphology of HL-60 as a function of ATRA
concentration (t = 72 hr). Experimental data in panels A and B
were reproduced from Wang and Yen [242], data in panel E is
reported in this study. 52
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Figure 2.3: Model simulation following exposure to 1µM ATRA. A: BLR1
mRNA versus time with and without MAPK inhibitor. B: cRaf-
pS621 versus time following pulsed exposure to 1µM ATRA
with and without BLR1. Solid lines denote the mean model
performance, while shaded regions denote the 99% confidence
interval calculated over the parameter ensemble. C: Western
blot analysis of phosphorylated ERK1/2 in ATRA washout ex-
periments. Experimental data in panels A and B were repro-
duced from Wang and Yen [242], data in panel C is reported in
this study. The images of the raw gel for panel C is given in the
Supplemental Materials.
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at time t = 0 hr. B: Scaled Gene expression at t = 48 hr following
ATRA exposure. Gene expression was normalized to expres-
sion in the absence of ATRA. The gene expression is quanti-
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(from at least three biological repeat nuclear lysates) using Im-
ageJ. Experimental data in panels A and B were reproduced
from Jensen et al. [119]. Model simulations were conducted
using the ten best parameter sets collected during model iden-
tification. Solid lines (or bars) denote the mean model perfor-
mance, while the shaded region (or error bars) denote the 95%
confidence interval calculated over the parameter ensemble.
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Figure 2.6: Robustness of the HL-60 differentiation program following ex-
posure to 1µM ATRA at t = 0 hr. A: Singular value decom-
position of the average system response (l2-norm between the
perturbed and nominal state) following pairwise gene knock-
out simulations using the top ten best fit parameter sets. The
rows denote the deleted genes, while columns denote the re-
sponse mode. B: Singular value decomposition of the average
system response (l2-norm between the perturbed and nominal
state) following the pairwise removal of protein-DNA connec-
tions for the top ten best fit parameter sets. The rows denote
protein-DNA interactions at the labeled promoter, while the
columns denote the top ranked response modes (combinations
of deletions). The percentage at the top of each column de-
scribes the fraction of the variance in the system state captured
by the node combinations in the rows.
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Figure 2.7: Robustness of the HL-60 differentiation program following ex-
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Figure 2.8: Investigation of a panel of possible Raf interaction partners in
the presence and absence of ATRA. A: Species identified to pre-
cipitate out with Raf: first column shows Western blot analy-
sis on total Raf immunoprecipitation with and without 24 hr
ATRA treatment and the second on total lysate. B: The expres-
sion of species considered that did not precipitate out with Raf
at levels detectable by Western blot analysis on total lysate. C:
Effect of the Raf inhibitor GW5074 on Raf interactions as deter-
mined by Western blot analysis of total Raf immunoprecipita-
tion. The Authors note the the signal associated with Src was
weak. D: Cell Cycle distribution as determined by flow cytom-
etry indicated arrest induced by ATRA, which was increased
by the addition of GW5074. E: Expression of the cell surface
marker CD11b as determined by flow cytometry indicated in-
creased expression induced by ATRA, which was enhanced by
the addition of GW5074. F: Inducible reactive oxygen species
(ROS) as determined by DCF flow cytometry. The functional
differentiation response of ATRA treated cells was mitigated
by GW5074. GAPDH was used as a loading control. The black
lines frame groupings from independent gels and each image
is typical of three repeats. Images of the raw gels for panels A,
B C and F are given in the Supplemental Materials.
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Figure 2.9: This schematic diagram shows the hypothetical principal
pathways in the ATRA–induced signaling that results in cell
differentiation in the HL-60 myeloid leukemia model [238, 34,
35, 208, 21, 207]. It is based on modules and feedback loops.
There are three main arms (shown top to bottom): 1. Direct
ATRA targeting of RAREs in genes such as CD38 or BLR1;
2. Formation of a signalsome that has a regulatory module
that includes Vav (a guanine nucleotide exchange factor), CBL
and SLP-76 (adaptors), and Lyn (a Src family kinase) that reg-
ulates a Raf/Mek/Erk axis that incorporates Erk to Raf feed-
back, where the regulators are modulated by AhR and CD38
receptors; and 3. Direct ATRA targeted up regulation of CDKI
to control RB hypophosphorylation. The Raf/Mek/Erk axis is
embedded in the signalsome and subject to modulation by the
regulators. The output of the signalsome is discharge of the Raf
from the cytosol to the nucleus where it binds (hyper)phospho-
RB and other targets, including NFATc3, which enables activa-
tion of the ATRA bound RAR/RXR poised on the BLR1 pro-
moter, and also GSK3, phosphorylation of which relieves its in-
hibitory effect on RARα. CDKI directed hypophosphorylation
of RB releases Raf sequestered by RB to go to NFATc3, GSK3,
and other targets. A significant consequence of the nuclear
RAF is ergo ultimately to enable or hyperactivate transcrip-
tional activation by RARα to drive differentiation. It might be
noted that this proposed general model provides a mechanistic
rationalization for why cell cycle arrest is historically oft times
perceived as a precondition for phenotypic maturation.
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Table 2.1: Myelomonocytic transcription factor connectivity used in the signal
integration and phenotype modules.
Effector Effect Target Source
RARα + RARα [192]
+ PU.1 [175]
+ C/EBPα [76]
+ IRF-1 [160]
- Oct4 [220]
+ CD38 [53]
+ p21 [155]
+ AhR [23]
+ Egr-1 [7]
PPARγ + C/EBPα [195]
+ IRF-1 [232]
+ Oct1 [20]
- AP-1 [47]
- E2F [4]
- Egr-1 [66]
+ CD38 [211]
+ CD14 [221]
+ p21 [86]
- p47Phox [236]
PU.1 - PPARγ [49]
+ PU.1 [28]
+ AP-1 [215]
+ Egr-1 [142]
+ CD11b [185]
+ p21 [257]
+ p47Phox [149]
C/EBPα + PPARγ [195]
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+ PU.1 [43]
+ C/EBPα [227]
+ Gfi-1 [153]
- E2F [44]
+ CD14 [187]
+ p21 [89]
IRF-1 + CD38 [9]
+ p21 [189]
- PU.1 [42]
- C/EBPα [54]
- E2F [54]
- Egr-1 [142]
- p21 [54]
Oct1 + PU.1 [29]
AP-1 - PPARγ [47]
+ PU.1 [11]
+ p21 [125]
E2F + E2F [123]
Egr-1 + PPARγ [77]
- Gfi-1 [163]
+ CD14 [27]
AhR + AP-1 [217]
+ IRF-1 [206]
- Oct4 [22]
- PU.1 [14]
61
Table 2.2: Characteristic model parameters estimated from literature.
Symbol Description Value Units Source
R1 RNA polymerase abundance 85,000 copies/cell [112, 261]
R2 Ribosome abundance 1 x 106 copies/cell [75]
Gi Characteristic gene abundance 2 copies/cell this study
KX Saturation constant transcription 600 copies/cell this study
KT Saturation constant translation 95,000 copies/cell this study
t1/2,m characteristic mRNA half-life (transcription factor) 2-4 hr [250]
t1/2,p characteristic protein half-life 10 hr [50]
θm, j characteristic mRNA degradation constant 0.34 hr−1 derived
θp, j characteristic protein degradation constant 0.07 hr−1 derived
td HL-60 doubling time 19.5 hr this study
µ growth rate 0.035 hr−1 derived
kd death rate 0.10µ hr−1 derived
eT elongation rate RNA polymerase 50-100 nt/s [202, 46, 140, 45]
eX elongation rate Ribosome 5 aa/s [15]
LT,o characteristic gene length 44,192 nt [169]
LX,o characteristic transcript length 1,374 nt derived
kT characteristic transcription rate 1.44 hr−1 derived
kX characteristic translation rate 3.60 hr−1 derived
k+,cRa f characteristic cRaf-S621 activation rate constant 1 hr−1 this study
K+,cRa f characteristic saturation constant governing cRaf-pS621 formation 60 nM this study
KD characteristic MAPK inhibitor affinity 10 nM this study
D Diameter of an HL-60 cell 12.4 µm3 [196]
fC cytoplasmic fraction 0.51 dimensionless [196]
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Table 2.3: Sequence lengths from NCBI RefSeq database were used in the signal
integration and phenotype modules [184]. The RNA sequence length used rep-
resents the total distance of transcription, and assume to be equal to the gene
length.
Gene Name Gene (bp) RNA (bp) Protein (aa) Gene ID Protein ID
AP-1 10323 10323 331 Gene ID: 3725 NP 002219
AhR 47530 47530 848 Gene ID: 196 NP 001621
CD11b 72925 72925 1153 Gene ID: 3684 NP 001139280
CD14 8974 8974 375 Gene ID: 929 NP 001035110
CD38 174978 74978 300 Gene ID: 952 NP 001766
C/EBPα 2630 2630 393 Gene ID: 1050 NP 001274353.1
E2F 17919 17919 437 Gene ID: 1869 NP 005216
Egr-1 10824 10824 543 Gene ID: 1958 NP 001955
Gfi-1 13833 13833 422 Gene ID: 2672 NP 005254
IRF-1 16165 16165 325 Gene ID: 3659 NP 002189
Oct1 206516 206516 741.33 Gene ID: 5451 NP 002688.3, NP 001185712.1, NP 001185715.1
Oct4 6356 6356 206.33 Gene ID: 5460 NP 001167002, NP 001167015, NP 001167016
P21 15651 15651 198 NG 009364.1 NP 001621
P47 3074 3074 390 GenBank: AF003533.1 NP 000256
PPARγ 153507 153507 250 Gene ID: 5468 NP 001317544
PU.1 40782 40782 270.5 Gene ID: 6688 NP 001074016, NP 003111
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CHAPTER 3
MODELING AND ANALYSIS OF COMBINATION TREATMENT OF HL60
TRANSCRIPTION FACTOR NETWORK
3.1 Abstract
In this study, we present an effective model All-Trans Retinoic Acid (ATRA)-
induced differentiation of HL-60 cells. The model describes a key architectural
feature of ATRA-induced differentiation, positive feedback between an ATRA-
inducible signalsome complex involving many proteins including Vav1, a gua-
nine nucleotide exchange factor, and the activation of the mitogen activated
protein kinase (MAPK) cascade. The model, which was developed by integrat-
ing logical rules with kinetic modeling, was significantly smaller than previ-
ous models. However, despite its simplicity, it captured key features of ATRA
induced differentiation of HL-60 cells. We identified an ensemble of effective
model parameters using measurements taken from ATRA-induced HL-60 cells.
Using these parameters, model analysis predicted that MAPK activation was
bistable as a function of ATRA exposure. Conformational experiments sup-
ported ATRA-induced bistability. These findings, combined with other litera-
ture evidence, suggest that positive feedback is central to a diversity of cell fate
programs.
Keywords: leukemia, cancer, mathematical modeling
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3.2 Introduction
It was suggested by Bailey, more than a decade ago, that qualitative and quan-
titative knowledge of complex biological systems could be achieved in the ab-
sence of complete structural and parameter knowledge [?]. Although this is
true, the incomplete knowledge of biological phenomenon often limits the im-
pact of computational models. Unknown or even disputed network structures
can lead to incomplete fitting of computation models, requiring additional ex-
periments and updating of the model. Since ODE kinetic models typically re-
quire extensive prior knowledge of network structure, rate constants and initial
conditions [?], often a single “correct” network structure is assumed. Villaverde
et al. discussed three main strategies in the reverse engineering of dynamic
models: (1) full network inference, (2) network selections, and (3) kinetic param-
eter estimations [?]. Strategy 1, where the kinetic model structure and kinetic
parameters are unknown, is typically solved by identifying the model interac-
tion network without dynamics and then identifying the kinetic parameters. In
this study, we will consider strategy 2; we have an initial model network struc-
ture that will be perturbed to find modifications to fit the experimental data for
six different leukemia cell lines.
Leukemia is the 6th leading cause of cancer death in both males and females
in the United States [?]. Approximately 72% of cancer related leukemia deaths
were caused by four main types of leukemia; acute lymphocyctic leukemia
(ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML),
and chronic myeloid leukemia (CML). ALL and CLL are characterized by accu-
mulation of lymphocytes in the bone marrow, with ALL progressing at a faster
rate (i.e. acute vs. chronic). ALL occurs in both children and adults and has
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a 90% five year survival rate in children [?], while CLL is rare in children and
has a 66% five year survival rate (2001-2009) [?]. The 10 year survival rate for
CML has improved to 80-90% due to the use of targeted treatments for BCR-
ABL and adenosine triphosphate (ATP) [?]. AML is characterized by the accu-
mulation of abnormally differentiated cells of the hematopoietic system in the
bone marrow and blood, with a survival rate of 35 to 40% in adults under the
age of 60 (5 to 15% in patients older than 60) [?]. AML is a group of extremely
heterogeneous diseases, with over 200 known chromosome translocations and
mutations in patient leukemic cells [?]. The use of differentiation induction ther-
apy agents like all-trans retinoic acid (RA) and 1,25-dihyrodyvitamin D3 (D3)
have been explored in many cancer cell types, including myeloid leukemias,
and lung, liver, prostate, and breast cancer (RA treatment) [?, ?] and in prostate,
breast, colorectal, leukemia, and brain (D3 treatment) [?]. Acute promyelocytic
leukemia (APL), a subtype of AML, was once one of the most fatal forms of
acute leukemia until the introduction of RA increased remission rates of pa-
tients to between 80 and 90 % [?]. Failure of RA treatment can occur initially in
patients with RA resistant variants (PLZF-RARA-positive APL), and relapse oc-
curs in 5-20% of cases due to the emergence of RA resistance. To understand the
response of multiple leukemia cell lines to RA and D3 treatments, we developed
a network structure of well known transcription factors governing myelomono-
cytic lineage selection (granulocytic or monocytic).
In this study we considered data from RA, D3, and RA plus D3 treatments
on six human myeloid leukemia cell lines; (1) K562 (FAB M1), (2) HL60 (FAB
M2), (3) NB4 (FAB M3), (4) U937 (FAB 5), (5) HL60 R38+ and (6) HL60 R38- (5
and 6 are described previously [?]). K562, a CML cell line with a Bcr-Abl fu-
sion protein [?], was used as a control because the cells are not responsive to
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both RA [?] and D3 treatment [?]. HL60 cells, an AML cell line, are lineage-
bipotent myelobasts [?, ?] that can differentiate to either granulocytic lineage
(using RA) or monocytic lineage (using D3). The two RA-resistant HL60 cell
lines, R38+ and R38-, were described previously [?, ?]. NB4, an APL cell line,
are highly RA-responsive, but require combination treatments for monocytic
differentiation (i.e. low response to D3) [?, ?]. U937, histiocytic lymphoma cell
line, are highly responsive to D3 induced monocytic differentiation, but have
ambiguous differentiation effects due to RA (either monocytic or granulocytic)
[?, ?, ?]. The model network contained two inputs (RA and D3) and 18 main
species. We included two receptors, reinoic acid receptor alpha (RARα) and vi-
tamin D receptor (VDR), but excluded their heterodimer receptor pair, retinoid
receptor (RXR), for simplicity (assumption RXR is readily available). Also, in-
cluded in the model were transcription factors important in myelomonocytic
lineage selection (listed in Table ??). Finally upstream markers for differentia-
tion were included, including CD38, CD11b, CD14, G1/GO cell cycle arrest and
inducible oxidative metabolism. CD38 and CD11b are myelomonocytic markers
and CD14 is a monocytic specific marker.
In this study we first determined that a network structure of a small three
node protein model could be identified with sufficient experimental data. A
model structure search in combination with particle swarm optimization to de-
termine parameter values narrowed down total possible model structures from
19683 to twenty. After additional experimental data was implemented, we were
able to find the synthetic model structure with no a priori knowledge. Next
we investigated possible network structures for transcription factor and up-
stream markers in six leukemia cell lines treated with RA and D3 (data from
[?]). The upstream markers CD38 and CD11b (myelomonocytic markers) and
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CD14 (monocytic specific marker) were included in the model. Also, included
in the model were transcription factors important in myelomonocytic lineage
selection. Starting from an initial best model structure curated from literature
sources, we were able to improve the model fits for six leukemia cell lines versus
experimental data.
3.3 Results
We constructed an effective model of ATRA and D3 induced HL-60 differenti-
ation which described gene expression events following the addition of ATRA
and D3 (Fig. 3.1). The model connectivity was developed from literature and the
studies presented here (Table 3.1). In this study, we present the ATRA and D3
program into two modules; a signal integration module that controlled the ex-
pression of upstream transcription factors given cRaf-pS621 and activated Trig-
ger signals (Fig. 3.1); and a phenotype module which encoded the expression of
functional differentiation markers from the ATRA-inducible transcription fac-
tors (Fig. 5.1). Each component of these modules was described by a mRNA
and protein balance equation. Lastly, because the population of HL-60 cells was
dividing (at least before ATRA-induced cell cycle arrest), we also considered a
dilution term in all balance equations. The signal integration and phenotype
modules were collectively encoded by 54 differential equations. Model parame-
ters were taken literature (Table 2.2), or estimated from experimental data using
heuristic optimization (see materials and methods).
The signal integration module that controlled the expression of upstream
transcription factors takes signaling cues from an upstream module (not in-
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cluded) as the input. The signal initiation module produced two outputs, ac-
tivated Triggers (ATRA and D3) and cRaf-pS621 which drove the expression of
ATRA and D3-induced transcription factors. The expression of transcriptions
factors initiated a cascade gene expression that activated the phenotypic pro-
gram. In particular, Trigger ATRA, which is a surrogate for the RARα/RXR
transcriptional complex, regulated the expression of the transcription factors
CCATT/enhancer binding protein α (C/EBPα), PU.1, and EGR1. Meanwhile,
Trigger D3 is a surrogate for the VDR/RXR transcriptional complex that regu-
lates the expression of PPARγ and PU.1. In turn, these transcription factors, in
combination with cRaf-pS621, regulated the expression of downstream pheno-
typic markers such as CD38, CD11b or P47Phox.
We assembled the connectivity of the signal integration and phenotypic pro-
grams driven by the Triggers and cRaf-pS621 from literature (Table 3.1). The sig-
naling events driven by ATRA activates the ATRA trigger that drives the tran-
scription activation (TA) of IRF-1, AhR, PPARg, and master regulators CEBPa
and PU.1. Analogously, D3 activates D3 trigger and drives the TA of PPARg and
PU.1. These transcription factors directly induced by the activation of ATRA
and D3 triggers in turn drives or inhibits expression of other gene in the gene
regulatory network. A combination of these expression levels and the sustained
activation of MAPK are then used to determine the expression of phenotypic
markers in the phenotypical module.
To make sense of such a complicated network with multiple incoherent in-
teraction, we used effective kinetics coupled with logical rules that describes
transcription regulation. We estimated the parameters which appeared in the
control laws regulating these programs from steady-state and dynamic mea-
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surements of transcription factor and phenotypic marker expression following
the addition of ATRA and/or D3 [REFHERE]. However, the bulk of the remain-
ing model parameters were taken from directly from literature [172] and were
not estimated in this study (see materials and methods) which created reduced
the number of undetermined parameters. The model simulations captured the
time dependent expression of CD38, CD11b, and CD14 following the addition
of different combinations of ATRA and D3 treatments.
The induction of ATRA induces expression of surface markers that are as-
sociated with myeloid differentiation, CD38 and CD11b but not CD14. Using
our model, we generated an ensemble set of 495 parameter sets that was able
to capture the transcritpion factor expression measured at 48 hours in the sig-
nal integration module (Fig 3.2 and the time course expression of key pheno-
typic markers (Fig. 3.3). Although we capture most of the TF expression at 48
hours, the model fail to capture some combination treatment results showed
synergistic or antonisitic effect when compared to the sum of the ATRA and
D3 treatments. For example, EGR1 and GFI1 shoedw synergistic effect, while
AhR showed antagonistic effects. For the time course simulations, the black
lines represent the ensemble means, the dark colored bands are the 99% stan-
dard error from the mean, and the light colored bands are the 99% confidence
interval. Similarly, the induction of D3 induces expression of surface markers
that are associated with monocyte differentiation, CD38, CD11b, and CD14 are
all expressed. Using the network structure, and 491 parameter ensemble, we
were able to capture the time dependent phenotypic markers(Fig. 3.3). Finally,
we tested to see if our model was able to capture the complexity involved with
differentiation induced with ATRA and D3 at the same time (Fig. 3.3).Taken to-
gether, the signal integration and phenotypic simulations were consistent with
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measurements, thereby validating the assumed molecular connectivity.
A question we wanted to answer was how ATRA induced differentiation
differs from D3 or combination induced differentiation , and how might the
role of parameters change based on the different treatments. To help answer
the question, we performed sensitivity analysis on the model and the parame-
ter sensitivity for the treatments were ranked from low to high. The sensitivity
rankings of the treatments were plotted against one another for direct compari-
son (ATRA vs D3, ATRA vs combination, and D3 vs combination; Figs. 3.4-3.6)
with respect to 9 species. The most sensitive parameters have higher rank order,
while the lest sensitive parameters are localized towards the origin. The analy-
sis showed the weight parameters (W; that govern the individual contribution to
gene expression associated with individual TF binding) to be the most sensitive
across all treatments. Parameters that diverged from the 45 degree axis indi-
cated a change in parameter sensitivity between the who treatments compared.
The labels on the sensitivity figure represent the parameter associated with a
gene and influences of transcription factors. A closer analysis was taken at the
measurable phenotypical markers of CD11b, CD14, CD38, and p47Phox. The
parameters that were sensitive to change between treatments for CD11b were
related to the regulation of PU1 across all comparisons, with the highest change
in sensitivity (distance from 45 degree axis) in the saturation constants. Inter-
estingly, the parameters sensitivity associated with the expression of CD11b did
not change between treatments. Next we looked at CD14, the monocytic surface
marker that is only induced by D3. Since CD14 is not ATRA inducible, sensi-
tivity comparison of ATRA alone with respect to CD14 showed a high number
of sensitivity changes. However when treatments of D3 and combination were
compared (Fig. 3.6, the comparison showed that with D3 alone, the expres-
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sion of CD14 relies more on the expression of PPARγ, while the combination of
ATRA and D3 treatment showed higher sensitivity for EGR1 and CEBPα. CD38
is an important early marker in both granucyctic and monocytic differentiation.
Although PPARγ is a key TF that regulates CD38 expression, ATRA induced
differentiation is more sensitive to the induction of PPARγ through EGR1 while
D3 showed higher sensitivity towards PPARγ expression through PU1 activa-
tion. Interestingly, when ATRA was compared to combination treatment (Fig.
3.5) for CD38, only the weight of PU1 on the expression of PPARγ showed a
change in sensitivity. However CD38 sensitivity for D3 compared to combina-
tion showed a variety of changes such as OCT1 basal expression having a higher
sensitivity for combination treatment. P47phox, the NADPH oxidase required
for phagocytes to generate reactive oxygen species (ROS) for host defense, was
used as functional markers for differentiation. We compared the P47phox pa-
rameter sensitivity between ATRA induced and D3 induced differentiation and
combination treatments. While P47phox relies on the TF binding of PU1 and
CEBPα, the analysis showed that PU1 is sensitive for ATRA-induced differenti-
ation, while CEBPα is more sensitive for D3-induced differentiation.
To make sense of the change in parameter sensitivities across the different
treatments, we counted the off-axis frequencies of each parameters on all the
protein species and presented them in Fig. 3.7. The grey points are the compari-
son between ATRA and D3, blue represents the comparison between ATRA and
combination, and red is the comparison etween D3 and combination. The pos-
itive frequencies indicate the parameter favored the respective treatment rep-
resented above zero and vise versa. The parameters with the highest absolute
frequencies indicates their change in sensitivity across all species between the
treatments compared. When ATRA and D3 induced differentiation were com-
73
pared, the parameter sensitivities that heavily favored ATRA treatment were
related to Trigger ATRA induced gene expression (w parameters of Trigger
ATRA activating expressions of PPARγ, EGR1, CEBPa, and PU1). Interestingly,
parameter that showed up off-axis the most for ATRA vs D3 was the weight
parameters of Trigger ATRA’s regulation of PPARγ that was most sensitive to
ATRA treatment, however when D3 was combined with ATRA, the parameter
gained even more sensitivity compared to ATRA alone (Fig. 3.7 blue). Lastly
as a validation step of our model, we plotted the cost function of our ensem-
ble of parameters against two 495-parameter-set ensembles that was randomly
and semi-randomly generated using sobol sequences (Fig. 3.8. The error plot
showed that the best fit parameter ensemble performed better across all cost
functions and that performance was not solely due to the structure of the model.
3.4 Discussion
In this study, we presented an effective model of ATRA and D3 inducible dif-
ferentiation of HL-60 cells which integrates signals into a gene regulatory net-
work and expressed measurable phenotypic markers. Despite its simplicity, the
model captured key features of the ATRA and D3 induced differentiation such
as the expressions of CD38, CD11b, and CD14.
Sensitivity analysis showed that the parameters sensitivity associated with
differential marker expression were robust across the different treatments, but
rather the change in sensitivity comes from parameters associated with TF ex-
pression that impact the downstream phenotypic markers. This finding may
seem trivial but may offer some insight into responders and non-responders
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of ATRA treatment. Performing this series of sensitivity analysis on ATRA-
resistant cells that can be rescued with combination treatment shown by Jensen
and coworkers (REFERENCE) will reveal a great amount of detail in how the
sensitivity changes upon rescue. Although we capture most of the TF expres-
sion at 48 hours, the model fail to capture some combination treatment results
showed synergistic or antonisitic effect when compared to the sum of the ATRA
and D3 treatments. For example, EGR1 and GFI1 showed synergistic effect,
while AhR showed antagonistic effects. Within the network, the expression of
AhR is activated by Trigger ATRA, therefore the level was increased during
ATRA-induced differentiation and having no change during D3-induced dif-
ferentiation. However, in the presence of both ATRA and D3, AhR showed a
decrease in concentration compared to the baseline at time zero although there
is no TF that inhibit it’s expression in the network. The balance of AhR concen-
tration is determined by the rate of production and the rate of degradation. AhR
degradation is ubiquitin mediated and occurs via the 26S proteasome pathway
(REFERENCE: https://www.ncbi.nlm.nih.gov/pubmed/12213384). The acti-
vation of both Trigger ATRA and D3 may increase AhR ubiquination leading
to a higher rate of degradation, we look to further explore this mechanism in
the future. Similarly, we captured the 48hr expression of PU1 for monotherapy
of ATRA and D3-induced differentiation, however the combination treatment
yielded interesting results because the addition of D3 to ATRA treatment re-
duced the 48hr expression for PU1. This nonaddictive effect may be due to
the upregulation of GFI1 at 48hrs from the combination treatment that was ob-
served in the experiments but not capture in our simulations. GFI1 inhibits
the expression of PU1, therefore the higher level GFI1 for the combination case
will contribute to more inhibited level of PU1 expression, leading to a lower
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level at 48 hours. This brings up the questions of why GFI1 level is synergis-
tic increased with combination treatment, while not increased from monotreat-
ments for ATRA or D3 alone. The expression of GFI1 is induced by one TF,
CEBPα, which is not heavily upregulated in the combination treatment com-
pared to monotreatments, therefore the upregulation of GFI1 must be to ad-
dition biology that we do not account for in our model. Similarly, EGR1 also
behaves in a similar manner. Both GFI1 and EGR1 and TFs that determines
the terminal fate of differentiation with GFI1 and EGR1 supporting granulcytic
and monotypic differentiation respectively. The combination treatment show
synergistic effect of expression of the two terminal regulators, and the mech-
anism behind the synergistic effect is still undetermined. The upregulation of
GFI1 is not only involved in hemopoesis, but Xing and coworkers also showed
that GFI1 downregulation promotes inflammation-linked metastasis of colorec-
tal cancer (https://www.nature.com/articles/cdd201750). Analogously, EGR1
is a direct regulator of multiple tumor suppressors including TGFβ1, PTEN, p53
and fibronectin (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2455793/).
There is a huge opportunity in understanding the mechanisms behind the syn-
ergistic effect of ATRA and D3 that overexpresses GFI1 and EGR1 for the treat-
ment of resistance subpopulation or other types of cancer.
CD38 is an important early marker in both granucyctic and monocytic differ-
entiation. Although PPARγ is a key TF that regulates CD38 expression, ATRA
induced differentiation is more sensitive to the induction of PPARγ through
EGR1 while D3 showed higher sensitivity towards PPARγ expression through
PU1 activation. This finding suggest that parameters directly associated with
CD38 expression are robust and the sensitivtiy does not change with respect
to different treatment, therefore any effect that changes the expression of CD38
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would be due to upstream TFs that regulate CD38 rather than CD38 regula-
tion itself. This hypothesis is further supported by the sensitivity comparison
between ATRA and D3 induced differentiation where EGR1 and PU1 were the
key players in PPARγ and CD38 expression for ATRA and D3 treatments respec-
tively. The two monotreatment took different pathways to activate and express
the terminal phenotypic marker. With a better quantitative understanding of the
signal integration circuitry and the new analytical methodology, we believe this
is the first step in understanding ATRA resistance. With model aided interroga-
tion, we can identify which portion of the network that may be unresponsive or
identify unexplained mechanisms in the unresponsive cases.
3.5 Materials and Methods
Gene expression model equations.
We decomposed the ATRA-induced differentiation program into three modules;
a signal initiation module that sensed and transformed the ATRA signal into ac-
tivated cRaf-pS621 and the ATRA-RXR/RAR (activated Trigger) signals; a sig-
nal integration module that controlled the expression of upstream transcription
factors given cRaf-pS621 and activated Trigger signals; and a phenotype mod-
ule which encoded the expression of functional differentiation markers from the
ATRA-inducible transcription factors. The output of the signal initiation mod-
ule was the input to the gene expression model. For each gene j = 1, 2, . . . ,G,
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we modeled both the mRNA (m j) and protein (p j) abundance:
dm j
dt
= rT, j −
(
µ + θm, j
)
m j + λ j (3.1)
dp j
dt
= rX, j −
(
µ + θp, j
)
p j (3.2)
The terms rT, j and rX, j denote the specific rates of transcription, and translation
while the terms θm, j and θp, j denote first-order degradation constants for mRNA
and protein, respectively. The specific transcription rate rT, j was modeled as
the product of a kinetic term r¯T, j and a control term u j which described how the
abundance of transcription factors, or other regulators influenced the expression
of gene j. The kinetic transcription term r¯T, j was modeled as:
r¯T, j = VmaxT
(
LT,o
LT, j
) (
G j
KT +G j
)
(3.3)
where the maximum gene expression rate VmaxT was defined as the product of a
characteristic transcription rate constant (kT ) and the abundance of RNA poly-
merase (R1), VmaxT = kT (R1). The
(
LT,o/LT, j
)
term denotes the ratio of transcription
read lengths; LT,o represents a characteristic gene length, while LT, j denotes the
length of gene j. Thus, the ratio
(
LT,o/LT, j
)
is a gene specific correction to the
characteristic transcription rate VmaxT . The degradation rate constants were de-
fined as θm, j and θp, j denote characteristic degradation constants for mRNA and
protein, respectively. Lastly, the λ j term denotes the constitutive rate of expres-
sion of gene j.
The gene expression control term 0 ≤ u j ≤ 1 depended upon the combi-
nation of factors which influenced the expression of gene j. If the expression
of gene j was influenced by 1, . . . ,m factors, we modeled this relationship as
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u j = I j
(
f1 j (·) , . . . , fmj (·)
)
where 0 ≤ fi j (·) ≤ 1 denotes a regulatory transfer func-
tion quantifying the influence of factor i on the expression of gene j, and I j (·)
denotes an integration rule which combines the individual regulatory inputs
for gene j into a single control term. In this study, the integration rule govern-
ing gene expression was the weighted fraction of promoter configurations that
resulted in gene expression [REFHERE]:
u j =
WR1, j +
∑
n
Wn j fn j
1 + WR1, j +
∑
d
Wd j fd j
(3.4)
The numerator, the weighted sum (with weights Wn j) of promoter configura-
tions leading to gene expression, was normalized by all possible promoter con-
figurations. The likelihood of each configuration was quantified by the transfer
function fn j (which we modeled using hill like functions), while the lead term
in the numerator WR1, j denotes the weight of constitutive expression for gene j.
Given this formulation, the rate of constitutive expression was then given by:
λ j = r¯T, j
(
WR1, j
1 + WR1, j
)
(3.5)
If a gene expression process had no modifying factors, u j = 1. Lastly, the specific
translation rate was modeled as:
rX, j = VmaxX
(
LX,o
LX, j
) (
m j
KX + m j
)
(3.6)
where VmaxX denotes a characteristic maximum translation rate estimated from
literature, and KX denotes a translation saturation constant. The characteristic
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maximum translation rate was defined as the product of a characteristic transla-
tion rate constant (kX) and the Ribosome abundance (R2), VmaxX = kX (R2). As was
the case for transcription, we corrected the characteristic translation rate by the
ratio of the length of a characteristic transcription normalized by the length of
transcript j.
Effective cell cycle arrest model.
A defining feature of ATRA-induced differentiation is G1/G0 cell cycle arrest
followed by differentiation. While we included E2F transcription, we do not
consider a detailed model of restriction point regulation. Instead, we formu-
lated an effective model of the fraction of cells undergoing ATRA-induced cell
cycle arrest,A as:
dA
dt
= 1 (E2F)2 (3.7)
The parameters 1 and 2 were estimated from experimental cell distribution
measurements by log transforming Eq. (3.7):
log 1 + 2 log (E2F1) = log A˙21 (3.8)
log 1 + 2 log (E2F2) = log A˙32 (3.9)
where subscripts denote the experimental time point (1 = 24 hr, 2 = 48 hr, and 3 =
72 hr), E2Fi denotes the E2F abundance at time point i, and A˙i j denotes the time
derivative of the fraction of arrested cells (estimated from data). We calculated
candidate values for  j by solving the log-transformed system of equations for
10 biological replicates.
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Estimation of model parameters.
We estimated parameters appearing in the mRNA and protein balances, and
the abundance of polymerases and ribosomes, from estimates of transcription
and translation rates, the half-life of a typical mRNA and protein, and typical
values for the copies per cell of RNA polymerase and ribosomes from literature
(Table ZZ). For the remaining parameters, e.g., the Wi j appearing in the control
laws, or parameters appearing in the transfer functions fd j, were estimated from
the gene expression and signaling data sets discussed here. The saturation con-
stants KX and KT were adjusted so that gene expression and translation resulted
in gene products on a biologically realistic concentration scale. Lastly, we calcu-
lated the concentration for gene G j by assuming, on average, that a cell had two
copies of each gene at any given time. Thus, the bulk of our gene expression
parameters were based directly upon literature values, and were not adjusted
during model identification. The values used for the characteristic transcrip-
tion/translation parameters, degradation constants and macromolecular copy
number are given in the supplemental materials along with the specific formu-
las required to calculate all derived constants.
Signal and gene expression model parameters were estimated by minimiz-
ing the squared difference between simulations and experimental data set j:
E j(k) =
T j∑
i=1
(
Mˆi j − yˆi j(k)
)2
+
M′i j −max yi jM′i j
2 (3.10)
The terms Mˆi j and yˆi j denote scaled experimental observations and simulation
outputs at time i from training set j, whereT j denoted the number of time points
for data set j. The first term in Eqn. (3.10) quantified the relative simulation
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error. We used immunoblot intensity measurements for model training. Thus,
we trained the model on the relative change between bands within each data set.
Suppose we have the intensity of species x at time {t1, t2, .., tn} in condition j. The
scaled value 0 ≤ Mˆi j ≤ 1 is given by:
Mˆi j =
(
Mi j −min
i
Mi j
)
/
(
max
i
Mi j −min
i
Mi j
)
(3.11)
where Mˆi j = 0 and Mˆi j = 1 describe the lowest (highest) intensity bands. A sim-
ilar scaling was used for the simulation output. The second term in the objective
function ensured a realistic concentration scale was estimated by the model. We
set the highest intensity band to M′i j = 10 [AU] for all simulations. We mini-
mized the total model residual
∑
j E j using heuristic optimization starting from
a random initial parameter guess.
The signaling and gene expression model equations were implemented
in the Julia programming language, and solved using the ODE23s routine
of the ODE package [12]. The model code and parameter ensemble is
freely available under an MIT software license and can be downloaded from
http://www.varnerlab.org. Model parameters estimated directly or derived
from literature, or data presented in this study are given in Table 2.2.
Cell culture and treatment
Human myeloblastic leukemia cells (HL-60 cells) were grown in a humidified
atmosphere of 5% CO2 at 37oC and maintained in RPMI 1640 from Gibco (Carls-
bad, CA) supplemented with 5% heat inactivated fetal bovine serum from Hy-
clone (Logan, UT) and 1× antibiotic/antimicotic (Gibco, Carlsbad, CA). Cells
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were cultured in constant exponential growth [19]. Experimental cultures were
initiated at 0.1 × 106 cells/mL 24 hr prior to ATRA treatment; if indicated, cells
were also treated with GW5074 (2µM) 18 hr before ATRA treatment. For the cell
culture washout experiments, cells were treated with ATRA for 24 hr, washed
3x with prewarmed serum supplemented culture medium to remove ATRA,
and reseeded in ATRA-free media as described. Western blot analysis was per-
formed at incremental time points after removal of ATRA.
Chemicals
All-Trans Retinoic Acid (ATRA) from Sigma-Aldrich (St. Louis, MO) was dis-
solved in 100% ethanol with a stock concentration of 5mM, and used at a fi-
nal concentration of 1µM (unless otherwise noted). The cRaf inhibitor GW5074
from Sigma-Aldrich (St. Louis, MO) was dissolved in DMSO with a stock con-
centration of 10mM, and used at a final concentration of 2µM. HL-60 cells were
treated with 2µM GW5074 with or without ATRA (1µM) at 0 hr. This GW5074
dosage had a negligible effect on the cell cycle distribution, compared to ATRA
treatment alone.
Immunoprecipitation and western blotting
Approximately 1.2× 107 cells were lysed using 400µL of M-Per lysis buffer from
Thermo Scientific (Waltham, MA). Lysates were cleared by centrifugation at
16,950 × g in a micro-centrifuge for 20 min at 4oC. Lysates were pre-cleared
using 100µL protein A/G Plus agarose beads from Santa Cruz Biotechnology
(Santa Cruz, CA) by inverting overnight at 4oC. Beads were cleared by centrifu-
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gation and total protein concentration was determined by a BCA assay (Thermo
Scientific, Waltham, MA). Immunoprecipitations were setup by bringing lysate
to a concentration of 1g/L in a total volume of 300µL (M-Per buffer was used for
dilution). The anti-Raf antibody was added at 3µL. A negative control with no
bait protein was also used to exclude the direct interaction of proteins with the
A/G beads. After 1 hr of inversion at 4oC, 20µL of agarose beads was added and
samples were left to invert overnight at 4oC. Samples were then washed three
times with M-Per buffer by centrifugation. Finally proteins were eluted from
agarose beads using a laemmli loading buffer. Eluted proteins were resolved by
SDS-PAGE and Western blotting. Total lysate samples were normalized by total
protein concentration (20µg per sample) and resolved by SDS-PAGE and West-
ern blotting. Secondary HRP bound antibody was used for visualization. All
antibodies were purchased from Cell Signaling (Boston, MA) with the excep-
tion of α-p621 Raf which was purchased from Biosource/Invitrogen (Carlsbad,
CA), and α-CK2 from BD Biosciences (San Jose, CA).
Morphology assessment
Untreated and ATRA-treated HL-60 cells were collected after 72 hr and cyto-
centrifuged for 3 min at 700 rpm onto glass slides. Slides were air-dried and
stained with Wrightaˆs stain. Slide images were captured at 40X (Leica DM LB
100T microscope, Leica Microsystems).
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Figure 3.2: ATRA, D3, and combination induced expression of key pro-
teins in the gene regulatory network at 48 hours after induc-
tion. The error bars represent standard errors, 491 samples for
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Figure 3.3: Dynamic phenotypic markers of ATRA, D3, and combina-
tion induced differentiation of HL60. The simulation cap-
tured time-course experimental measurements of CD38 (blue),
CD11b (red), and CD14 (purple). The points are experimen-
tal measurements with error bars representing standard error.
The black lines are the simulated average of the 491 parameter
set ensemble, with the darker colored band representing 99 %
standard error of the simulated mean, and the lighter colored
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Table 3.1: Myelomonocytic transcription factor connectivity used in the signal
integration and phenotype modules.
Effector Effect Target Source
RARα + RARα [192]
+ PU.1 [175]
+ C/EBPα [76]
+ IRF-1 [160]
- Oct4 [220]
+ CD38 [53]
+ p21 [155]
+ AhR [23]
+ Egr-1 [7]
PPARγ + C/EBPα [195]
+ IRF-1 [232]
+ Oct1 [20]
- AP-1 [47]
- E2F [4]
- Egr-1 [66]
+ CD38 [211]
+ CD14 [221]
+ p21 [86]
- p47Phox [236]
PU.1 - PPARγ [49]
+ PU.1 [28]
+ AP-1 [215]
+ Egr-1 [142]
+ CD11b [185]
+ p21 [257]
+ p47Phox [149]
C/EBPα + PPARγ [195]
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+ PU.1 [43]
+ C/EBPα [227]
+ Gfi-1 [153]
- E2F [44]
+ CD14 [187]
+ p21 [89]
IRF-1 + CD38 [9]
+ p21 [189]
- PU.1 [42]
- C/EBPα [54]
- E2F [54]
- Egr-1 [142]
- p21 [54]
Oct1 + PU.1 [29]
AP-1 - PPARγ [47]
+ PU.1 [11]
+ p21 [125]
E2F + E2F [123]
Egr-1 + PPARγ [77]
- Gfi-1 [163]
+ CD14 [27]
AhR + AP-1 [217]
+ IRF-1 [206]
- Oct4 [22]
- PU.1 [14]
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CHAPTER 4
SRC FAMILY KINASE INHIBITOR BOSUTINIB ENHANCES RETINOIC
ACID-INDUCED DIFFERENTIATION OF HL-60 LEUKEMIA CELLS
4.1 Abstract1
A subtype of acute myeloid leukemia (AML), acute promyelocytic leukemia,
has been treated with all-trans retinoic acid (RA) for several decades; the drug
induces differentiation of cancerous cells. However, many patients relapse and
cancers become RA resistant. Combination therapy is a way to maintain and
potentially broaden efficacy of the treatment. Using the RA-responsive AML
cell line HL-60, we tested the efficacy of the Src family kinase (SFK) inhibitor
bosutinib (B) on RA-induced differentiation. We found that co-treatment with
RA and B enhanced differentiation evidenced by increased CD11b expression,
G1/G0 cell cycle arrest, and respiratory burst. Expression of the SFK members
Fgr and Lyn was enhanced, while SFK activation was inhibited. Phosphoryla-
tion of several sites of c-Raf was increased, and expression of AhR and p85 PI3K
was enhanced. Expression of c-Cbl and mTOR was decreased. Our study sug-
gests that SFK inhibition enhances RA-induced differentiation and may have
therapeutic value.
1This work is published and adopted from Leukemia Lymphoma
DOI:10.1080/10428194.2018.1452213
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4.2 Introduction
Acute myeloid leukemia (AML), the most common form of acute leukemia in
adults, is characterized by defective differentiation and excessive accumulation
of proliferatively active progenitor cells in bone marrow and blood [105, 111].
One of the most successful treatments of AML is of its subtype, acute promye-
locytic leukemia (APL). APL is characterized by a t(15,17) cytogenetic marker
seminal to a block of leukocyte differentiation at the promyelocyte stage and ac-
counts for approximately 10–15% of all AML cases [107, 246]. Once considered
one of the most lethal forms of acute leukemia, the advent of all trans-retinoic
acid (RA) and arsenic trioxide therapy has revolutionized treatment of this dis-
ease [246]. Now, APL is characterized by complete remission rates of 90% and
cure rates of around 80% [38]. While RA is effective in treating APL, it is not
effective in treating other subtypes of AML. Moreover, many APL patients who
initially respond to RA treatment relapse; subsequent RA treatment is ineffec-
tive due to RA-resistance [245, 74]. It is therefore of great interest to combine RA
with other agents, such as other differentiation-inducing compounds or kinase
inhibitors, in order to promote RA-induced differentiation of APL as well as
non-APL AML [116]. Src family kinases (SFKs) are a group of enzymes that are
important in leukemia cell proliferation, survival, adhesion, and differentiation
[111]. SFKs have been shown to positively regulate MAPK signaling, cell prolif-
eration, and contribute to cell transformation [135]. SFKs are overexpressed in
many cancer types and are typically associated with acute and chronic myeloid
malignancies and metastasis [156, 136]. Lyn has been found to be the primary
active SFK expressed in AML cells [52, 141]. SFK inhibition has been effective
in slowing leukemic cell growth [?]. It is therefore of interest to determine the
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impact of SFK expression and activity on RA-induced differentiation therapy.
SFK inhibitors PP2 and dasatinib have been reported to enhance RA-induced
differentiation [141, 173, 34, 128, 118]. However, some reports demonstrate that
SFKs positively regulate RA-induced differentiation. It is ergo unclear what
role SFKs have in regulating RA-induced differentiation. One focus of interest
is the impact of SFK inhibitors on the MAPK pathway, where different signal-
ing/phosphorylation signatures on the same targeted signaling molecules can
cause different outcomes. Defining these signatures is important to understand-
ing the differential signaling attributes that might be exploited for therapeutic
intervention. RA has been found to elicit MAPK pathway activation necessary
for HL-60 cell differentiation and growth arrest [254]. PP2 and dasatinib co-
treatments with RA were found to affect the Raf/MEK/ERK axis by upregu-
lating c-Raf pS259 while not impacting MEK or ERK expression or phosphory-
lation [34]. The results are somewhat counter-intuitive, but suggest signaling
events of importance to inducing differentiation of the leukemic cells, and they
motivate targeting SFKs to probe for signaling attributes driving differentiation.
Bosutinib (B) is a second-generation SFK inhibitor that has been used clinically
to treat phases of intolerant or resistant Philadelphia chromosome (t(19,21)/Bcr-
Abl) – positive chronic myeloid leukemias (CML) that do not harbor the T315I
or V299LABL kinase domain mutations [2]. While B treatments have been stud-
ied extensively in CML, its effects on AML have not been characterized. B’s
clinical usage to treat CML and benign toxicity profile make it an attractive can-
didate for combination treatment on AML [2, 39]. We examined the effects of
RA/B co-treatments on WT HL-60 cells to determine the effects of bosutinib
on HL-60 differentiation and the MAPK and mTOR pathways. We found that
RA/B enhanced RA-induced expression of the differentiation marker CD11b at
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48 and 72 h and G0/G1 arrest at 48 h. Induced oxidative metabolism and as-
sociated marker p47phox, a component of the NADPH oxidative metabolism
machine, were also enhanced with RA/B compared to RA. With RA/B treat-
ment, SFK members Fgr and Lyn saw an increase in expression, while pan-SFK
activation decreased. B also enhanced RA-induced c-Raf phosphorylation at
S259, S621, and the C-terminal domain. B decreased expression of c-Cbl and
mTOR compared to RA alone. B enhanced RA-induced expression of AhR and
p85 PI3K. Hence B affected several known key signaling molecule regulators
of RA-induced leukemic cell differentiation. Like dasatinib, combined RA/B
therapy may be useful in future AML treatments.
4.3 Materials and Methods
Cell culture and treatments Reagents, unless specified otherwise, were pur-
chased from commercial suppliers in the highest purity available. HL-60 hu-
man myeloblastic leukemia cells, derived from the original patient isolates were
maintained in this laboratory in RPMI 1640 supplemented with 5% fetal bovine
serum (GE Healthcare, Chicago, IL) and 1x antibiotic/antimycotic (Thermo
Fisher Scientific, Waltham, MA) in a 5% CO2 humidified atmosphere at 37C. The
cells used were certified as mycoplasma free HL-60 by Bio-Synthesis, Lewisville,
TX, in August 2017. Viability was monitored by 0.2% trypan blue (Invitrogen,
Carlsbad, CA) exclusion and routinely exceeded 95%. Experimental cultures
were initiated at a density of 0.1106 cells/ml. There were three treatment regi-
mens studied: (1) untreated, (2) RA, and (3) RA/B. All-trans retinoic acid (RA)
(Sigma, St. Louis, MO) was added from a 5 mM stock solution in 100% ethanol
to a final concentration of 1 in culture. Bosutinib (Sigma, St. Louis, MO) was
98
used from a stock of 5mM in DMSO to make the final concentrations in culture
indicated. Flow cytometric phenotypic analysis Immunostaining for CD11b
and CD38 was performed as previously described and analyzed using a Bec-
ton Dickinson LSR II flow cytometer (San Jose, CA). Gating was set to exclude
95% of the untreated wild-type HL-60 samples. Propidium iodide (PI) cell cycle
analysis was performed as previously described. Respiratory burst quantifi-
cation Respiratory burst quantification was performed as previously described
and analyzed using a Becton Dickinson LSR II flow cytometer (San Jose, CA).
Gating was set to exclude 95% of the samples not induced with TPA. The shift
in fluorescence intensity in response to TPA was used to determine the percent
cells with the capability to generate inducible oxidative metabolites. Antibodies
Lyn, Fgr, pY416-SFK, AhR, p47phox, mTOR, pS259c-Raf, pS621c-Raf, GAPDH,
horseradish peroxidase anti-mouse and anti-rabbit antibodies were from Cell
Signaling (Danvers, MA, USA). c-Cbl (C-15) and AhR (H211) were from Santa
Cruz Biotechnology (Santa Cruz, CA). Western blot analysis Cells were pelleted,
washed twice with PBS, and lysed with ice cold M-PER Mammalian Protein
Extraction Reagent (Pierce, Rockford, IL) with protease and phosphatase in-
hibitor cocktails (Sigma, St. Louis, MO). Samples were incubated overnight
at 80C and debris was pelleted. Protein concentration was determined using
the Pierce BCA Protein Assay according to the manufacturer’s protocol. Lysate
was subjected to standard SDS-PAGE, using 25of lysate per lane under denatur-
ing conditions. Membranes were blocked with 5% dry nonfat milk in PBS and
probed with antibodies described above. Enhanced chemiluminescence reagent
(GE Healthcare, Pittsburg, PA) was used for detection. Films were scanned and
quantitated using NIH Image J. Statistical analysis Statistics were analyzed us-
ing Microsoft Excel. Means of treatment groups of interest were compared using
99
paired sample T-tests. The data represent the means of three repeats S.E.M. A
p-value of ¡0.05 was considered significant.
4.4 Results
RA/B enhances CD11b and G1/G0 arrest We first determined the effect of B on
RA-induced differentiation in HL-60 cells by comparing differentiation mark-
ers of cells treated with RA alone or in combination with B (RA/B) over a 72 h
treatment period: we assessed CD38 and CD11b expression, G1/G0 cell cycle
arrest, and population growth. We chose to use 0.25 B based on an initial dose-
response experiment, included in the supplementary information (Figure S1). A
previous study also found that this dosage of B inhibited cancer cell migration
and invasion [237]. We measured expression of two cell surface markers, CD38
and CD11b, using flow cytometry. CD38 expression was nearly 100% in both
RA and RA/B treated cells at 24, 48, and 72 hours (Fig. 1A). CD38 mean ex-
pression per cell also yielded no difference between RA and RA/B at the three
time points (Fig. 1B). We measured CD11b, a later differentiation marker of RA-
induced differentiation, at 48 h and 72 h. RA/B significantly increases CD11b
expression at 72 h (Fig. 1C, p ¡ 0.05, n=3). Mean expression per cell of CD11b
also shows a significant increase with RA/B treatment at both 48 h and 72 h (Fig.
1D, p ¡ 0.05, n=3). At 48 h but not 72 h, RA/B showed significant enhancement
of G0/G1 arrest compared to RA alone (Fig. 1E, p ¡ 0.05, n=4). Addition of B to
the cells did not result in any apparent toxicity compared to RA, as both RA/B
and RA treatments yield similar cell growth patterns over the 72 h treatment
period (Fig. 1F). Both RA and RA/B induce growth retardation compared to
untreated cells (Fig. 1F). RA/B increases RA-induced respiratory burst activity
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To determine the effects of RA/B on a functional differentiation marker, respira-
tory burst, we measured inducible reactive oxygen species production (ROS) by
flow cytometry at 72 h. RA caused an increase in ROS compared to untreated
cells, and RA/B treated cells show a significant further increase in oxidative
metabolism compared to RA alone (Fig. 2A, p ¡ 0.05, n=3). To corroborate the
ROS assay, we also measured expression of a subunit of the NADPH oxidase
complex that produces the respiratory burst, p47phox (21,22). After a 48 h treat-
ment period, we collected cell lysate and performed western blots for p47phox
(Fig. 2B). Expression was greater in both RA and RA/B compared to untreated
cells, and RA/B further enhanced p47phox levels compared to RA alone (Fig.
2B). RA/B increases RA-induced SFK expression, but decreases SFK activation
As B is an SFK inhibitor and the SFK members Fgr and Lyn have been shown
to be upregulated by RA treatment in HL-60 cells [107, 34, ?], we assessed lev-
els and phosphorylation of these members by western blot. We collected lysate
following a 48 h treatment period. Both RA and RA/B increased Fgr and Lyn
levels compared to untreated cells, and RA/B induced further increases of Fgr
and Lyn levels compared to RA alone (Fig. 3A, 3B). We measured SFK activa-
tion using a pan-SFK antibody that detects active site (Y416) phosphorylation
in all family members, including Fgr and Lyn. While treatment with RA and
RA/B both caused in increase in SFK phosphorylation compared to untreated
cells, treatment with RA/B decreased SFK phosphorylation compared to RA
alone (Fig. 3, A-C). RA/B augments RA-induced c-Raf phosphorylation We also
examined phosphorylation of several sites of c-Raf previously shown to drive
RA-induced differentiation. [256]. Since SFKs can regulate MAPK signaling, we
analyzed the effect of B on RA-induced c-Raf activation. We evaluated the phos-
phorylation status of c-Raf regulatory phosphorylations at S259, S621, and the
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c-Raf C-terminal domain by western blot following a 48 h treatment period. RA
increases the amount of c-Raf pS259, c-Raf pS621, and c-Raf C-terminal domain
phosphorylation. We observed modest enhancements of levels of each of these
in cells treated with RA/B compared to RA alone (Fig. 4, A-C). RA/B inhibits
c-Cbl and mTOR expression and enhances AhR and p85 PI3K expression We
next assessed levels of several proteins associated with RA-induced differentia-
tion, AhR, c-Cbl, and p85 PI3K, as well as one known to be aberrantly activated
in AML, mTOR [119, 52, ?, 35]. After a 48 h treatment period, we collected cell
lysate and analyzed expression of these proteins via western blot. C-Cbl expres-
sion was upregulated in cells treated with RA and RA/B, but RA/B inhibited
c-Cbl expression compared to cells treated with RA alone (Fig. 5A). mTOR ex-
pression followed a similar pattern (Fig. 5B). AhR and p85 PI3K levels, how-
ever, were further upregulated in RA/B-treated cells compared to RA-treated
cells (Fig 5C, 5D).
4.5 Discussion
We sought to provide an initial characterization of the effects of treatment with
B on RA-induced differentiation of HL-60 cells. We observed that RA/B treat-
ment enhanced several myeloid lineage differentiation markers compared with
RA treatment alone: CD11b expression, G1/G0 cell cycle arrest, and respira-
tory burst, a functional marker of mature myeloid series cells [115]. Expres-
sion of CD38, another feature of RA-induced differentiation, was not affected
by the addition of B. Recent reports from our laboratory, however, suggest that
CD38 may not play an important role in the differentiation process (Sci Rep
paper, Oncotarget paper). Since addition of B enhanced phenotypic and func-
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tional markers of RA-induced differentiation, we explored its effects on acti-
vation of the key signaling protein c-Raf. Cells treated with RA/B displayed
increased phorphorylated c-Raf levels. The particular phosphorylation sites as-
sayed, S259, S621, and the C-terminal domain, are all associated with active c-
Raf in HL-60 cells and thus drive RA-induced differentiation [256]. Our western
blotting results are consistent with our phenotypic results and previous find-
ings that RA co-treatments with PP2 or dasatinib also increased c-Raf phos-
phorylation, namely c-Raf pS259 and c-Raf pS621, in HL-60 cells [34]. These
findings are congruous with the notion that c-Raf is a downstream target of
SFK inhibitors like B. Given that B is a SFK inhibitor, we assessed its effects
on two SFK members, Fgr and Lyn, the primary active SFK expressed in AML
cells [52, 141]). As anticipated, we saw that RA/B treatment decreased levels
of phosphorylated Y416, a mark of activated SFKs. We did, however, observe
increased levels of Fgr and Lyn in RA/B compared to RA alone; increase in
expression could perhaps be an attempt to compensate for the inhibited activ-
ity of the proteins. These results are consistent with previous findings with
RA/dasatinib co-treatments [34]. Dasatinib, like B, is a second generation SFK
inhibitor that is used clinically to treat chronic myeloid leukemia (CML). B has
a lower toxicity profile compared to dasatinib and is used in patients with CML
who have shown intolerance to dasatinib [124]. c-Cbl interacts with CD38 to
promote RA-induced differentiation and G1/G0 arrest of HL-60 cells [?]. As
previously reported, c-Cbl expression is upregulated by RA treatment; RA/B
treatment partially inhibits RA-induced upregulation. Since c-Cbl expression
has been shown to drive RA-induced differentiation, this is surprising, but it
is possible that B drives RA-induced differentiation via other pathways such
as c-Raf activation. The mTOR/p70S6K/4EBP1 pathway, a driver of cellular
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anabolism/metabolism, is constitutively activated in AML cells, leading to in-
creased cell proliferation and inhibition of differentiation [52]. mTOR is thought
to be downstream of the pathways implicated above to regulate differentiation.
Dasatinib inactivates the mTOR pathway, correlating with an improvement in
cell survival in the AML-derived cell line PVTL-1 [177]. Lyn is hypothesized to
serve as the intermediary; Lyn stimulates mTOR expression, and is inhibited by
dasatinib [177]. Lending credence to this, silencing Lyn was found to inhibit the
mTOR pathway in primary AML cells, and PP2 mimics rapamycin, a selective
inhibitor of mTOR [52]. To our knowledge, the effects of SFK inhibitors on the
mTOR pathway in APL are unknown. It was hence of interest to determine if B
has an inhibitory effect on mTOR in an RA-responsive AML cell line as found
in other forms of AML. Both RA and RA/B induced greater mTOR expression
compared to untreated cells, however, RA/B decreased mTOR expression com-
pared to RA (Fig. 5B). It appears that a decrease in the activated SFKs yields
an inhibitory effect on the mTOR pathway in RA-treated cells. This inhibitory
effect on the mTOR pathway suggests part of the process by which B enhances
differentiation compared to RA alone. We note that MAPK signaling pathway
activation is promoting differentiation and cell cycle arrest in RA-treated HL-60
cells, yet it is also thought to drive mTOR and, consequentially, cellular an-
abolism to promote proliferation. Hence, RA appears to be redirecting these
pathways to support differentiation instead of proliferation. The mechanism of
this is a profound but yet unresolved question in leukemic cell differentiation.
AhR is known to drive differentiation and to be linked to phosphorylated c-Raf
in an RA-activated signalsome (8). We found that RA treatment increased AhR
levels, consistent with previous studies (Fig. 5C) [107, 190, 177]. Co-treatment
with B further increased AhR expression, consistent with the increase in phos-
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phorylated c-Raf expression in RA/B treated samples (Fig. 3, Fig. 5C). p85 PI3K
activity is upregulated during granulocytic maturation [35]. It was therefore of
interest to determine the effect of B on p85 PI3K expression; the protein exhib-
ited an expression pattern similar to that of AhR, as B caused an increase in RA-
induced upregulation of p85 PI3K expression. Interestingly, while both CD38
and c-Cbl are known to interact with p85 PI3K [35], RA/B treatment did not
affect the RA-induced expression of these proteins in the same fashion. B, like
other SFK inhibitors, has promising effects on enhancing RA-induced differen-
tiation in HL-60 cells. These effects include modulation of the SFK members Fgr
and Lyn and impacts on the MAPK and mTOR pathways. Further studies may
elucidate the effects of RA/B co-treatments on RA-resistant APL cell lines or
other myeloid leukemias. B is already in clinical trials as a cytotoxic chemother-
apeutic agent, but our results suggest it is potentially useful as an agent used in
combination therapy with RA for differentiation therapy of AML.
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Figure 4.1: Phenotypic analysis of HL-60 cells treated with RA/bosutinib.
(A) HL-60 cells were cultured in the presence of 1RA or 1RA
and 0.25bosutinib as indicated. CD38 expression was assessed
by flow cytometry following 24, 48, and 72h treatment peri-
ods. Gating to discriminate positive cells was set to exclude
95% of untreated controls (n=3). Error bars indicate SEM. (B)
Normalized means of CD38 expression per cell at 24, 48, or
72h (n=3). (C) CD11b expression was assessed by flow cytom-
etry at 48 and 72h (n=3). *p¡.05 comparing RA-treated samples
to RA/bosutinib-treated samples. Two-tailed paired-sample
t-tests were used to determine significance. (D) Normalized
means of CD11b expression per cell at 48and 72h (n=3). *p¡.05
comparing RA-treated samples to RA/bosutinib-treated sam-
ples. (E) Cell cycle distribution showing the percentage of cells
in G1/G0 was analyzed using flow cytometry with propid-
ium iodide staining at 24, 48, and 72h (n=4). *p¡.05 comparing
RA-treated samples to RA/bosutinib-treated samples. (F) Cell
counts were taken at 24, 48, and 72h using a hemocytometer
and 0.2% Trypan Blue exclusion staining (n=3).
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Figure 4.2: HL-60 cells treated with RA/bosutinib displayed enhanced
respiratory burst and p47phox expression. (A) HL-60 cells
were cultured in the presence of 1RA or 1RA and 0.25bosu-
tinib as indicated. Respiratory burst was analyzed by mea-
suring inducible reactive oxygen species (ROS) production by
flow cytometry using the 2,7-dichlorofluorescein (DCF) assay.
Gates to determine percent increase of expression with treat-
ment were set to exclude 95% of the DMSO-treated control
population for each culture condition; TPA-treated samples
show induced ROS (n=3). Error bars indicate SEM. *p¡.05 com-
paring RA-treated samples to RA/bosutinib-treated samples.
Two-tailed paired-sample t-tests were used to determine sig-
nificance. (B) HL-60 cells were cultured for 48h in the presence
of 1RA or 1RA and 0.25B as indicated and whole cell lysate
was collected. Twenty five microgram of lysate per lane was
run. Western blots of PAGE-resolved lysates were probed for
p47phox (n=3). Films were scanned and bands of interest were
quantified using NIH ImageJ. Error bars indicate SEM. A rep-
resentative blot, cropped to show only the band of interest, is
included. (C) Western blots of GAPDH were used as loading
controls following the procedure described above.
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Figure 4.3: Bosutinib enhances RA-induced SFK expression and dimin-
ishes SFK phosphorylation. (A) HL-60 cells were cultured for
48h in the presence of 1RA or 1RA and 0.25bosutinib (B) as
indicated and whole cell lysate was collected. Twenty five mi-
crogram of lysate per lane was run. Western blots of PAGE-
resolved lysates were probed for Fgr (n=3). Films were scanned
and bands of interest were quantified using NIH ImageJ. Er-
ror bars indicate SEM. A representative blot, cropped to show
only the band of interest, is included. (B) Western blots of Lyn
following the procedure described above. (C) Western blots
of phosphorylated pan-Y416 SFK following the procedure de-
scribed above. (D) Western blots of GAPDH were used as load-
ing controls following the procedure described above.
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Figure 4.4: Bosutinib enhances levels of RA-induced phosphorylated c-
Raf. (A) HL-60 cells were cultured for 48h in the presence
of 1RA or 1RA and 0.25bosutinib as indicated and whole cell
lysate was collected. Twenty five microgram of lysate per lane
was run. Western blots of PAGE-resolved lysates were probed
for c-Raf pS259 (n=3). Films were scanned and bands of in-
terest were quantified using NIH ImageJ. Error bars indicate
SEM. A representative blot, cropped to show only the band of
interest, is included. (B) Western blots of c-Raf pS621 following
the procedure described above. (C) Western blots of c-Raf pC-
terminal domain following the procedure described above. (D)
Western blots of total c-Raf following the procedure described
above. (E) Western blots of GAPDH were used as loading con-
trols following the procedure described above.
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Figure 4.5: The effect of bosutinib on c-Cbl, mTOR, AhR, and p85 PI3K.
(A) HL-60 cells were cultured for 48h in the presence of 1RA
or 1RA and 0.25bosutinib (B) as indicated and whole cell lysate
was collected. Twenty five microgram of lysate per lane was
run. Western blots of PAGE-resolved lysates were probed for
c-Cbl (n=3). Films were scanned and bands of interest were
quantified using NIH ImageJ. Error bars indicate SEM. A rep-
resentative blot, cropped to show only the band of interest,
is included. (B) Western blots of mTOR following the proce-
dure described above. (C) Western blots of AhR following the
procedure described above. (D) Western blots of p85 PI3K fol-
lowing the procedure described above. (E) Western blots of
GAPDH were used as loading controls following the procedure
described above.
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CHAPTER 5
DYNAMIC SEQUENCE SPECIFIC CONSTRAINT-BASED MODELING OF
CELL-FREE PROTEIN SYNTHESIS
5.1 Abstract1
Cell-free protein expression has emerged as an important approach in systems
and synthetic biology, and a promising technology for personalized point of
care medicine. Cell-free systems derived from crude whole cell extracts have
shown remarkable utility as a protein synthesis technology. However, if cell-
free platforms for on-demand biomanufacturing are to become a reality, the per-
formance limits of these systems must be defined and optimized. Toward this
goal, we modeled E. coli cell-free protein expression using a sequence specific
dynamic constraint based approach in which metabolite measurements were
directly incorporated into the flux estimation problem. A cell free metabolic
network was constructed by removing growth associated reactions from the
iAF1260 reconstruction of K-12 MG1655 E. coli. Sequence specific descriptions
of transcription and translation processes were then added to this metabolic
network to describe protein production. A linear programming problem was
then solved over short time intervals to estimate metabolic fluxes through the
augmented cell free network, subject to material balances, time rate of change
and metabolite measurement constraints. The approach captured the biphasic
cell free production of a model protein, chloramphenicol acetyltransferase. Flux
variability analysis suggested that cell free metabolism was potentially robust;
for example, the rate of protein production could be met by flux through the
1This work is published and adopted from Processes https://doi.org/10.3390/pr6080132
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glycolytic, pentose phosphate, or the Entner-Doudoroff pathways. Variation of
the metabolite constraints revealed central carbon metabolites, specifically up-
per glycolysis, TCA cycle, and pentose phosphate, to be the most effective at
training a predictive model, while energy and amino acid measurements were
less effective. Irrespective of the measurement set, the metabolic fluxes (for the
most part) remained unidentifiable. These findings suggested dynamic con-
straint based modeling could aid in the design of cell free protein expression
experiments for metabolite prediction, but the flux estimation problem remains
challenging. Further, while we modeled the cell-free production of only a single
protein in this study, the sequence specific dynamic constraint based modeling
approach presented here could be extended to multi-protein synthetic circuits,
RNA circuits or even small molecule production.
5.2 Introduction
Cell-free protein expression has become a widely used research tool in systems
and synthetic biology, and a promising technology for personalized point of use
biotechnology [188]. Cell-free systems offer many advantages for the study, ma-
nipulation and modeling of metabolism compared to in vivo processes. Central
amongst these is direct access to metabolites and the biosynthetic machinery,
without the interference of a cell wall or the complications associated with cell
growth. This allows us to interrogate (and potentially manipulate) the chemical
microenvironment while the biosynthetic machinery is operating, potentially at
a fine time resolution. Cell-free protein synthesis (CFPS) systems are arguably
the most prominent examples of cell-free systems used today [121]. However,
CFPS in crude E. coli extracts has been used previously to explore fundamen-
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tal biological questions. For example, Matthaei and Nirenberg used E. coli cell
free extracts to decipher the genetic code [167, 179]. Later, Spirin and cowork-
ers continuously exchanged reactants and products in a CFPS reaction, which
improved protein production. However, while these extracts could run for up
to tens of hours, they could only synthesize a single product and were likely
energy limited [213]. More recently, energy and cofactor regeneration in CFPS
has been significantly improved; for example ATP can be regenerated using
substrate level phosphorylation [134] or even oxidative phosphorylation [121].
Today, cell-free systems are used in a variety of applications ranging from ther-
apeutic protein production [157] to synthetic biology [99, 188]. There are also
several CFPS technology platforms, such as the PANOx-SP and Cytomin plat-
forms developed by Swartz and coworkers [122, 121], and the TX/TL platform
of Noireaux [79]. Taken together, CFPS is a promising technology for protein
production. However, if CFPS is to become a mainstream technology for appli-
cations such as point of care biomanufacturing, we must first understand the
performance limits of these systems, and eventually optimize their yield and
productivity. Toward this unmet need, we have developed a dynamic constraint
based modeling that can be used to interrogate cell free systems.
Genome scale stoichiometric reconstructions of microbial metabolism pop-
ularized by static, constraint based modeling techniques such as flux balance
analysis (FBA) have become standard tools [147]. Since the first genome scale
stoichiometric model of E. coli, developed by Edwards and Palsson [58], well
over 100 organisms, including industrially important prokaryotes such as E. coli
[67] or B. subtilis [183], are now available [70]. Stoichiometric models rely on a
pseudo-steady-state assumption to reduce unidentifiable genome-scale kinetic
models to an underdetermined linear algebraic system, which can be solved effi-
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ciently even for large systems using linear programming. Traditionally, stoichio-
metric models have also neglected explicit descriptions of metabolic regulation
and control mechanisms, instead opting to describe the choice of pathways by
prescribing an objective function on metabolism. Interestingly, similar to early
cybernetic models, the most common metabolic objective function has been the
optimization of biomass formation [109], although other metabolic objectives
have also been estimated [201]. Recent advances in constraint based modeling
have overcome the early shortcomings of the platform, including describing
metabolic regulation and control [106] and incorporating genome sequence into
the model [3, 181]. Dynamic constraint based methods have also been devel-
oped in which the metabolic flux is computed over short-time intervals subject
to time-varying constraints [162]. These methods are common, have been used
in varied applications, [97, 96, 88, 93], and there are open source packages to
support this class of calculation [100, 81, 82]. Thus, constraint based approaches,
and their dynamic extensions, have proven useful in the discovery of metabolic
engineering strategies and represent the state of the art in metabolic modeling
[168, 265]. However, while constraint based tools have been used extensively
to analyze whole cells systems, they have not yet been widely applied to study
cell free reactions.
In this study, we constructed a dynamic constraint based model of cell-
free protein expression. This approach avoids the pseudo-steady-state assump-
tion found in traditional constraint based approaches, which allowed for the
direct integration of dynamic metabolite measurements into the flux estima-
tion problem, along with the accumulation or depletion of network metabo-
lites. We adapted the sequence specific constraint based model of Vilkhovoy
and coworkers [235] into a dynamic constraint based model of cell-free E. coli
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metabolism and protein production, and leveraged the kinetic model of Hor-
vath and coworkers [103] to provide synthetic data to inform metabolite con-
straints. CFPS synthesis is often (but not always) conducted in small scale batch
reactors. Thus, the concentration of the components of the reaction mixture,
and the associated rates of the metabolic processes in the reaction are not al-
ways constant. The Vilkhovoy et al study considered only the first hour of
the CFPS reaction producing the model protein, chloramphenicol acetyltrans-
ferase (CAT). During this initial phase, the metabolic rates were approximately
constant and a classical sequence specific flux balance analysis approach was
sufficient to describe protein synthesis [235]. However, after this initial phase,
there was a significant shift in productivity following the exhaustion of glu-
cose (which occurred at approximately 1.5 hr). Horvath and coworkers de-
veloped a fully kinetic model that described the complete three hour reaction
time course, including the shift in productivity following glucose exhaustion
[103]. While this model described the CFPS dynamics, and the decrease in pro-
ductivity following the exhaustion of glucose, the identification of the model
from 37 measured metabolite trajectories was difficult. Thus, there was an
unmet need for a tool that could describe the dynamics of a CFPS reaction,
without the burden of identifying a full kinetic model. Toward this need, we
developed a dynamic constraint based modeling approach for CFPS reactions
which directly incorporated metabolite measurements (as constraints) into the
flux calculation. The dynamic constraint based model satisfied time-dependent
metabolite constraints, while predicting the concentration of the CAT protein
and unconstrained metabolite concentrations. Model interrogation suggested
the most important metabolite constraint was glucose, as excluding glucose
yielded the greatest metabolite prediction error, and the greatest uncertainty in
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the estimated metabolic flux. Further, we evaluated metabolite constraint sets
with one more and one fewer metabolites than the base case (the 37 measured
metabolites) to explore the impact of measurement selection on model perfor-
mance. The single addition of metabolites yielded no significant improvement
in the predictive power, while the single exclusion suggested glucose to be the
most important measured metabolite in the base case. Next, we selected mea-
surement species based on the results of singular value decomposition on the
stoichiometric matrix. The top 36 species from the SVD analysis with the ad-
dition of glucose improved the predictive power and reduced flux uncertainty
compared with the base case. Finally, we developed a heuristic optimization
approach to estimate the optimal list of metabolite measurements. This ap-
proach significantly improved metabolite prediction compared to the base case.
However, both the base measurement set and the heuristically optimized exper-
imental design poorly characterized flux uncertainty. Taken together, this sug-
gested dynamic constraint based modeling can aid in experimental design and
measurement selection for metabolite prediction, but the flux estimation prob-
lem remains challenging. Further, while we modeled the cell-free production
of only a single protein in this study, the sequence specific dynamic constraint
based modeling approach presented here could be extended to multi-protein
synthetic circuits, RNA circuits [104] or even small molecule production.
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5.3 Results
5.3.1 Cell-free E. coli metabolic network.
We constructed the cell-free stoichiometric network by removing growth asso-
ciated reactions from the iAF1260 reconstruction of K-12 MG1655 E. coli [67],
and removing reactions not present in the cell-free system (see Materials and
Methods). We then added the transcription and translation template reactions
of Allen and Palsson for the CAT protein [3]. Thus, our stoichiometric network
described the material and energetic demands for transcription and translation
at sequence specific level. The metabolic network consisted of 264 reactions and
146 species; a schematic of the central carbon metabolism is shown in Fig. 5.1.
The network described the major carbon and energy pathways and amino acid
biosynthesis and degradation pathways. Lastly, we removed genes from the
network that were knocked out in the E. coli host strain used to make the cell free
extract (A19 ∆tonA ∆tnaA ∆speA ∆endA ∆sdaA ∆sdaB ∆gshA), see Jewett et al
for further details of the host strain and the cell free extract preparation [120].
Using this network, we simulated time-dependent cell-free production of the
model protein CAT. We used dynamic modified flux balance analysis, a stoichio-
metric modeling technique that does not make the pseudo steady state assump-
tion and allows the accumulation and depletion of metabolite species. Horvath
and coworkers predicted time-dependent cell-free production of CAT using a
fully kinetic model trained against an experimental dataset of 37 metabolites,
including the substrate glucose, the protein product CAT, organic acids, amino
acids, and energy species [103]. This model was used to generate the metabolite
constraints used in this study. Transcription and translation rates were subject
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to resource constraints encoded by the metabolic network, and transcription
and translation model parameters were largely derived from literature (Table
5.1). In this study, we did not explicitly consider protein folding. However, the
addition of chaperone or other protein maturation steps could easily be accom-
modated within the approach by updating the template reactions, see Palsson
and coworkers [181]. The cell-free metabolic network and all model code and
parameters can be downloaded under an MIT software license from the Varner-
lab website [234].
5.3.2 Dynamic constrained simulation of cell free protein syn-
thesis.
Cell free synthesis of the CAT protein showed two production phases, an initial
fast production phase before glucose exhaustion (at approximately 1.5 hrs) and
a slow production phase following glucose exhaustion. The metabolite pro-
file varied significantly between these phases; for example, pyruvate and lac-
tate were produced during the first phase but consumed during the second.
Thus, a static pseudo steady state flux balance approach was not possible for
this system. However, a central advantage of cell free systems is direct access
to metabolite measurements, and the biosynthetic machinery during produc-
tion. If we could directly integrate dynamic metabolite and protein concen-
tration measurements into the flux estimation problem, we could potentially
get a better estimate of the flux distribution. Toward this question, we devel-
oped a dynamic modeling approach in which metabolic fluxes were estimated
so that all metabolites were non-negative and the simulated metabolites were
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constrained to lie within a bounded range of the measured value. Using this
technique, we simulated the cell free production of CAT subject to dynamic
metabolite measurements.
We explored the influence of uncertainty in the transcription (TX) and trans-
lation parameters (TL) by sampling different values for the abundance and elon-
gation rates of RNA polymerases and ribosomes, the polysome amplification
constant, the mRNA degradation rate and other kinetic parameters appearing
in the transcription and translation bounds. The base values for the TX/TL
parameters are given in Table 5.1, and the uniform sampling procedure is de-
scribed in the Materials and Methods. Central carbon metabolites (Fig. 5.2),
amino acids (Fig. 5.3), and energy species (Fig. 5.4) in the synthetic measure-
ment set were captured, within experimental error, by an ensemble of dynamic
constraint based simulations. The 95% confidence interval (CI) estimates of the
experimental error shown in each of the simulation figures was derived from
the kinetic model of Horvath et al [103], which was trained on the 37 metabo-
lites shown in Fig. 5.2 - 5.4. Thus, the 95% confidence estimates shown in this
study were calculated based upon the kinetic model, which shows high fidelity
with the experimental measurements. The flux estimation problem converged
in greater than 99% of the simulation time intervals, given these metabolite con-
straints. This suggested there were not gross measurement errors in the mea-
surement constraints, as the stoichiometric constraints were satisfied. More-
over, it suggested the error introduced by the time discretization scheme did
not lead to inconsistent metabolite estimates. The ensemble of models captured
the time evolution of protein biosynthesis, and the consumption and produc-
tion of organic acid, amino acid and energy species. Arginine and glutamate
were excluded from the constraint set, but were still largely captured by the en-
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semble of dynamic constraint based models, although with wide variance than
the synthetic measurement set. During the first hour, glucose was consumed as
the primary carbon source for ATP, amino acids, and protein synthesis. After
glucose was depleted, lactate and pyruvate were consumed as alternate sub-
strates for energy production and CAT synthesis. Taken together, we captured
the 37 metabolite measurements in the base synthetic data set, and captured the
biphasic behavior of CAT production, although we significantly over-predicted
the translation rate for some elements of the ensemble. This suggested there
was excess capacity in the metabolic network, that could be used to enhance
protein production.
We quantified the uncertainty in the estimated metabolic flux distribution,
given constrained CAT production using flux variability analysis (FVA) for the
base synthetic data across the three hours of measurement (Tables 5.2 and 5.3).
The analysis was divided into two phases: phase 1 where glucose was con-
sumed as the carbon source, and phase 2 when glucose was depleted and lac-
tate and pyruvate were utilized. The reactions associated with protein synthesis
(translation initiation, translation, tRNA charging, mRNA degradation) were
unsurprisingly the most constrained, as CAT production was forced to remain
the same. Transcription was not varied in this analysis. On the other hand,
glycolytic, pentose phosphate, and Entner-Doudoroff reactions were not highly
constrained, indicating the robustness of substrate utilization. However, one
exception to this was the net reaction through zwf reaction, which was tightly
constrained, suggesting that glycolysis alone cannot support protein produc-
tion. Interestingly, although the two phases consumed different carbon sources,
the flux variability remained similar. Taken together, these results suggested
there was significant flexibility in the ability of the metabolic network to meet
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the carbon and energy demands of protein synthesis. Next, we explored alterna-
tive measurement sets to constrain the simulation of cell free protein synthesis.
5.3.3 Alternative measurement sets.
The base synthetic data set, consisting of 36 metabolite time series and the pro-
tein product CAT, was the measurement set used to train the kinetic model of
Horvath et al [103]. Thus, the error confidence intervals used in this study as
constraints on the flux estimation problem were informed by experimental mea-
surements of glucose, organic and amino acids, energy species and the protein
product CAT. However, we have no a priori reason to suppose that this exper-
imental design was optimal. Toward this question, we performed simulations
and flux variability analysis (FVA) for alternative synthetic data sets to under-
stand the importance of measurement selection when characterizing CFPS (Fig.
5.5 and Fig. 5.6). In all cases, we assumed the same sampling frequency as the
base synthetic dataset, but we varied which species were measured. First, we
removed each of the 37 metabolites from the base set, one at a time, to create
37 measurement exclusion sets, consisting of 36 metabolites each (Fig. 5.5, light
gray dots). For each set, the state the dynamic model was used to calculate a
value of error against the synthetic data, and FVA was used to calculate a value
of flux uncertainty. Most of the exclusion sets clustered around the base case,
with error values between 75% and 110%, and flux uncertainties between 93%
and 103%, of the base case. The exception to this was the glucose exclusion set,
which showed 89% higher error and 7% greater flux uncertainty. Within the
primary cluster, a slight pattern emerged: the sets in which an organic acid was
removed tended to result in increased error, while the removal of an amino acid
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tended to reduce error; however, this was not true across all metabolites. We
also performed the analysis on several inclusion sets to determine which addi-
tional metabolites could improve predictive power (Fig. 5.5, black dots). In par-
ticular, we added unmeasured central carbon metabolites to the base case which
resulted in 23 inclusion sets, consisting of 38 metabolites each. As with the ex-
clusion sets, most of the inclusion sets clustered around the base case, with error
values between 72% and 103%, and flux uncertainties between 94% and 102%,
of the base case. Considering all exclusion and inclusion sets, there was gener-
ally no correlation between the metabolite prediction error and flux uncertainty.
Taken together, these suggested central carbon metabolites, especially glucose,
were important to characterizing the network, but performing single additional
measurements was not enough to significantly increase predictive power. Next,
we explored whether measurement selection could be based upon the structural
features of a metabolic network. Toward this question, we used singular value
decomposition (SVD) of the stoichiometric matrix to suggest which metabolites
should be measured.
Singular value decomposition (SVD) measurement selection outperformed
the base case, with a prediction error improvement of 11% and similar flux vari-
ability (Fig. 5.5, open square). SVD was used to decompose the stoichiometric
matrix into 105 modes. The top 36 metabolites that had the greatest weighted
sum across the modes that accounted for 95% of the network were estimated.
Since our exclusion analysis identified glucose as the single most important
metabolite, we added it to the top metabolites as determined by SVD to obtain
a 37-metabolite constraint set, consisting of: GTP, GDP, GMP, ATP, ADP, AMP,
UTP, UMP, CTP, CMP, GLN, GLU, ASP, LYS, LEU, HIS, THR, PHE, ALA, VAL,
TYR, GLY, SER, H, ASN, ILE, MET, AKG, PYR, ARG, CYS, NH3, FUM, SUCC,
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TRP, ACCOA, and glucose. The SVD measurement set suggested that energy,
and amino acid species carried the most information compared to central car-
bon species which made up a relatively smaller fraction of the list. Surprisingly,
the measurement set selected by SVD was approximately 80% similar to the
original synthetic data generated by hand. However, the 20% difference was
enough to improve the prediction error by approximately 11%. Taken together,
measurements selected by SVD decomposition of the stoichiometric matrix im-
proved the prediction of metabolite abundance, but SVD-based measurement
selection did not improve flux variability.
Next, we used heuristic optimization to systematically investigate the ef-
fect of changing the dimension and identify of the measurement constraints
(Fig. 5.6). In particular, we minimized the error and flux variability of model
predictions by varying the metabolites which appeared in the synthetic con-
straint set. We used a binary simulated annealing algorithm to switch metabo-
lite membership in the constraint set on or off, and thus generated an ensemble
of > 200 measurement constraint sets (Fig. 5.6A). While there was no strict er-
ror threshold, the simulated annealing algorithm was less likely to accept high-
error sets into the ensemble; thus, the error of most sets in the ensemble was
less than that of the base case. Specifically, the error varied from just over dou-
ble to less than one ten-thousandth of the base case. Flux uncertainty was also
a component of the objective function, but was only improved by 7%, suggest-
ing this performance metric was tightly constrained; network flux values were
not be well characterized, even with comprehensive training datasets. As ex-
pected, there was an inverse relationship between the number of metabolite
constraints and the prediction error (Fig. 5.6B). However, the slope of that trend
was striking; error was improved by three to four orders of magnitude, simply
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by increasing the number of constraints by 11 or fewer. Furthermore, the base
synthetic measurement set was outperformed by the majority of the ensemble;
often the simulated annealing approach achieved the same error with fewer
constraints, or much lower error with the same, or even fewer, constraints. This
suggests that while comprehensive, the original synthetic dataset was not opti-
mal in terms of predictive power per measurement. However, the base case was
one of the best in terms of reducing flux uncertainty.
Lastly, we investigated which metabolites were most effective at improving
predictive power by considering how often it appeared in the ensemble (Ta-
ble 5.4). Glucose unsurprisingly appeared most often (tied with G6P), but in-
terestingly was not in every constraint set. Those that did not contain glucose
had some of the highest errors, but also some of the smallest constraint set sizes
(Fig. 5.6B, black dots). The most frequent metabolites from the heuristic method
were largely from glycolysis, pentose phosphate, and the TCA cycle (compared
to the SVD analysis which gave greater consideration to energetic and amino
acid species). To further understand the species selection, we calculated the fre-
quency of appearance in the 57 best sets, those with error of least three orders
of magnitude lower than the base case (Table 5.5). Nineteen metabolites ap-
peared in all of these sets, and all but Alanine were central carbon metabolites
(defined here as glycolysis, pentose phosphate, TCA). Taken together, measure-
ment selection made a significant difference in capturing dynamic metabolite
abundance in cell free protein synthesis. Although the error decreased with in-
creasing measurement number overall, the specific combination of metabolites
was arguably even more important. Metabolic fluxes, however, remained un-
known despite the large number of measurements taken.
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5.4 Discussion
In this study, we presented a dynamic constraint based model of cell-free protein
expression. This approach avoids the pseudo-steady-state assumption found
in traditional constraint based approaches, which allowed for the direct inte-
gration of metabolite measurements into the flux estimation problem, and the
the accumulation or depletion of network metabolites. The approach used the
E.coli cell free protein synthesis metabolic network from Vilkhovoy and cowork-
ers [235], and the simulated metabolite trajectories from the kinetic model of
Horvath et al [103] as constraints on the CFPS flux calculation. The dynamic
constraint based model satisfied time-dependent metabolite measurement con-
straints, predicted unconstrained metabolite concentrations as well as the con-
centration of a model protein, chloramphenicol acetyltransferase (CAT). Model
interrogation suggested the most important metabolite measurement within the
dataset to be glucose, as excluding the glucose yielded the greatest metabolite
prediction error, and the greatest uncertainty in the estimated metabolic flux.
Further, we evaluated metabolite constraint sets with one more and one fewer
metabolites than the base case (37 metabolites) to explore the impact of mea-
surement selection on model performance. The single addition of metabolites
yielded no significant improvement in the predictive power, while the single
exclusion suggested glucose to be the most important measured metabolite in
the base case. Next, we selected measurement species based on the results of
singular value decomposition on the stoichiometric matrix. The top 36 species
from the SVD analysis with the addition of glucose improved the predictive
power and reduced flux uncertainty compared with the base case. Finally,
we described a heuristic optimization approach to estimate the optimal list of
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metabolite measurements. Measurement sets determined by heuristic optimiza-
tion vastly outperformed the accuracy of the base synthetic dataset; model pre-
cision, meanwhile, was virtually unchanged despite comprehensive measure-
ment sets. Taken together, model interrogation showed that even with a com-
prehensive dataset, there still exists a great amount of uncertainty associated
with metabolic fluxes. This highlights the need for fluxomic data to fully under-
stand biological networks.
Despite synthetic datasets consisting of greater than 30 metabolite time se-
ries, estimates of metabolic flux were largely uncertain. Flux variability analysis
suggested that the metabolite constraints could be met with a wide range of dif-
ferent flux distributions. For instance, an open question in cell-free systems is
the balance between glycolytic versus pentose phosphate pathway flux. In pre-
vious studies of E. coli cell free protein synthesis, the kinetic model of Horvath
and coworkers suggested that glucose was consumed primarily by glycolytic
reactions, with minimal flux into the pentose phosphate pathway. However,
Vilkhovoy et al estimated, using sequence specific flux balance analysis with
the same experimental dataset, that the CAT production was unaffected by the
choice of pentose phosphate pathway versus glycolysis; deletion of either path-
way did not change protein productivity. To answer this discrepancy, model
analysis showed, during the first phase when glucose was being consumed, gly-
colytic and pentose phosphate fluxes (pgi and zwf, respectively) exhibited large
uncertainty, as either could be utilized to satisfy CAT production. The measure-
ment selection analysis was conducted by excluding or including a metabolite
from the constraint set. The exclusion sets were dominated by the removal of
glucose, and to a lesser extent the organic acids, suggesting measurements of
central carbon metabolism intermediates were more important than energetic
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and amino acid measurements. However, the inclusion sets showed no signif-
icant effect on error and flux uncertainty. There was generally no correlation
between the error and flux uncertainty of a model constrained to a particular
metabolite set, except with respect to the outlier glucose. Model calculations
showed that even with a comprehensive data set of 37 metabolite measure-
ments, there was significant flux uncertainty. This suggested there were many
flux combinations that could give rise to the same set of time course measure-
ments. This phenomenon was further supported by analyzing the ensemble of
constraint sets determined by heuristic optimization. Although the optimiza-
tion algorithm reduced the objective function by four degrees of magnitude,
the flux variability remained stagnant in comparison. An ensemble of measure-
ment sets ranging from 22 to 48 metabolite constraints was only able to reduce
flux uncertainty by 7% from the base synthetic data set. The dynamic constraint
based model showed high flux variability in important branch points, includ-
ing the glucose-6-phosphate split between glycolysis and pentose phosphate,
the 6PGC split into pentose phosphate and Entner-Doudoroff, and the pyruvate
split into TCA cycle versus lactate production. This may be why the high overall
flux variability was robust to the varying of metabolite constraints. Using three
different sampling approaches (single additions/exclusions, singular value de-
composition, simulated annealing) coupled with the dynamic constraint based
model, we estimated key metabolites that could be prioritized in measurement
selection, such as glucose. Although measuring central carbon metabolites and
amino acids is the intuition of most researchers, model interrogation was able
to provide the importance of certain species over others; for instance, measur-
ing G6P, G3P, and F6P would be more fruitful than measuring PEP. Interest-
ingly, many of the most valuable measurements were involved in upper gly-
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colysis and pentose phosphate, such as glucose, G6P, and 6PGL. This may be
because upstream metabolites have an effect on more of the network; any error
or uncertainty in these metabolites will cascade down the rest of the network
and magnify throughout. Taken together, the dynamic constraint based model
quantitatively affirmed the robustness of metabolism, and illustrated the com-
plexity of inferring flux information from metabolite concentrations. Ultimately,
to determine the metabolic flux distribution occurring in a cell free system, we
need to add additional constraints to the flux estimation calculation. This study
suggested metabolite measurements alone were not sufficient. However, these
are not the only experimentally realizable types of constraints. For example,
thermodynamic feasibility constraints may result in a better depiction of the
flux distribution [92, 85], and 13C labeling constraints in cell free systems could
provide significant insight. However, while 13C labeling techniques are well es-
tablished for in vivo processes [258], application of these techniques to cell free
systems remains an active area of research.
In summary, we used a dynamic constraint based modeling approach to sim-
ulate cell free metabolism, and to study how measurement selection impacts
model performance. We extended sequence specific flux balance analysis, by
removing the pseudo steady state assumption, and adding synthetic metabo-
lite measurement constraints to the flux calculation. Using this method, we
simulated the cell free synthesis of a model protein, chloramphenicol acetyl-
transferase, we identified the most important measured species in the cell free
system, and additional species that yielded the lowest metabolite prediction er-
ror and flux uncertainty. Only synthetic metabolite measurements were used
in this study; however, this work built a foundation to rationally design ex-
perimental measurement protocols, that could be implemented with a variety
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of analytical techniques. Taken together, these findings represent a novel tool
for dynamic cell free simulations, measurement selection and pathway analy-
sis, not only for E. coli, but potentially for align variety of metabolic networks,
whether in vivo or cell-free. However, while this first study was promising, there
were several issues to consider in future work. First, while we described tran-
scription and translation at a sequence specific level, we have not considered
the complexities of protein folding, or post-translational modifications such as
protein glycosylation. A more detailed description of transcription and trans-
lation reactions, including the role of chaperones in protein folding, has been
used in in-vivo genome scale ME models e.g., see O’Brien et al [181]. These tem-
plate reactions could easily be adapted to a cell free system, thereby providing
a potentially higher fidelity description protein synthesis and folding. Next, the
inclusion of post-translational modifications such as protein glycosylation in the
next generation of models will be important to describe the cell free synthesis of
therapeutic proteins. DeLisa and coworkers recently showed that glycoproteins
can be synthesized in a cell free system, using extract generated from modified
E.coli cells capable of asparagine-linked protein glycosylation [113]. Simulation
of the generation and attachment of glycans to protein targets could be an im-
portant step to optimizing cell free glycoprotein production. Lastly, while we
modeled the cell-free production of a only single protein in this study, sequence
specific dynamic constraint models could be developed for multi-protein syn-
thetic circuits, RNA circuits or even small molecule production. Thus, this ap-
proach offers a unique tool to model and potentially optimize a wide variety of
application areas in synthetic biology.
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5.5 Materials and Methods
5.5.1 Formulation of the model equations.
We modeled the time evolution of the ith metabolite concentration (xi), the
scaled activity of network enzymes (i), transcription processes generating the
mRNA m and translation processes generating the proteinP in an E. coli cell-free
metabolic network as a system of ordinary differential equations:
x˙i =
R∑
j=1
σi jr j (x, ,k) i = 1, 2, . . . ,M (5.1)
˙i = −λii i = 1, 2, . . . ,N (5.2)
m˙ = rT − λm (5.3)
P˙ = rX (5.4)
The quantity R denotes the number of metabolic reactions,M denotes the num-
ber of metabolites and N denotes the number of metabolic enzymes in the
model. The quantity r j (x, ,k) denotes the rate of reaction j. Typically, reac-
tion j is a non-linear function of metabolite and enzyme abundance, as well as
unknown kinetic parameters k (K×1). The quantity σi j denotes the stoichiomet-
ric coefficient for species i in reaction j. If σi j > 0, metabolite i is produced by
reaction j. Conversely, if σi j < 0, metabolite i is consumed by reaction j, while
σi j = 0 indicates metabolite i is not connected with reaction j. Lastly, λi denotes
the scaled enzyme activity decay constant. The system material balances were
subject to the initial conditions x (to) = xo and  (to) = 1 (initially we have 100%
cell-free enzyme activity).
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The cell-free model equations were solved using a dynamic constraint based
approach in which the rates of the metabolic fluxes, transcription and transla-
tion processes were estimated by solving an optimization subproblem from t
to t + ∆t. In particular, the biochemical fluxes r1, r2, . . . , rR which appear in the
balance equations were calculated from t to t + ∆t by solving a constrained opti-
mization subproblem with (potentially non-linear) objective O (x1, x2, . . . , xM):
max
r1,r2,...,rR
O (x1, x2, . . . , xM) (5.5)
subject to species constraints and flux bounds:
 R∑
j=1
σi jr j − x˙i
 ≥ 0 i = 1, 2, . . . ,M (5.6)
0 ≤ r j ≤ U j (x1, x2, . . . , xM, κ) j = 1, 2, . . . ,R (5.7)
In this study, we maximized the rate of translation rX unless otherwise speci-
fied. We discretized the derivative term for each species using a constant width
h forward different approximation (however, this was done for convenience
and more sophisticated techniques could have been used). The reaction bounds
U j (x1, x2, . . . , xM, κ) are potentially complex functions of the system state, and can
be updated during each time step. Here, we modeled the upper bound for flux
j as Vˆmax j(k), where Vˆmax denotes a characteristic maximum reaction velocity,
and  j(k) denotes the scaled enzyme activity catalyzing reaction j at time step
k. The characteristic maximum reaction velocity was set to 600 mM/hr (which
corresponds to an average kcat ' 1000s−1 and and enzyme concentration of ap-
proximately 0.2 µM) unless otherwise specified. Additional species constraints
can be added to directly incorporate metabolomic, proteomic or transcriptomic
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measurements into the flux calculation. In this study, we incorporated metabo-
lite measurement constraints of the form:
χLm,k+1 ≤ xm,k+1 ≤ χUm,k+1 m = 1, 2, . . . ,Ξ (5.8)
where χLm,k+1 and χ
U
m,k+1 denote the lower and upper measurement bound for
metabolite m at time step k + 1, where Ξ metabolites were measured over the
time course of the cell free reaction. Lastly, we imposed a user-configurable
bound Bi on the maximum rate of change for metabolite i:
|x˙i| ≤ Bi i = 1, 2, . . . ,M (5.9)
and non-negativity constrains xi ≥ 0 for all metabolites and all time steps.
The bounds on the transcription rate (LT = rT = UT ) were modeled as:
rT = VmaxT
(
GP
KT +GP
)
(5.10)
whereGP denotes the concentration of the gene encoding the protein of interest,
and KT denotes a transcription saturation coefficient. The maximum transcrip-
tion rate VmaxT was formulated as:
VmaxT ≡
[
RT
(
v˙T
lG
)
u (κ)
]
(5.11)
where RT denotes the RNA polymerase concentration (nM), v˙T denotes the RNA
polymerase elongation rate (nt/h), lG denotes the gene length (nt). The term u (κ)
(dimensionless, 0 ≤ u (κ) ≤ 1) is an effective model of promoter activity, where κ
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denotes promoter specific parameters. The general form for the promoter mod-
els was taken from Moon et al. [174]; which was based on earlier studies from
Bintu and coworkers [13], and similar to the genetically structured modeling
approach of Lee and Bailey [143]. In this study, we considered only the T7 pro-
moter model:
uT7 =
KT7
1 + KT7
(5.12)
where KT7 denotes a T7 RNA polymerase binding constant. The values for all
promoter parameters are given in Table 5.1.
The translation rate (rX) was bounded by:
0 ≤ rX ≤ VmaxX
(
m
KX + m
)
(5.13)
where m denotes the mRNA abundance and KX denotes a translation saturation
constant. The maximum translation rate VmaxX was formulated as:
VmaxX ≡
[
KPRX
(
v˙X
lP
)]
(5.14)
The term KP denotes the polysome amplification constant, v˙X denotes the ri-
bosome elongation rate (amino acids per hour), and lP denotes the number of
amino acids in the protein of interest. The mRNA abundance m was estimated
as:
mk+1 = mk + (rT − mkλ)h (5.15)
where λ denotes the mRNA degradation rate constant (h−1). All translation pa-
rameters are given in Table 5.1.
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Sampling of transcription and translation parameters.
The influence of the uncertainty in the transcription (TX) and translation (TL)
parameters was estimated by sampling the expected physiological ranges for
these parameters as determined from literature. We generated uniform random
samples between an upper (u) and lower (l) parameter bound of the form:
p∗ = l + (u − l) ×U (0, 1) (5.16)
The T7 RNA polymerase concentration was sampled between 990 and 1010 nM,
ribosome levels between 1.8 and 2.2 µM, the RNA polymerase elongation rate
between 20 and 30 nt/s, and the ribosome elongation rate between 1.0 and 3.0
aa/s [228, 79].
5.5.2 Generation and evaluation of alternative measurement
sets.
The measurement sets consisted of the base (one set of 37 metabolites), inclu-
sion sets (23 sets of 38 metabolites each), exclusion sets (37 sets of 36 metabolites
each), SVD-guided (one set of 37 metabolites), and simulated annealing sam-
ples (238 sets of varying length). In all cases, we assumed the same sampling
frequency as the base synthetic dataset, but we varied which species were mea-
sured. The exclusion or inclusion measurement sets were constructed by re-
moving or adding a metabolite to the base set, while the SVD-guided measure-
ment set was constructed from high importance metabolites; the top 36 metabo-
lites (plus glucose) that had the greatest singular value weighted sum across
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the SVD-modes, accounting for 95% of the network structure, were designated
the SVD measurement set. Lastly, we used simulated annealing to generate
potentially optimal measurements sets, where the objective was to minimize
the product of the prediction error, and flux uncertainty. The prediction error,
E, was computed by comparing the simulated versus the measured value of a
metabolite, for aMcore set of metabolites. On the other hand, the flux variability
was computed using flux variability analysis (FVA) [176], subject to constraints
on the CAT production rate, and the selected metabolite trajectories. In partic-
ular, the metabolite prediction error was calculated from the time-dependent
state array:
E =
Mcore∑
i=1
T∑
t=ti
(
max
(
xi(t) − yUi (t), 0
)
+ max
(
yLi (t) − xi(t), 0
))
where xi(t) denotes the simulated value of metabolite i at time t, yUi (t) denotes the
upper bound of the 95% confidence interval on the synthetic data for metabo-
lite i at time t, yLi (t) denotes the lower bound of the 95% confidence interval
on the synthetic data for metabolite i at time t, andMcore denotes the subset of
metabolites in the core metabolism. For this calculation, the entire time course
was considered (ti = 0 h, T = 3 h). The flux uncertainty was calculated from the
maximal and minimal flux arrays:
σoverall =
∑
r j∈Rcore
T∑
t=ti
(
rmaxj (t) − rminj (t)
)2
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where rmaxj (t) denotes the maximum value of flux j, while r
min
j (t) denotes the
value of flux j at time t, calculated using flux variability analysis. The quantity
Rcore denotes the subset of reactions that constitute the core metabolism. For the
flux uncertainty calculations, either the entire reaction time course was consid-
ered (ti = 0 h, T = 3 h), or the uncertainty was calculated separately for each
phase (phase 1: ti = 0 h, T = 1 h; phase 2: ti = 1 h, T = 3 h).
The simulated annealing algorithm began by evaluating the error and flux
uncertainty of the base case and multiplying these to obtain a cost function:
cost = E · σoverall (5.17)
Then, each metabolite that was considered measurable was added to or re-
moved from the constraint set with a certain probability pswitch:
θnewi =

1 − θi Runiform0,1 < pswitch
θi Runiform0,1 > pswitch
i = 1, 2, . . . ,Mmeasurable (5.18)
where θi ∈ {0, 1} denotes a binary parameter encoding whether or not metabo-
lite i is in the constraint set, Runiform0,1 denotes a uniform random number taken
from a distribution between 0 and 1, and Mmeasurable denotes the set of metabo-
lites deemed to be measurable. For each newly generated constraint set, we
re-solved the dFBA and FVA problems, and re-calculated the cost function. All
sets with a lower cost were accepted into the ensemble. Sets with a higher cost
were also accepted into the ensemble, if they satisfied the acceptance constraint:
Runiform0,1 < exp
(
−α · costnew − cost
cost
)
(5.19)
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where Runiform0,1 denotes a random number taken from a uniform distribution be-
tween 0 and 1, cost denotes the cost of the current parameter set, costnew de-
notes the cost of the new parameter set, and α denotes an adjustable parameter
to control the tolerance to high-error sets. A total of 238 samples were accepted
into the ensemble, of which there were 219 unique sets. BothMcore and Rcore and
user-configurable, and defined in the model code repository available from the
Varnerlab website [234].
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Table 5.1: Reference values for transcription, translation, and mRNA
degradation from literature. Transcription rate calculated from
elongation rate, mRNA length, and promoter activity level.
Translation rate calculated from elongation rate, protein length,
and polysome amplification constant. The mRNA degradation
rate calculated from a characteristic mRNA half-life.
Description Parameter Value Units Reference
T7 RNA polymerase concentration RT 1.0 µM
Ribosome concentration RX 2 µM [79]
CAT mRNA length lG 660 nt [133]
CAT protein length lP 219 aa [133]
Transcription saturation coefficient KT 100 nM estimated
Transcription elongation rate v˙T 25 nt/s [79]
Translation saturation coefficient KX 45 µM estimated
Translation elongation rate v˙X 1.5 aa/s [79]
T7 Promoter activity level u 0.9 estimated
Transcription rate kTcat =
(
v˙T
lG
)
u 123 h-1 calculated
Polysome amplification constant KP 10 estimated
Translation rate kXcat =
(
v˙X
lP
)
KP 247 h-1 calculated
mRNA degradation time t1/2 8 min BNID 106253
mRNA degradation rate kdeg =
ln(2)
t1/2
5.2 h-1 calculated
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Table 5.2: Flux uncertainty calculated using flux variability analysis for the base
synthetic dataset during the first production phase (0 h to 1.5 h), normalized to
the glucose consumption rate.
Effector Effect Target
Source
RNA polymerase Translation <0.01
RNA polymerase Translation initiation <0.01
tRNA charging of alanine tRNA charging (ALA) <0.01
tRNA charging of cysteine tRNA charging (CYS) <0.01
tRNA charging of aspartate tRNA charging (ASP) <0.01
tRNA charging of histidine tRNA charging (HIS) <0.01
tRNA charging of serine tRNA charging (SER) <0.01
tRNA charging of tyrosine tRNA charging (TYR) <0.01
tRNA charging of phenylalanine tRNA charging (PHE) <0.01
tRNA charging of arginine tRNA charging (ARG) <0.01
tRNA charging of glutamate tRNA charging (GLU) <0.01
mRNA degradation mRNA degradation <0.01
tRNA charging of tryptophan tRNA charging (TRP) <0.01
tRNA charging of proline tRNA charging (PRO) <0.01
tRNA charging of asparagine tRNA charging (ASN) <0.01
tRNA charging of isoleucine tRNA charging (ILE) <0.01
tRNA charging of glycine tRNA charging (GLY) <0.01
tRNA charging of glutamine tRNA charging (GLN) <0.01
tRNA charging of lysine tRNA charging (LYS) <0.01
tRNA charging of threonine tRNA charging (THR) <0.01
tRNA charging of valine tRNA charging (VAL) <0.01
tRNA charging of methionine tRNA charging (MET) <0.01
tRNA charging of leucine tRNA charging (LEU) <0.01
Step 6 of AMP synthesis R A syn 6 <0.01
Orotate synthase 1 R or syn 1 <0.01
Metionine biosynthesis R met 0.01
Valine biosynthesis R val 0.01
Continued on next page
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Enzyme/Pathway Reaction Uncertainty
Leucine biosynthesis R leu 0.01
Aldhyde-alcohol dehydrogenase R adhE net 0.01
Malate dehydrogenase R mdh net 0.01
Glycine biosynthesis R gly deg 0.02
Threonine degradation 2 R thr deg2 0.02
Acetate kinase R ackA net 0.02
Alanine biosynthesis R alaAC net 0.02
Isoleucine biosynthesis R ile 0.03
Tyrosine biosynthesis R tyr 0.03
Histidine biosynthesis R his 0.03
Methylglyoxal degradation R mglx deg 0.03
Transaldolase R talAB net 0.04
Glycine cleavage system R gly fol net 0.04
Ribulose-phosphate 3-epimerase R rpe net 0.04
Phosphate acetyltransferase R pta net 0.04
Phosphoglycerate kinase R pgk net 0.05
Glyceraldehyde-3-phosphate dehydrogenase R gapA net 0.05
Fructose 1,6-bisphosphate aldolase R fbaA net 0.05
Enolase R eno net 0.05
Phenylalanine biosynthesis R phe 0.05
Transketolase 2 R tkt2 net 0.06
Fumarate hydratase R fum net 0.06
Transketolase 1 R tkt1 net 0.07
Orotate synthase 2 R or syn 2 0.07
Phosphoglycerate mutase R gpm net 0.08
Ribose-5-phosphate isomerase R rpi net 0.09
CTP synthetase 1 R ctp 1 0.09
CTP synthetase 2 R ctp 2 0.09
Triosephosphate isomerase R tpiA net 0.1
Step 7 of AMP synthesis R A syn 7 0.15
Step 12 of AMP synthesis R A syn 12 0.17
Continued on next page
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Enzyme/Pathway Reaction Uncertainty
Lactate dehydrogenase R ldh net 0.17
Step 5 of AMP synthesis R A syn 5 0.2
Methylenetetrahydrofolate reductase R mthfr2a 0.2
Glucose-6-phosphate dehydrogenase R zwf net 0.21
Methylenetetrahydrofolate dehydrogenase R mthfd net 0.21
UMP synthesis R ump syn 0.22
OMP synthesis R omp syn 0.22
Lysine degradation R lys deg 0.23
Lysine biosynthesis R lys 0.23
Isocitrate dehydrogenase R icd net 0.23
Threonine degradation 3 R thr deg3 0.24
Step 8 of AMP synthesis R A syn 8 0.26
Tryptophan degradation R trp deg 0.27
Methylenetetrahydrofolate dehydrogenase R mthfc net 0.28
Tryptophan biosynthesis R trp 0.28
Aconitase R acn net 0.33
Phosphoglucose isomerase R pgi net 0.33
Step e of folate synthesis R fol e 0.34
Step 4 of AMP synthesis R A syn 4 0.4
GMP synthetase R gmp syn 0.44
Step 9 of AMP synthesis R A syn 9 0.48
XMP synthase R xmp syn 0.53
Step 3 of AMP synthesis R A syn 3 0.6
Step 10 of AMP synthesis R A syn 10 0.63
Step 2b of folate synthesis R fol 2b 0.63
Glutamate dehydrogenase R gdhA net 0.71
Step 3 of folate synthesis R fol 3 0.74
Step 4 of folate synthesis R fol 4 0.79
Pyruvate formate lyase R pflAB 0.8
Step 2 of AMP synthesis R A syn 2 0.81
Step 2a of folate synthesis R fol 2a 0.81
Continued on next page
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Enzyme/Pathway Reaction Uncertainty
Step 1 of folate synthesis R fol 1 0.99
Glucokinase R glk atp 1
Step 1 of AMP synthesis R A syn 1 1
Arginine degradation R arg deg 1.23
Glycine biosynthesis R glyA 1.33
Phosphoribosylpyrophosphate synthase R prpp syn 1.34
Chorismate synthesis R chor 1.35
Succinate thiokinase R sucCD 1.55
2-Ketoglutarate dehydrogenase R sucAB 1.55
GABA degradation 1 R gaba deg1 1.56
GABA degradation 2 R gaba deg2 1.56
Glutamate degradation R glu deg 1.56
Arginine biosynthesis R arg 1.68
Pyruvate dehydrogenase R pdh 2.06
Malate synthase R aceB 2.3
Threonine degradation 1 R thr deg1 2.32
Isocitrate lyase R aceA 2.36
Threonine biosynthesis R thr 2.48
Citrate synthase R gltA 2.62
6-Phosphogluconate dehydrogenase R gnd 2.62
Cysteine biosynthesis R cysEMK 4.59
Cysteine degradation R cys deg 4.6
Proline biosynthesis R pro 5.45
Proline degradation R pro deg 5.47
6-Phosphogluconate dehydrase R edd 5.96
2-Keto-3-deoxy-6-phospho-gluconate aldolase R eda 5.96
Serine degradation R ser deg 6.43
Nucleotide diphosphatase (ATP) R atp amp 6.53
Nucleotide diphosphatase (UTP) R utp ump 6.53
Nucleotide diphosphatase (GTP) R gtp gmp 6.53
Nucleotide diphosphatase (CTP) R ctp cmp 6.53
Continued on next page
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Enzyme/Pathway Reaction Uncertainty
Cytidylate kinase R atp cmp 6.56
Guanylate kinase R atp gmp 6.6
UMP kinase R atp ump 6.62
6-Phosphogluconolactonase R pgl 6.67
Serine biosynthesis R serABC 6.72
NADH:ubiquinone oxidoreductase R nuo 7.39
NADH dehydrogenase 1 R ndh1 7.39
NADH dehydrogenase 2 R ndh2 7.39
Fumurate reductase R frd 7.44
Succinate dehydrogenase R sdh 7.93
Malic enzyme A R maeA 7.99
Malic enzyme B R maeB 8.01
Cytochrome oxidase bo R cyo 8.03
Cytochrome oxidase bd R cyd 8.03
ATP synthase R atp 11.71
PEP synthase R pps 12.98
Fructose-1,6-bisphosphate aldolase R fdp 12.98
Adenosinetriphosphatase R atp adp 12.98
PEP carboxykinase R pck 12.98
Asparagine biosynthesis R asnB 13
Glutamate biosynthesis R gltBD 13
Glutamine degradation R gln deg 13
Glutamine biosynthesis R glnA 13.05
Acetyl-CoA synthetase R acs 13.06
Inorganic pyrophosphatase R ppa 13.08
Adenylate kinase R adk atp 13.36
PEP carboxylase R ppc 14.22
Phosphofructokinase R pfk 14.9
Pyruvate kinase R pyk 15.89
Transhydrogenase R pnt2 22.45
Transhydrogenase R pnt1 25.5
Continued on next page
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Aspartate degradation R asp deg 25.5
Aspartate biosynthesis R aspC 25.83
Asparagine biosynthesis R asnA 247.53
Asparagine degradation R asn deg 247.53
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Table 5.3: Flux uncertainty calculated using flux variability analysis for the base
synthetic dataset during the second production phase (1 h to 3 h), normalized
to the glucose consumption rate.
Effector Effect Target
Source
Step 6 of AMP synthesis R A syn 6 <0.01
Orotate synthase 1 R or syn 1 <0.01
Orotate synthase 2 R or syn 2 <0.01
Aldhyde-alcohol dehydrogenase R adhE net <0.01
RNA polymerase Translation <0.01
tRNA charging of phenylalanine tRNA charging (PHE) <0.01
tRNA charging of alanine tRNA charging (ALA) <0.01
tRNA charging of glutamine tRNA charging (GLN) <0.01
tRNA charging of threonine tRNA charging (THR) <0.01
tRNA charging of aspartate tRNA charging (ASP) <0.01
tRNA charging of glutamate tRNA charging (GLU) <0.01
tRNA charging of histidine tRNA charging (HIS) <0.01
tRNA charging of lysine tRNA charging (LYS) <0.01
tRNA charging of tyrosine tRNA charging (TYR) <0.01
tRNA charging of asparagine tRNA charging (ASN) <0.01
tRNA charging of serine tRNA charging (SER) <0.01
tRNA charging of methionine tRNA charging (MET) <0.01
tRNA charging of isoleucine tRNA charging (ILE) <0.01
tRNA charging of valine tRNA charging (VAL) <0.01
tRNA charging of proline tRNA charging (PRO) <0.01
tRNA charging of leucine tRNA charging (LEU) <0.01
tRNA charging of arginine tRNA charging (ARG) <0.01
tRNA charging of tryptophan tRNA charging (TRP) <0.01
tRNA charging of cysteine tRNA charging (CYS) <0.01
tRNA charging of glycine tRNA charging (GLY) <0.01
RNA polymerase Translation initiation <0.01
mRNA degradation mRNA degradation <0.01
Continued on next page
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Glycine cleavage system R gly fol net 0.01
Transaldolase R talAB net 0.02
Transketolase 1 R tkt1 net 0.02
Ribulose-phosphate 3-epimerase R rpe net 0.02
Ribose-5-phosphate isomerase R rpi net 0.03
Transketolase 2 R tkt2 net 0.04
Valine biosynthesis R val 0.05
Leucine biosynthesis R leu 0.05
Malate dehydrogenase R mdh net 0.06
Triosephosphate isomerase R tpiA net 0.07
Fructose 1,6-bisphosphate aldolase R fbaA net 0.07
Glycine biosynthesis R gly deg 0.09
Threonine degradation 2 R thr deg2 0.09
Phosphoglucose isomerase R pgi net 0.09
Methylglyoxal degradation R mglx deg 0.09
Methylenetetrahydrofolate dehydrogenase R mthfd net 0.13
Glucose-6-phosphate dehydrogenase R zwf net 0.18
Tyrosine biosynthesis R tyr 0.2
Enolase R eno net 0.2
Phosphoglycerate mutase R gpm net 0.2
Phosphoglycerate kinase R pgk net 0.21
Glyceraldehyde-3-phosphate dehydrogenase R gapA net 0.21
Methylenetetrahydrofolate dehydrogenase R mthfc net 0.28
Metionine biosynthesis R met 0.34
Phosphate acetyltransferase R pta net 0.4
Acetate kinase R ackA net 0.41
Fumarate hydratase R fum net 0.43
Phenylalanine biosynthesis R phe 0.53
Glucokinase R glk atp 1
Step 5 of AMP synthesis R A syn 5 1
Step 7 of AMP synthesis R A syn 7 1
Continued on next page
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OMP synthesis R omp syn 1.09
Isoleucine biosynthesis R ile 1.13
Alanine biosynthesis R alaAC net 1.49
Step 8 of AMP synthesis R A syn 8 1.76
Methylenetetrahydrofolate reductase R mthfr2a 1.85
Isocitrate dehydrogenase R icd net 1.87
Histidine biosynthesis R his 1.95
Step 4 of AMP synthesis R A syn 4 2.02
Threonine degradation 3 R thr deg3 2.08
CTP synthetase 1 R ctp 1 2.09
CTP synthetase 2 R ctp 2 2.09
Lysine biosynthesis R lys 2.13
Lysine degradation R lys deg 2.13
Lactate dehydrogenase R ldh net 2.27
Tryptophan degradation R trp deg 2.55
Tryptophan biosynthesis R trp 2.7
Aconitase R acn net 2.82
UMP synthesis R ump syn 2.85
Step 3 of AMP synthesis R A syn 3 3.07
XMP synthase R xmp syn 4.04
GMP synthetase R gmp syn 4.04
Step 12 of AMP synthesis R A syn 12 4.13
Step e of folate synthesis R fol e 4.37
Step 2 of AMP synthesis R A syn 2 4.74
Step 9 of AMP synthesis R A syn 9 4.83
Step 10 of AMP synthesis R A syn 10 4.83
Step 1 of AMP synthesis R A syn 1 5.02
Glutamate dehydrogenase R gdhA net 5.14
Phosphoribosylpyrophosphate synthase R prpp syn 6.11
Step 4 of folate synthesis R fol 4 6.24
Step 3 of folate synthesis R fol 3 6.24
Continued on next page
148
Enzyme Reaction Uncertainty
Step 2b of folate synthesis R fol 2b 7.03
Step 2a of folate synthesis R fol 2a 8.04
Step 1 of folate synthesis R fol 1 9.04
Glycine biosynthesis R glyA 9.58
Chorismate synthesis R chor 13.98
Arginine degradation R arg deg 14.97
Succinate thiokinase R sucCD 17.94
GABA degradation 1 R gaba deg1 17.95
GABA degradation 2 R gaba deg2 17.95
Glutamate degradation R glu deg 17.95
2-Ketoglutarate dehydrogenase R sucAB 18.06
Arginine biosynthesis R arg 18.14
Threonine degradation 1 R thr deg1 19.06
Pyruvate formate lyase R pflAB 19.97
Threonine biosynthesis R thr 22.23
Malate synthase R aceB 28.81
Isocitrate lyase R aceA 28.81
Pyruvate dehydrogenase R pdh 29.86
6-Phosphogluconate dehydrogenase R gnd 31.9
Citrate synthase R gltA 32.2
Cysteine biosynthesis R cysEMK 48.93
Cysteine degradation R cys deg 49.31
Proline biosynthesis R pro 61.2
2-Keto-3-deoxy-6-phospho-gluconate aldolase R eda 61.86
6-Phosphogluconate dehydrase R edd 61.86
Proline degradation R pro deg 62.62
Serine degradation R ser deg 68.5
6-Phosphogluconolactonase R pgl 70.12
Serine biosynthesis R serABC 72.05
Nucleotide diphosphatase (ATP) R atp amp 74.22
Nucleotide diphosphatase (UTP) R utp ump 74.22
Continued on next page
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Nucleotide diphosphatase (GTP) R gtp gmp 74.22
Nucleotide diphosphatase (CTP) R ctp cmp 74.22
Cytidylate kinase R atp cmp 74.74
Guanylate kinase R atp gmp 76.11
UMP kinase R atp ump 76.78
NADH dehydrogenase 1 R ndh1 86.63
NADH:ubiquinone oxidoreductase R nuo 86.63
Malic enzyme A R maeA 86.77
NADH dehydrogenase 2 R ndh2 87.01
Fumurate reductase R frd 87.01
Malic enzyme B R maeB 88.17
Succinate dehydrogenase R sdh 90.66
Cytochrome oxidase bo R cyo 92.08
Cytochrome oxidase bd R cyd 92.08
ATP synthase R atp 134.61
PEP synthase R pps 148.45
Asparagine biosynthesis R asnB 148.45
Glutamine degradation R gln deg 148.45
Glutamate biosynthesis R gltBD 148.45
Acetyl-CoA synthetase R acs 148.45
Adenosinetriphosphatase R atp adp 148.45
Fructose-1,6-bisphosphate aldolase R fdp 148.45
PEP carboxykinase R pck 148.45
Glutamine biosynthesis R glnA 149.67
Inorganic pyrophosphatase R ppa 150.79
Adenylate kinase R adk atp 152.88
PEP carboxylase R ppc 158.68
Phosphofructokinase R pfk 161.64
Pyruvate kinase R pyk 170.95
Transhydrogenase R pnt2 258.03
Aspartate degradation R asp deg 286.46
Continued on next page
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Transhydrogenase R pnt1 286.46
Aspartate biosynthesis R aspC 290.86
Asparagine biosynthesis R asnA 4421.48
Asparagine degradation R asn deg 4421.48
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Table 5.4: Metabolites by frequency of appearance in the simulated an-
nealing constraint sets.
Metabolite Symbol Frequency
alpha-D-Glucose GLC 89.9%
Glucose 6-phosphate G6P 89.9%
Citrate CIT 85.7%
Isocitrate ICIT 84.9%
Fumarate FUM 84.5%
Fructose 6-phosphate F6P 83.6%
6-Phospho-D-glucono-1,5-lactone 6PGL 81.5%
sedo-Heptulose 7-phosphate S7P 79.4%
Alanine ALA 77.7%
Guanosine triphosphate GTP 77.3%
Malate MAL 75.6%
D-Ribulose 5-phosphate RU5P 74.8%
Erythrose 4-phosphate E4P 73.1%
Adenosine diphosphate ADP 72.3%
alpha-Ketoglutarate AKG 71.8%
Uridine diphosphate UDP 70.2%
Succinate SUCC 69.7%
Cytidine monophosphate CMP 69.3%
Guanosine diphosphate GDP 67.2%
6-Phospho-D-gluconate 6PGC 67.2%
Arginine ARG 66.8%
Ribose 5-phosphate R5P 66.4%
Methionine MET 65.5%
Glyoxylate GLX 65.5%
Glutamine GLN 63.9%
Phenylalanine PHE 63.4%
Valine VAL 62.6%
Glyceraldehyde 3-phosphate G3P 62.2%
Adenosine monophosphate AMP 62.2%
Proline PRO 60.1%
Fructose 1,6-diphosphate FDP 60.1%
Dihydroxyacetone phosphate DHAP 60.1%
Histidine HIS 59.7%
Glycine GLY 59.7%
Oxaloacetate OAA 58.4%
2-Dehydro-3-deoxy-D-gluconate 6-phosphate 2DDG6P 58.4%
Chloramphenicol acetyltransferase CAT 56.3%
Cysteine CYS 55.5%
Acetate AC 54.2%
Succinyl coenzyme A SUCCOA 53.8%
Uridine monophosphate UMP 52.9%
Tryptophan TRP 52.5%
Lactate LAC 52.5%
Uridine triphosphate UTP 52.1%
Aspartate ASP 51.7%
Guanosine monophosphate GMP 50.8%
Asparagine ASN 50.4%
Cytidine diphosphate CDP 50.0%
Phosphoenolpyruvate PEP 48.3%
3-Phosphoglycerate 3PG 47.9%
2-Phosphoglycerate 2PG 47.1%
Lysine LYS 43.3%
Threonine THR 42.0%
Glutamate GLU 38.7%
Tyrosine TYR 37.0%
Adenosine triphosphate ATP 37.0%
D-Xylulose 5-phosphate XU5P 35.7%
Acetyl coenzyme A ACCOA 34.9%
Cytidine triphosphate CTP 33.2%
Serine SER 31.9%
Isoleucine ILE 29.8%
Leucine LEU 26.5%
Pyruvate PYR 21.8%
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Table 5.5: Metabolites by frequency of appearance in the 57 best simulated
annealing constraint sets, those with error at least three orders
of magnitude lower than the base synthetic dataset.
Metabolite Symbol Frequency
D-Xylulose 5-phosphate XU5P 100%
sedo-Heptulose 7-phosphate S7P 100%
D-Ribulose 5-phosphate RU5P 100%
Ribose 5-phosphate R5P 100%
Oxaloacetate OAA 100%
Isocitrate ICIT 100%
alpha-D-Glucose GLC 100%
Glucose 6-phosphate G6P 100%
Glyceraldehyde 3-phosphate G3P 100%
Fumarate FUM 100%
Fructose 1,6-diphosphate FDP 100%
Fructose 6-phosphate F6P 100%
Erythrose 4-phosphate E4P 100%
Dihydroxyacetone phosphate DHAP 100%
Citrate CIT 100%
Alanine ALA 100%
6-Phospho-D-glucono-1,5-lactone 6PGL 100%
6-Phospho-D-gluconate 6PGC 100%
2-Dehydro-3-deoxy-D-gluconate 6-phosphate 2DDG6P 100%
Uridine triphosphate UTP 98.2%
alpha-Ketoglutarate AKG 98.2%
Succinate SUCC 94.7%
Arginine ARG 94.7%
3-Phosphoglycerate 3PG 94.7%
Guanosine triphosphate GTP 91.2%
Uridine monophosphate UMP 89.5%
Glutamine GLN 87.7%
Cytidine monophosphate CMP 87.7%
Tyrosine TYR 82.5%
Threonine THR 82.5%
Aspartate ASP 80.7%
Cytidine diphosphate CDP 75.4%
Uridine diphosphate UDP 71.9%
Valine VAL 70.2%
Methionine MET 68.4%
Guanosine monophosphate GMP 68.4%
Glycine GLY 68.4%
Adenosine diphosphate ADP 68.4%
Tryptophan TRP 61.4%
Phenylalanine PHE 59.6%
Acetate AC 57.9%
Malate MAL 52.6%
Phosphoenolpyruvate PEP 50.9%
Leucine LEU 49.1%
Proline PRO 47.4%
Isoleucine ILE 47.4%
Histidine HIS 47.4%
Adenosine monophosphate AMP 45.6%
Glyoxylate GLX 43.9%
Lactate LAC 40.4%
Chloramphenicol acetyltransferase CAT 38.6%
Cysteine CYS 36.8%
Asparagine ASN 35.1%
Pyruvate PYR 33.3%
Glutamate GLU 31.6%
Succinyl coenzyme A SUCCOA 22.8%
Guanosine diphosphate GDP 22.8%
2-Phosphoglycerate 2PG 22.8%
Cytidine triphosphate CTP 14%
Acetyl coenzyme A ACCOA 14%
Lysine LYS 7%
Adenosine triphosphate ATP 5.3%
Serine SER 0%
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Figure 5.1: Schematic of the core portion of the cell-free E. coli metabolic
network. The network consisted of 264 reactions and 146
metabolites. Metabolites of glycolysis, pentose phosphate
pathway, Entner-Doudoroff pathway, and TCA cycle are
shown. Metabolites of oxidative phosphorylation, amino acid
biosynthesis and degradation, transcription/translation, cho-
rismate metabolism, and energy metabolism are not shown.
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Figure 5.2: Simulated metabolite concentration versus synthetic data as a
function of time. Central carbon metabolism, including glu-
cose (substrate), CAT (product), and intermediates, as well as
total concentration of energy species (energy total). The en-
ergy total denotes the summation of all energy species in the
model (all bases and all phosphate states). The 95% confi-
dence interval for the simulation conducted over the ensemble
of transcription/translation parameter sets is shown in the or-
ange shaded region, while the 95% confidence interval for the
synthetic constraint data is shown in the blue shaded region.
The synthetic data constraints were generated from the kinetic
model of Horvath et al, which was trained using experimental
measurements of the system simulated in this study [103].
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Figure 5.3: Simulation of amino acid concentration versus synthetic data
as a function of time. The 95% confidence interval for
the simulation conducted over the ensemble of transcrip-
tion/translation parameter sets is shown in the orange shaded
region, while the synthetic constraint data is shown in the blue
shaded region. Arginine and glutamate were excluded from
the constraint set. The synthetic data constraints were gener-
ated from the kinetic model of Horvath et al, which was trained
using experimental measurements of the system simulated in
this study [103].
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Figure 5.4: Simulation of energy species and energy totals by base versus
synthetic data as a function of time. The 95% confidence in-
terval for the simulation conducted over the ensemble of tran-
scription/translation parameter sets is shown in the orange
shaded region, while the synthetic constraint data is shown in
the blue shaded region. The synthetic data constraints were
generated from the kinetic model of Horvath et al, which was
trained using experimental measurements of the system simu-
lated in this study [103].
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Figure 5.5: Flux uncertainty versus metabolite prediction error against
synthetic data, normalized to the base case (white star), for ex-
clusion (gray) and inclusion (black) metabolite constraint sets.
The performance of the SVD-determined metabolite constraint
set is shown by the white square.
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Figure 5.6: Flux uncertainty and metabolite prediction error for the sim-
ulated annealing experimental design approach. A: Normal-
ized flux uncertainty versus normalized metabolite prediction
error. B: Number of metabolite constraints versus normalized
metabolite prediction error. Error was computed for the syn-
thetic experimental designs normalized to the base synthetic
dataset (white star). Sets that include glucose are show as gray
circles, while those that do not are represented with black cir-
cles.
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CHAPTER 6
METABOLIC CHARACTERIZATION OF ATRA-INDUCED HL60
DIFFERENTIATION
We developed liquid chromatography / mass spectrometry (LC/MS) meth-
ods for targeted metabolomics to characterize and quantify the changes in
the metabolic profile caused by ATRA-induced differentiation. An ACQUITY
UPLC BEH Amide Column was used on an ACQUITY UPLC H-Class System
for compound separation at room temperature. The instrument used a single-
quadrupole mass spectrometer (Waters, QDa) that was equipped with a pre-
optimized electrospray ionization source.
To characterize metabolic profiles of ATRA-induced differentiation, we cul-
tured ATRA-treated HL60 cells following standard protocol. Cells were counted
and media samples were collected at 12 hour intervals for 72 hours. We charac-
terized the glucose concentration using a Bayer Contour glucose meter, and lac-
tate concentration using the LC/MS protocol. We observed that ATRA-treated
cells lead to a decrease cell count, higher glucose concentration, and lower lac-
tate concentration compared to the control (Fig. 6.1). To ensure that the cells
were differentiated with ATRA treatment, flow cytometry was used to char-
acterize the early myeloid differential marker, CD38 (Fig. 6.1). The specific
growth, glucose consumption, and lactate production rates were determined to
be: 0.37/hr, 0.125 mmol glucose/gDWhr, and 0.325 mmol lactate/gDWhr for
untreated cultures, and 0.31/hr, 0.109 mmol glucose/gDWhr, and 0.502 mmol
lactate/gDWhr for ATRA-treated cultures. The specific growth rate and glu-
cose uptake rate were reduced with ATRA-induced differentiation as expected,
however ATRA-treated cells produced more lactate compared to the control.
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Amino acids were separated with a reverse-phase chromatography and quan-
tified with a TUV detector at 260nm using a AccQ-Tag Ultra Derivatization Kit
(Waters Corporation, Milford, MA) (Figs. 6.2-6.5).
To better understand the metabolic rewiring associated with differentiation,
we used the specific rates above as extracellular constraints in a flux balance
analysis (FBA) problem (Fig. 6.6). The metabolic reconstruction was adopted
from Palsson and coworker’s RECON 2.2 [219]. The network is a genome
scale reconstruction with 6048 metabolites and 11567 reactions. The increased
lactate production with ATRA-treated cells was unexpected due to the de-
creased glucose utilization and growth rate. Interestingly, to account for the
increased lactate production, while decreasing glucose, the FBA predicted an in-
creased glutamine utilization. This increased glutamine consumption provided
a secondary substrate to replenish TCA cycle metabolites that are required for
biomass synthesis and oxidative phosphorylation. We experienced challenges
in determining the intracellular flux distribution due to the large number of pos-
sible solutions to the linear programming problem. To overcome this challenge,
we began expanding our experimental efforts to incorporate nucleic acid quan-
tification and enzyme activities to introduce more constraints into the model
(Fig.6.7).
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Figure 6.1: HL60 culture seeded at 100k cells/mL cultured for 72 hours.
Growth curve, glucose and lactate media concentrations. The
light gray represent the control while the dark gray are the
ATRA-treated cells. The error bars represent one standard de-
viation of three biological replicates. The arrows represents the
exchange of metabolic fluxes.
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Figure 6.2: HL60 culture seeded at 100k cells/mL cultured for 72 hours.
Time course of serine, glycine, and cysteine media concentra-
tions. The light gray represent the control while the dark gray
are the ATRA-treated cells. The error bars represent one stan-
dard deviation of three biological replicates. The arrows repre-
sents the exchange of metabolic fluxes.
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Figure 6.3: HL60 culture seeded at 100k cells/mL cultured for 72 hours.
Time course of alanine, valine, leucine, phenylalanine, and
tryptophan media concentrations. The light gray represent the
control while the dark gray are the ATRA-treated cells. The
error bars represent one standard deviation of three biological
replicates. The arrows represents the exchange of metabolic
fluxes.
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Figure 6.4: HL60 culture seeded at 100k cells/mL cultured for 72 hours.
Time course of histidine, glutamine, glutamate, and proline
media concentration. The light gray represent untreated cul-
tures while the dark gray are the ATRA-treated cultures. The
error bars represent one standard deviation of three biological
replicates.
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Figure 6.5: HL60 culture seeded at 100k cells/mL cultured for 72 hours.
Time course of arginine, aspartate, threonine, lysine, methion-
ine, isoleucine media concentration. The light gray represent
untreated cultures while the dark gray are the ATRA-treated
cultures. The error bars represent one standard deviation of
three biological replicates.
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Figure 6.6: Flux balance analysis model using RECON 2.2 with constraints
from extracellular media measurements. Light gray indicates
untreated HL60 fluxes while Dark gray indicates ATRA-treated
HL60 fluxes. All fluxes are in the units of mmol/gDW.
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cellular decision making.
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CHAPTER 7
ON GOING AND FUTURE WORKS
7.1 Response Resistance and Rescue - Metabolic characteriza-
tion of ATRA-induced differentiation
The main motivation of this work was to create an integrated systems biology
approach to better understand resistance in cancer and the how we can use
combination therapy to alleviate make the cells responsive. In the future, we
expand the metabolic characterization of ATRA-resistant cell lines [118]. An ini-
tial control would be conducted using Am580, a nonmetabolizable analog of
ATRA to ensure ATRA-associated signaling is occurring throughout the time-
course. The resistant cell lines are characterized by loss of RA-inducible G1/G0
arrest, CD11b expression, inducible oxidative metabolism and p47(phox) ex-
pression. In a previous study, Jensen and coworkers showed that ATRA-treated
RA-resistant HL60 exhibits sustained MEK/ERK activation, and one of the two
sequentially emergent resistant lines retains ATRA-inducible CD38 expression.
Other signaling events that define the wild-type (WT) response are also com-
promised, including c-Raf phosphorylation [118]. Jensen and coworkers also
showed that SFK inhibitors such as PP2 treatment combined with ATRA initi-
ated characteristics of wild type HL60s but were potentially incapable of devel-
oping inducible oxidative metabolism [118].
We plan to develop methods to quantify glutamine using the LC/MS and
fully characterize conditioned media samples for a more comprehensive un-
derstanding of nutrient utilization of HL60 metabolism. With the additional
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metabolic measurements in the conditioned media, we would expand our core
metabolic model to incorporate amino acid synthesis and uptake to provide a
more accurate flux distribution. In addition, other metabolic targets such as hex-
okinase II (total and active Thr473) and lactate dehydrogenase will be probed as
well, since they represent enzymes that catalyze the first and last reaction of
aerobic glycolysis, respectively. To incorporate new constraints and nutrient
uptake into the flux balance analysis, the core network needs to be expanded to
incorporate additional exchange biosynthetic reactions. One way of achieving
this is to incorporate new pathways manually. Another approach is to adopt
the NetworkReducer of Erdich and coworkers, which can be used to systemat-
ically reduce a genome-scale model into a more manageable core network with
user specifications [64]. To validate the FBA model, we propose probing for
metabolic enzymes that (1) showed zero flux, and (2) had large change in flux
between treatments of ATRA and/or SFK inhibitor treatment. Zero-flux en-
zymes include: phosphofructose kinase (PFK) that converts G6P to F6P in up-
per glycolysis, citrate synthase, aconitase 2, and isocitrate dehydrogenase (IDH)
2/3 that catalyzes the first 3 steps in the TCA cycle within the mitochondria. In
addition, we propose conducting splitting analysis using enzymatic assay kits
of the respective enzymes at a branch point. To better understand the mecha-
nisms of the metabolic reprogramming associated with ATRA-induced differ-
entiation or lack thereof, we aim to probe for specific signaling molecules as-
sociated with the aerobic glycolysis metabolism, especially PI3K/AKT/mTOR
pathway and transcription factor downstream of MAPK such as MYC and
HIF1-α [65, 145, 65, 170, 203]. We also aim to characterize the rate of tran-
scription through quantitative real time polymerase chain reaction (RT-qPCR)
analysis. This method will offer an additional quantitative measurement that
171
can bridge the gap between measurements in signaling molecules, transcrip-
tion factors, and enzyme expression. More importantly, RT-PCR will be crucial
in determining alternative splicing variants, for instance pyruvate kinase iso-
form 2 (PKM2), which is known to induce LDH [159]. Ultimately, transcription
data and mRNA levels provide an independent validation for enzyme expres-
sion, and training data for gene expression models.
Lastly, with the development of our experimental methods, we propose to
conduct an set of exploratory experiments that look at enzyme translocation
and noncanonical epigenic functions of metabolic enzymes in the nucleus. This
can be done using the same experiments with the additional step of nuclear
fractionation. One particular metabolic enzyme of interest is pyruvate kinase
(specifically PKM2) and pyruvate dehydrogenase complex (PDC) that can be
translocated to the nucleus and form complexes with histone acetyltransferases
(HATs) and provide acetyl-coa (normally impermeable to mitochondria mem-
brane and unstable) for histone acetylation and gene expression [218, 166, 16].
7.2 Connecting Signaling to Metabolism using Kinetic and
Constraint-based Modeling
The Warburg effect, the metabolic phenomenon of increased glucose uptake that
is fermented into lactate in the presence of oxygen, has been observed across all
cancer cells and is seen as a hallmark of cancer metabolism. One hypothesis
suggests that expression of TCA enzymes is too costly to keep up with the dilu-
tion attributed by the uncontrolled cell division. We propose an integrated plat-
form that integrates signaling , gene expression, and metabolism . The novel
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modeling platform aims to capture cellular decision making at a global level
for a more comprehensive understanding of phenotypic changes such as dif-
ferentiation or metabolic programming. The main purpose of this model is to
implement regulatory layers on top of the flux balance analysis model to cou-
ple gene expression data such as enzyme and RNA levels to metabolic fluxes.
Having additional layers of regulation and constraints would greatly reduce the
solution space and increase the predictive power of the model.
For this comprehensive model to include signaling, gene expression, and
metabolism, the individual components or modules must be constructed and
then integrated together. For the signaling module, we propose adapting
Lequieu and coworkers’ signaling model of insulin induced translation initia-
tion [144]. The model has 823 parameters (573 kinetic parameters and 250 initial
conditions) and a comprehensive representation including phosphorylation, ac-
tivation, and complex formation of key species in the P13K/AKT/mTOR path-
way that lead to downstream formation of 80S initiation complex. Although
this model was developed to study insulin response, the core components of
the PI3K/AKT/mTOR signaling can be adopted and expanded to other down-
stream transcription factor targets such as MYC and HIF1-α.
For the expression of transcription factors and metabolic enzymes, we pro-
pose the adoption of the effective kinetic modeling framework used in gene
regulatory networks. We propose a model of metabolism, transcription, and
translation in an HL60 metabolic network, encoded as a system of ordinary dif-
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ferential equations using the same formulations as previously done:
dxi
dt
=
R∑
j=1
σi jr j (x, ,k) − xiµ i = 1, 2, . . . ,M (7.1)
dm j
dt
= rT, j −
(
µ + θm, j
)
m j + λ j (7.2)
dp j
dt
= rX, j −
(
µ + θp, j
)
p j (7.3)
(7.4)
The quantities xi, m j, and p j denote metabolite i, mRNA species j, and protein
j, respectively. The quantityM denotes the number of metabolites. The quan-
tity r j (x, ,k) denotes the rate of reaction j. Typically, reaction j is a non-linear
function of metabolite and enzyme abundance, as well as unknown kinetic pa-
rameters k (K × 1). The quantity σi j denotes the stoichiometric coefficient for
species i in reaction j. If σi j > 0, metabolite i is produced by reaction j. Con-
versely, if σi j < 0, metabolite i is consumed by reaction j, while σi j = 0 indicates
metabolite i is not connected with reaction j. The rate of reaction ,r j (x, ,k), is a
function of active enzyme level for the specific reaction j:
r j = kcatE∗jx (7.5)
E∗j = E jα j (7.6)
Although mass action kinetics is shown above, other forms of kinetics can also
be implemented. The variable kcat is a kinetic constant that can be determined
through enzymatic assays for each enzyme of interest, or estimated based on lit-
erature values. E∗j is the active form of E j, and its level can be directly measured
or determined as a function α j of post-translational modulators.
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We plan to solve the metabolic model equations using a integrated dynamic
constraint-based approach in which the rates of the signaling events, and tran-
scription and translation of metabolic enzymes and fluxes, are estimated by
solving a convex optimization subproblem at each time step k. We will pose
this subproblem as a linear programming problem for convenience; however,
this does not need to be the case. A key advantage of proposing the subprob-
lem as a linear programming problem is the lack of parameters and parameter
estimation.
The convex subproblem will consist of an objective function, material bal-
ances, and flux bound constraints. The linear objective function:
min
r1,...,rC
 C∑
j=1
c jr j(k)
 (7.7)
is minimized subject to the material balance constraints:
θmini
h
≤
C∑
j=1
σi jr j(k) ≤
θmaxi
h
i = 1, . . . ,M
θmin/maxi ≡ xmin/maxi, k+1 − xi, k ≡ xmin/maxi (t + h) − xi(t) (7.8)
and flux bounds constraints:
L j(x) ≤ r j ≤ U j(x) j = 1, . . . ,C
at each time step k. The user configurable parameters govern the maximum
rate of increase and decrease of the ith species derived from the maximum and
minimum concentrations, xmin/maxi . The L j(x) and U j(x) functions encode the
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lower and upper bound for the jth flux, while h denotes the time step size. In
this subproblem, the intracellular metabolite level does not need to be a steady
state, allowing the model to predict accumulation and depletion of metabolites
that may be caused by signaling and a shift in gene expression.
7.3 Expansion of Framework into Triple Negative Breast Can-
cer
The homeobox domain transcription factor NANOG, a key regulator of em-
bryonic development and cellular reprogramming, is broadly expressed in hu-
man cancers. In addition to promoting self-renewal and long-term proliferative
potential of stem-like cancer cells, NANOG-mediated oncogenic reprogram-
ming may underlie clinical manifestations of malignant disease.In this study, we
characterized MDA-MB-231 cells at three different NANOG expressions: Null,
Low, and High. We quantified the extracellular metabolite concentration within
the media, and used the results are extracellular-exchange constraints for our
constraint-based modeling to interrogate the intracellular flux distributions.
A reporter line of MDA-MB-231 cells developed by Thiagarajan and cowork-
ers were used for this study [224]. These cells were transfected with NANOG-
GFP gene and the population were sorted into Null, Low, and High referring
to: non GFP expression, bottom and top 5% GFP-positive of the population.
Each sample was then cultured for 72 hours with media samples collected and
analyzed. The media from the time-course samples was analyzed for glucose,
lactate, and 20 amino acids using LC/MS analytical techniques. The rate of
change was estimated using time course data of the cell count and metabolite
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concentrations. The extracellular constraints for the FBA model were generated
by sampling the statistics of the rate of change at the time of interest and set-
ting the upper and lower limits to a standard deviation away from the sampled
average.
The cell mass, glucose, and lactate measurements were measured (Fig. 7.1).
With increasing NANOG expression, our analysis showed the following path-
ways increased per glucose consumed: upper and lower glycolysis, pyruvate
transport into the TCA cycle, and malate to OAA. Similarly, we observed a de-
creasing pattern with NANOG expression in: glutamine uptake, oxygen con-
sumption, electron transport chain, magic enzyme, and shunt from G6P into
pentose phosphate and G1P.
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Figure 7.1: The MDA-MB-231 reporter cell line consists of a transfected
vector that contains a NANOG promotor directly upstream of
GFP. Therefore in the presence of NANOG, green fluorescent
protein (GFP) will be produced, differentiation the high ex-
pressing NANOG cells from the low and null in the total pop-
ulation. In this study, we defined the high and low NANOG-
expressing cells to be top and bottom 5% of the GFP positive
cells, and null to be the subpopulation that are GFP negative.
Leveraging our metabolomic efforts, we used the change in
metabolite concentrations in the media as constraints for the
FBA model to determine intracellular flux estimates for each
subpopulations.
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CHAPTER 8
CONCLUDING REMARKS
Early on in my graduate studies, I realize what fascinated me was how cells
made decisions, adapting to their environment. The way they process infor-
mation can lead to variety of changes from metabolic reprogramming to dif-
ferentiation. This began my pursuit to understand how cells are regulated
from signal transduction, to gene expression, post-translation modification, and
metabolism. Leveraging the existing knowledge we had in signal transduc-
tion and metabolism, my PhD focused on addressing how environmental cues
trigger signaling transduction and how those signals influences downstream
metabolic programming in the context of metabolic diseases, specifically can-
cer. Having a mechanistic understanding between signaling and metabolism
will further our understanding of these diseases. More importantly, computa-
tional models that incorporate mechanistic understanding of multiple layers of
cellular decision making can be used to design combination therapies which
combine multiple treatment modalities.
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APPENDIX A
MODELS MADE AVAILABLE
Model URL
HL60 ATRA Transcriptional Factor Model https://github.com/varnerlab/cRAF-reduced-model-manuscript
HL60 ATRA&D3 Transcriptional Factor Model https://github.com/varnerlab/HL60-TF-Model v4
Cancer Metabolism Model https://github.com/varnerlab/Core-Cancer-Model
Cell Free Protein Synthesis Model https://github.com/varnerlab/publication cell free dFBA repository
Human Complement Model https://github.com/varnerlab/Complement model repository
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